

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
11 July 2002 (11.07.2002)

PCT

(10) International Publication Number
WO 02/053775 A2

- (51) International Patent Classification⁷: C12Q 1/68 24, 82347 Bernried (DE). HUSTERT, Elisabeth [DE/DE]; Geschwister Scholl Ring 2, 82110 Germering (DE).
- (21) International Application Number: PCT/EP01/15290 (74) Agent: VOSSIUS & PARTNER; Siebertstrasse 4, 81675 Munich (DE).
- (22) International Filing Date: 21 December 2001 (21.12.2001) (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.
- (25) Filing Language: English (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- (26) Publication Language: English
- (30) Priority Data:
00128627.7 28 December 2000 (28.12.2000) EP
60/258,684 28 December 2000 (28.12.2000) US
60/258,952 29 December 2000 (29.12.2000) US
01100172.4 16 January 2001 (16.01.2001) EP
60/262,859 18 January 2001 (18.01.2001) US
01118884.4 16 August 2001 (16.08.2001) EP
60/312,825 16 August 2001 (16.08.2001) US
- (71) Applicant (for all designated States except US): EPIDAUROS BIOTECHNOLOGIE AG [DE/DE]; Am Neuland 1, 82347 Bernried (DE). Published:
— without international search report and to be republished upon receipt of that report
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): WOJNOWSKI, Leszek [DE/DE]; Ebenauerstrasse 9, 80637 München (DE). HABERL, Michael [DE/DE]; Waxensteinstrasse
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: IDENTIFICATION OF THE GENETIC DETERMINANTS OF THE POLYMORPHIC CYP3A5 EXPRESSION

(57) Abstract: The present invention relates to a polymorphic CYP3A5 polynucleotide. Moreover, the invention relates to genes or vectors comprising the polynucleotides of the invention and to a host cell genetically engineered with the polynucleotide or gene of the invention. Further, the invention relates to methods for producing molecular variant polypeptides or fragments thereof, methods for producing calls capable of expressing a molecular variant polypeptide and to a polypeptide or fragment thereof encoded by the polynucleotide or the gene of the invention or which is obtainable by the method or from the cells produced by the method of the invention. Furthermore, the invention relates to an antibody which binds specifically the polypeptide of the invention. Moreover, the invention relates to a transgenic non-human animal. The invention also relates to a solid support comprising one or a plurality of the above mentioned polynucleotides, genes, vectors, polypeptides, antibodies or host cells. Furthermore, methods of identifying a polymorphism, identifying and obtaining a prodrug or drug or an inhibitor are also encompassed by the present invention. In addition, the invention relates to methods for producing of a pharmaceutical composition and methods of diagnosing a disease. Further, the invention relates to a method of detection of the polynucleotide of the invention. Furthermore, comprised by the present invention are a diagnostic and a pharmaceutical composition. Even more the invention relates to uses of the polynucleotides, genes, vectors, polypeptides or antibodies of the invention. Finally, the invention relates to a diagnostic kit.

WO 02/053775 A2

Identification of the genetic determinants of the polymorphic CYP3A5 expression

The present invention relates to a polymorphic CYP3A5 polynucleotide. Moreover, the invention relates to genes or vectors comprising the polynucleotides of the invention and to a host cell genetically engineered with the polynucleotide or gene of the invention. Further, the invention relates to methods for producing molecular variant polypeptides or fragments thereof, methods for producing cells capable of expressing a molecular variant polypeptide and to a polypeptide or fragment thereof encoded by the polynucleotide or the gene of the invention or which is obtainable by the method or from the cells produced by the method of the invention. Furthermore, the invention relates to an antibody which binds specifically the polypeptide of the invention. Moreover, the invention relates to a transgenic non-human animal. The invention also relates to a solid support comprising one or a plurality of the above mentioned polynucleotides, genes, vectors, polypeptides, antibodies or host cells. Furthermore, methods of identifying a polymorphism, identifying and obtaining a pro-drug or drug or an inhibitor are also encompassed by the present invention. In addition, the invention relates to methods for producing of a pharmaceutical composition and to methods of diagnosing a disease. Further, the invention relates to a method of detection of the polynucleotide of the invention. Furthermore, comprised by the present invention are a diagnostic and a pharmaceutical composition. Even more, the invention relates to uses of the polynucleotides, genes, vectors, polypeptides or antibodies of the invention. Finally, the invention relates to a diagnostic kit.

The CYP3A enzymes play a particularly important role in drug metabolism. This is due to their abundant expression in the liver combined with a broad substrate spectrum. Indeed, it is estimated that CYP3A isozymes collectively comprise the largest portion of the liver CYP protein (Thummel, Annu Rev Pharmacol Toxicol 38 (1998), 389-430) and that they are involved in the metabolism of 45 % - 60 % of all currently used drugs (Li, Toxicology 104 (1995), 1-8; Evans, Science 286 (1999), 487-91). In addition to drugs, CYP3A isozymes metabolise a variety of other compounds including steroid hormones, toxins and carcinogens. For example, CYP3A isozymes metabolise aflatoxin B₁ (Wang, Biochemistry

37 (1998), 12536 - 45; Gillam, Arch Biochem Biophys 317 (1995), 374-84; Li, Cancer Res 57 (1997), 641-5), a mycotoxin strongly implicated in the etiology of liver cancer, which is a major cause of premature death in many areas of Africa and Asia (Henry, Science 286 (1999), 2453-4).

The hepatic expression and activity of CYP3A isozymes is inter-individually variable and this variability is the reason for harmful interactions frequently encountered in development and application of drugs that are CYP3A substrates. It has also been postulated that variable CYP3A expression could affect an individual's predisposition to cancers caused by environmental carcinogens which are metabolised by CYP3A. The elucidation of factors controlling an individual's CYP3A activity could permit personalised dose adjustments in therapies with its substrates and also lead to the identification of sub-populations at increased risk for several common cancers. However, despite considerable efforts, our understanding of factors governing CYP3A activity and expression is limited. There are several reasons for this: An average human liver may express products of up to four *CYP3A* genes (Gellner, Pharmacogenetics 11 (2001), 111 - 121), but their respective contributions to the hepatic CYP3A pool are still a matter of debate. The differentiation between the individual CYP3A proteins by enzymatic methods has proven difficult due to overlapping substrate specificities and due to the considerable effect of reconstitution conditions on their catalytic activities. RNA and protein analysis indicate that CYP3A4 forms the bulk of the hepatic CYP3A protein and its expression is highly variable (Thummel, Annu Rev Pharmacol Toxicol 38 (1998), 389-430). Less well understood are the contributions of the other *CYP3A* genes. CYP3A5 is widely considered the second most important CYP3A protein in the liver, but the available data are conflicting, since its expression has been reported to be present in 10 % to 97 % of human livers (Aoyama, J Biol Chem 264 (1989), 10388-95; Wrighton, Mol Pharmacol 38 (1990), 207-13; Schuetz, Pharmacogenetics 4 (1994), 11-20; Jounaidi, Biochem Biophys Res Commun 221 (1996), 466-70; Boobis, Br J Clin Pharmacol 42 (1996), 81-9). The possible reasons for these discrepancies include small sample sizes, interethnic differences and poor specificity of probes used to measure CYP3A5 expression. The third CYP3A, CYP3A7, was originally described in the human fetal liver where it accounts for about 50 % of the total CYP protein (Wrighton, Biochem Pharmacol 37 (1988), 3053-5). More recent studies indicate constitutive or induced expression of CYP3A7 in adult human livers, but its quantification has been hampered by the lack of specific antibodies. Similarly, no protein expression

data are available for the recently identified fourth member of the family, CYP3A43 (Gellner, Pharmacogenetics 11 (2001), 111 - 121).

Clinical studies indicate that a major portion of the inter-individual CYP3A variability is caused by genetic factors (Ozdemir, Pharmacogenetics 10 (2000), 373-88), but the identities of the latter remain unknown. In respect of CYP3A5, a protein variant (Thr398Asn) has been found in 2 out of 5 individuals deficient in CYP3A5 expression (Jounaidi, Biochem Biophys Res Commun 221 (1996), 466-70), but its significance has not been verified on a larger number of liver samples and in functional studies. In addition, a haplotype consisting of two linked polymorphisms has been described in the 5' flanking region of the CYP3A5 gene which is associated with increased expression and activity of the gene (Paulussen, Pharmacogenetics 10 (2000), 415-24). However, only a small sample set (n=29) was analysed for the genotype and the phenotype. Moreover, the single nucleotide polymorphisms (SNPs) which have been disclosed in said document are not suitable for a reliable prediction of CYP3A5 dysfunction and/or dysregulation and the problems caused thereby. This document does not suggest the existence of further haplotypes.

Thus, improved means and methods for diagnosing and treating a variety of diseases and disorders based on dysfunctions or dysregulations of drug metabolism were not available yet but are nevertheless highly desirable. Thus, the technical problem underlying the present invention is to comply with the above specified needs.

The solution to this technical problem is achieved by providing the embodiments characterized in the claims.

Accordingly, the present invention relates to a polynucleotide comprising a polynucleotide selected from the group consisting of:

- (a) a polynucleotide having the nucleic acid sequence of SEQ ID NO: 54, 56, 58, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 106, 108, 110, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 128, 129, 130, 131, 133, 134, 135, 136, 137, 138, 139, 140, 142, 143, 149, 151, 153, 155, 157, 159, 161, 163, 165, 169, 171, 173, 175, 177, 179, 181, 183, 185, 187, 189, 193, 195, 197, 199, 201, 207, 208,

- 209, 210, 211, 212, 213, 214, 216, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 231, 232, 233, 235, or 236;
- (b) a polynucleotide encoding a polypeptide having the amino acid sequence of SEQ ID NO: 127, 132, 141, 215, 229, or 234;
- (c) a polynucleotide capable of hybridizing to a CYP3A5 gene, wherein said polynucleotide is having a nucleotide exchange, a nucleotide deletion of at least one nucleotide, or at least one additional nucleotide at a position corresponding to position -20643, -20555, -20359, -20367, -20329, -20323, -20310, -6200, -6177, -4336, -3990, -3868, -3844, -3557, -1617, -795, -86, -74, 136, 174 to 176, 230, 3705, 3709/3710, 5215, 5235, 5516, 7182, 7207, 7303, 7424/7427, 12907, 13028, 13077, 13173, 13226, 13376, 14720, 14836, 14903, 15788, 16079, 16931/16932, 16993, 17163, 19069, 19165, 19208, 27050, 27131/27132, 27526, 31499, 31551 or 31611 of the CYP3A5 gene (Accession No: AF280107.1, wherein position 166220 has been numbered +1 and position 174832 has been numbered +8613, and Accession No: AC005020.2, wherein position 27341 has been numbered +8614);
- (d) a polynucleotide capable of hybridizing to a CYP3A5 gene, wherein said polynucleotide is having an A at a position corresponding to position -20555, -20329, -20323, -4336, -3868, -3844, -795, -86, 230, 5235, 5516, 7182, 7303, 12907, 13028, 13376, 19069 or 19165 of the CYP3A5 gene (Accession No: AF280107.1, wherein position 166220 has been numbered +1 and position 174832 has been numbered +8613, and Accession No: AC005020.2, wherein position 27341 has been numbered +8614), a T at a position corresponding to position -20367, -6200, -74, 3705, 5215, 7207, 14836, 17163, 19208 or 27526 of the CYP3A5 gene (Accession No: AF280107.1, wherein position 166220 has been numbered +1 and position 174832 has been numbered +8613, and Accession No: AC005020.2, wherein position 27341 has been numbered +8614), a G at a position corresponding to position -6177, -3990, 13077, 14720, 14903, 16993 or 27050 of the CYP3A5 gene (Accession No: AF280107.1, wherein position 166220 has been numbered +1 and position 174832 has been numbered +8613, and Accession No: AC005020.2, wherein position 27341 has been numbered +8614), a C at a position corresponding to position -20643, -20310, -3557, -1617, 136, 13173, 13226, 15788, 16079, 31499, 31551 or

31611 of the CYP3A5 gene (Accession No: AF280107.1, wherein position 166220 has been numbered +1 and position 174832 has been numbered +8613, and Accession No: AC005020.2, wherein position 27341 has been numbered +8614), nucleotide deletions at positions corresponding to positions 174 to 176 of the CYP3A5 gene (Accession No: AF280107.1, wherein position 166220 has been numbered +1 and position 174832 has been numbered +8613), an additional nucleotide at a position corresponding to position 3709/3710 or 27131/27132 of the CYP3A5 gene (Accession No: AF280107.1, wherein position 166220 has been numbered +1 and position 174832 has been numbered +8613, and Accession No: AC005020.2, wherein position 27341 has been numbered +8614), three additional nucleotides at a position corresponding to position 16931/16932 of the CYP3A5 gene (Accession No: AF280107.1, wherein position 166220 has been numbered +1 and position 174832 has been numbered +8613, and Accession No: AC005020.2, wherein position 27341 has been numbered +8614), or a deletion of two nucleotides and nine additional nucleotides inserted at a position corresponding to position 7424 to 7427 of the CYP3A5 gene (Accession No: AF280107.1, wherein position 166220 has been numbered +1 and position 174832 has been numbered +8613);

- (e) a polynucleotide encoding a CYP3A5 polypeptide or fragment thereof, wherein said polypeptide comprises an amino acid substitution at a position corresponding to position 30, 100, 130, 149 or 488 of the CYP3A5 polypeptide (Accession No: NP_000768.1), or at least one amino acid exchange or a stop codon at a position corresponding to position 30 to 34 or 346 to 348 of the CYP3A5 polypeptide (Accession No: NP_000768.1); and
- (f) a polynucleotide encoding a CYP3A5 polypeptide or fragment thereof, wherein said polypeptide comprises amino acid substitutions of HGLFK to YGTF. (with the period meaning termination) at a position corresponding to position 30 to 34 of the CYP3A5 polypeptide (Accession No: NP_000768.1, an amino acid substitution of S to Y at a position corresponding to position 100 of the CYP3A5 polypeptide (Accession No: NP_000768.1), an amino acid substitution of R to Q at a position corresponding to position 130 of the CYP3A5 polypeptide (Accession No: NP_000768.1), an amino acid substitution of I to T at a position corresponding to position 149 of the CYP3A5 polypeptide (Accession No: NP_000768.1), an amino acid

substitutions of TYD to YL. (with the period meaning termination) at position corresponding to position 346 to 348 of the CYP3A5 polypeptide (Accession No: NP_000768.1), or an amino acid substitution of I to T at a position corresponding to position 488 of the CYP3A5 polypeptide (Accession No: NP_000768.1).

In the context of the present invention the term "polynucleotides" or the term "polypeptides" refers to different variants of a polynucleotide or polypeptide. Said variants comprise a reference or wild type sequence of the polynucleotides or polypeptides of the invention as well as variants which differ therefrom in structure or composition. Reference or wild type sequences for the polynucleotides are Accession No: AF280107.1 and AC005020.2. Reference or wild type sequence for the polypeptides of the invention is Accession No: NP_000768.1. The differences in structure or composition usually occur by way of nucleotide or amino acid substitution(s), addition(s) and/or deletion(s). Preferably, said nucleotide substitution(s), addition(s) or deletion(s) result(s) in one or more changes of the corresponding amino acid(s) of the polypeptides of the invention. The variant polynucleotides and polypeptides also comprise fragments of said polynucleotides or polypeptides of the invention. The polynucleotides and polypeptides as well as the aforementioned fragments thereof of the present invention are characterized as being associated with a CYP3A5 dysfunction or dysregulation. Preferably, said dysfunctions or dysregulations referred to in the present invention cause a disease or disorder or a prevalence for said disease or disorder. Preferably, as will be discussed below in detail, said disease is cancer or diseases including cardiovascular diseases, diabetes and AIDS or any other disease caused by a dysfunction or dysregulation due to a polynucleotide or polypeptides of the invention.

The polynucleotides of the invention include polynucleotides that have at least 70%, preferably at least 75%, at least 80%, at least 85%, at least 90% or at least 95% sequence identity to a CYP3A5 gene, wherein said polynucleotide is having a nucleotide exchange, a nucleotide deletion of at least one nucleotide, or at least one additional nucleotide at a position corresponding to position -20643, -20555, -20359, -20367, -20329, -20323, -20310, -6200, -6177, -4336, -3990, -3868, -3844, -3557, -1617, -795, -86, -74, 136, 174 to 176, 230, 3705, 3709/3710, 5215, 5235, 5516, 7182, 7207, 7303, 7424/7427, 12907, 13028, 13077, 13173, 13226, 13376, 14720, 14836, 14903, 15788, 16079, 16931/16932, 16993, 17163, 19069, 19165, 19208, 27050, 27131/27132, 27526, 31499, 31551 or 31611

of the CYP3A5 gene (Accession No: AF280107.1, wherein position 166220 has been numbered +1 and position 174832 has been numbered +8613, and Accession No: AC005020.2, wherein position 27341 has been numbered +8614).

The term "hybridizing" as used herein refers to polynucleotides which are capable of hybridizing to the polynucleotides of the invention or parts thereof which are associated with a CYP3A5 dysfunction or dysregulation. Thus, said hybridizing polynucleotides are also associated with said dysfunctions and dysregulations. Therefore, said polynucleotides may be useful as probes in Northern or Southern Blot analysis of RNA or DNA preparations, respectively, or can be used as oligonucleotide primers in PCR analysis dependent on their respective size. Also comprised by the invention are hybridizing polynucleotides which are useful for analysing DNA-Protein interactions via, e.g., electrophoretic mobility shift analysis (EMSA). Preferably, said hybridizing polynucleotides comprise at least 10, more preferably at least 15 nucleotides in length while a hybridizing polynucleotide of the present invention to be used as a probe preferably comprises at least 100, more preferably at least 200, or most preferably at least 500 nucleotides in length.

It is well known in the art how to perform hybridization experiments with nucleic acid molecules, i.e. the person skilled in the art knows what hybridization conditions s/he has to use in accordance with the present invention. Such hybridization conditions are referred to in standard text books such as *Molecular Cloning A Laboratory Manual*, Cold Spring Harbor Laboratory (1989) N.Y. Preferred in accordance with the present inventions are polynucleotides which are capable of hybridizing to the polynucleotides of the invention or parts thereof which are associated with a CYP3A5 dysfunction or dysregulation under stringent hybridization conditions, i.e. which do not cross hybridize to unrelated polynucleotides such as polynucleotides encoding a polypeptide different from the CYP3A5 polypeptides of the invention.

Nucleic acid hybridization will be affected by such conditions as salt concentration, temperature, or organic solvents, in addition to the base composition, length of the complementary strands and the number of nucleotide base mismatches between the hybridizing nucleic acids, as will be readily appreciated by those skilled in the art. Stringent temperature conditions will generally include temperatures in excess of 30°C, typically 37°C, and preferably in excess of 45°C. Stringent salt conditions will ordinarily be less than 1000 mM, typically less than 500 mM and preferably less than 200 mM. However, the combination of parameters is much more important than the measure of any single parameter. See, e.g., Wetmur and Davidson, 1968. Probe sequences may also hybridize

specifically to duplex DNA under certain conditions to form triplex or higher order DNA complexes. The preparation of such probes and suitable hybridization conditions are well known in the art.

The term "percent sequence identity" or "identical" in the context of nucleic acid sequences refers to the residues in the two sequences which are the same when aligned for maximum correspondence. The length of sequence identity comparison may be over a stretch of at least nine nucleotides, usually at least 20 nucleotides, more usually at least 24 nucleotides, typically at least 28 nucleotides, more typically at least 32 nucleotides, and preferably at least 36 nucleotides or more nucleotides. There are a number of different algorithms known in the art which can be used to measure nucleotide sequence identity. For instance, polynucleotide sequences can be compared using Fasta, a program in GCG Version 6.6, Fasta provides alignments and percent sequence identity of the regions of the best overlap between the query and the search sequence (Pearson, 1980, herein incorporated by reference). For instance, percent sequence identity between nucleic acid sequences can be determined using Fasta with its default parameters (a word size of 6 and the NOPAMfactor for the scoring matrix) as provided in GCG Version 6.1, herein incorporated by reference.

The term "corresponding" as used herein means that a position is not only determined by the number of the preceding nucleotides and amino acids, respectively. The position of a given nucleotide or amino acid in accordance with the present invention which may be deleted, substituted or comprise one or more additional nucleotide(s) may vary due to deletions or additional nucleotides or amino acids elsewhere in the gene or the polypeptide. Thus, under a "corresponding position" in accordance with the present invention it is to be understood that nucleotides or amino acids may differ in the indicated number but may still have similar neighboring nucleotides or amino acids. Said nucleotides or amino acids which may be exchanged, deleted or comprise additional nucleotides or amino acids are also comprised by the term "corresponding position". Said nucleotides or amino acids may for instance together with their neighbors form sequences which may be involved in the regulation of gene expression, stability of the corresponding RNA or RNA editing, as well as encode functional domains or motifs of the protein of the invention.

By, e.g., "position 3709/3710" it is meant that said polynucleotide comprises one or more additional nucleotide(s) which are inserted between positions 3709 and position 3710 of

the corresponding wild type version of said polynucleotide. The same applies mutatis mutandis to all other position numbers referred to in the above embodiment which are drafted in the same format, i.e. two consecutive position numbers separated by a slash (/). By, e.g., "position 7424 to 7427" is meant that said polynucleotide comprises one or more deleted nucleotides which are deleted between positions 7424 and position 7427 of the corresponding wild type version of said polynucleotide and/or one or more additional nucleotide(s) which are inserted between positions 7424 and position 7427 of the corresponding wild type version of said polynucleotide. The same applies mutatis mutandis to all other position numbers referred to in the above embodiment which are drafted in the same format.

The numbering of the polymorphisms refers to the aligned and joined genomic sequences AF280107.1 and AC005020.2, wherein the T at position 174832 (which has been numbered +8613) of the sequence AF280107.1 refers to position 27340 of the sequence AC005020.2. The nucleotide A at position 27341 of the sequence AC005020.2 has been numbered +8614. Numbering of polymorphisms to a position corresponding to a position up to +8613 refers to the genomic sequence AF280107.1, numbering of polymorphisms to a position corresponding to position +8614 and greater refer to the genomic sequence AC005020.2.

In accordance with the present invention, the mode and population distribution of genetic variations in the CYP3A5 gene has been analyzed by sequence analysis of relevant regions of the human said gene from many different individuals. It is a well known fact that genomic DNA of individuals, which harbor the individual genetic makeup of all genes, including the CYP3A5 gene, can easily be purified from individual blood samples. These individual DNA samples are then used for the analysis of the sequence composition of the alleles of the CYP3A5 gene that are present in the individual which provided the blood sample. The sequence analysis was carried out by PCR amplification of relevant regions of said genes, subsequent purification of the PCR products, followed by automated DNA sequencing with established methods (e.g. ABI dyeterminator cycle sequencing).

One important parameter that had to be considered in the attempt to determine the individual genotypes and identify novel variants of the CYP3A5 gene by direct DNA-sequencing of PCR-products from human blood genomic DNA is the fact that each human harbors (usually, with very few abnormal exceptions) two gene copies of each autosomal gene (diploidy). Because of that, great care had to be taken in the evaluation of the sequences to be able to identify unambiguously not only homozygous sequence variations

but also heterozygous variations. The details of the different steps in the identification and characterization of novel polymorphisms in the CYP3A5 gene (homozygous and heterozygous) are described in the Examples below.

Over the past 20 years, genetic heterogeneity has been increasingly recognized as a significant source of variation in drug response. Many scientific communications (Meyer, *Ann. Rev. Pharmacol. Toxicol.* 37 (1997), 269-296 and West, *J. Clin. Pharmacol.* 37 (1997), 635-648) have clearly shown that some drugs work better or may even be highly toxic in some patients than in others and that these variations in patient's responses to drugs can be related to molecular basis. This "pharmacogenomic" concept spots correlations between responses to drugs and genetic profiles of patient's (Marshall, *Nature Biotechnology*, 15 (1997), 954-957; Marshall, *Nature Biotechnology*, 15 (1997), 1249-1252). In this context of population variability with regard to drug therapy, pharmacogenomics has been proposed as a tool useful in the identification and selection of patients which can respond to a particular drug without side effects. This identification/selection can be based upon molecular diagnosis of genetic polymorphisms by genotyping DNA from leukocytes in the blood of patient, for example, and characterization of disease (Bertz, *Clin. Pharmacokinet.* 32 (1997), 210-256; Engel, *J. Chromatogr. B. Biomed. Appl.* 678 (1996), 93-103). For the founders of health care, such as health maintenance organizations in the US and government public health services in many European countries, this pharmacogenomics approach can represent a way of both improving health care and reducing overheads because there is a large cost to unnecessary drugs, ineffective drugs and drugs with side effects.

The mutations in the variant genes of the invention sometime result in amino acid deletion(s), insertion(s) and in particular in substitution(s) either alone or in combination. It is of course also possible to genetically engineer such mutations in wild type genes or other mutant forms. Methods for introducing such modifications in the DNA sequence of said genes are well known to the person skilled in the art; see, e.g., Sambrook, *Molecular Cloning A Laboratory Manual*, Cold Spring Harbor Laboratory (1989) N.Y.

For the investigation of the nature of the alterations in the amino acid sequence of the polypeptides of the invention software programs may be used such as RASMOL that are obtainable from the Internet. Furthermore, folding simulations and computer redesign of structural motifs can be performed using other appropriate computer programs (Olszewski,

Proteins 25 (1996), 286-299; Hoffman, Comput. Appl. Biosci. 11 (1995), 675-679). Computers can be used for the conformational and energetic analysis of detailed protein models (Monge, J. Mol. Biol. 247 (1995), 995-1012; Renouf, Adv. Exp. Med. Biol. 376 (1995), 37-45). These analysis can be used for the identification of the influence of a particular mutation on binding and/or processing of drugs.

Usually, said amino acid deletion, addition or substitution in the amino acid sequence of the protein encoded by the polynucleotide of the invention is due to one or more nucleotide substitution, insertion or deletion, or any combinations thereof. Preferably said nucleotide substitution, insertion or deletion may result in amino acid substitutions of HGLFK to YGTF. (with the period meaning termination) at a position corresponding to position 30 to 34 of the CYP3A5 polypeptide (Accession No: NP_000768.1), in an amino acid substitution of S to Y at a position corresponding to position 100 of the CYP3A5 polypeptide (Accession No: NP_000768.1), in amino acid substitutions of TYD to YL. (with the period meaning termination) at a position corresponding to position 346 to 348 of the CYP3A5 polypeptide (Accession No: NP_000768.1), or in an amino acid substitution of T to N at a position corresponding to position 398 of the CYP3A5 polypeptide (Accession No: NP_000768.1).

The mutations in the CYP3A5 gene detected in accordance with the present invention are listed in Table 2A-E. The methods of the mutation analysis followed standard protocols and are described in detail in the Examples. In general such methods are to be used in accordance with the present invention for evaluating the phenotypic spectrum as well as the overlapping clinical characteristics of diseases or conditions related to dysfunctions and diseases related to the drug metabolism. Advantageously, the characterization of said mutants may form the basis of the development of improved drugs, such as drugs which are used e.g. in cancer therapy and diseases including cardiovascular diseases, diabetes and AIDS. Said methods encompass for example haplotype analysis, single-strand conformation polymorphism analysis (SSCA), PCR and direct sequencing, or TaqMan® analysis. On the basis of thorough clinical characterization of many patients the phenotypes can then be correlated to these mutations as well as to mutations that had been described earlier, for example in Jounaidi, Biochem Biophys Res Commun, 221, pp. 466-470, 1996.

Also comprised by the polynucleotides referred to in the present invention are polynucleotides which comprise at least two, preferably at least three, of the polynucleotides specified hereinabove, i.e. polynucleotides having a nucleotide sequence which contains at least two, preferably three of the mutations comprised by the above polynucleotides or listed in the tables below. Thus, the haplotype determined in accordance with the present invention can be characterized by at least two, preferably three of said mutations in the CYP3A5 locus. Further, the polynucleotide of the invention may further comprise at least one nucleotide deletion, addition and/or substitution other than those specified hereinabove, for example those described in the prior art; e.g., in Jounaidi, *Biochem Biophys Res Commun*, 221, pp. 466-470, 1996, in Paulussen, *Pharmacogenetics* 10, pp. 415-424, 2000, in Kuehl, 2001, *Nature Genetics* 27: 383-391, or in Chou, 2001, *Drug Metab Dispos* 29: 1205-1209.

This allows the study of synergistic effects of said mutations in the CYP3A5 gene and/or a polypeptide encoded by said polynucleotide on the pharmacological profile of drugs in patients who bear such mutant forms of the gene or similar mutant forms that can be mimicked by the above described proteins. It is expected that the analysis of said synergistic effects provides deeper insights into the onset of dysfunctions or diseases related to drug metabolism as described supra. From said deeper insight the development of diagnostic and pharmaceutical compositions related to dysfunctions or diseases related to drug metabolism will greatly benefit.

Moreover, it has been surprisingly found that the so called positive predictive power for CYP3A5 dysfunctions or dysregulations can be significantly increased based on the polynucleotides of the present invention and thus allows a reliable prediction in contrast to positive predictive power based on the prior art. The increased CYP3A5 protein expression in all except one liver samples (17/18) identified in accordance with the present invention and described in detail in the examples below co-segregates with a haplotype which consists of at least three variants (ch-v-021, ch-v-026, ch-v-015) with distinct locations within or upstream of the gene locus. Genotyping these three variants has in no case led to the generation of false-positive predictions resulting in an estimated positive predictive power for the 3-variant genotype of about 99.95 %. This is in striking contrast to the positive predictive power determined for the haplotype described by Paulussen, *Pharmacogenetics* 10, pp. 415-424, 2000 which is about 65 %. Moreover, based on the polynucleotides of the invention and as described in the examples below, it has been found that the SNPs described by Paulussen, *Pharmacogenetics* 10, pp. 415-424, 2000

are located in contrary to what is reported in said document approximately 20 kb upstream of the transcriptional start site of the CYP3A5 gene in a sequence 5' to a CYP3A5 pseudogene locus.

Therefore, the haplotypes characterized on the basis of the polynucleotides of the present invention fulfil the criteria expected from a reliable marker of CYP3A5 expression. As is evident to the person skilled in the art, the genetic knowledge deduced from the present invention can now be used to exactly and reliably characterize the genotype of a patient. Advantageously, diseases or a prevalence for a disease which are associated with CYP3A5 dysfunction or dysregulation, such as cancer, diseases including cardiovascular diseases, diabetes and AIDS, can be predicted and preventive or therapeutical measures can be applied accordingly. Moreover in accordance with the foregoing, in cases where a given drug takes an unusual effect, a suitable individual therapy can be designed based on the knowledge of the individual genetic makeup of a subject with respect to the polynucleotides of the invention and improved therapeutics can be developed as will be further discussed below.

Finally, the polynucleotides and polypeptides referred to in accordance with the present invention are also useful as forensic markers, which improve the identification of subjects which have been murdered or killed by, for example, a crime of violence or any other violence and can not be identified by the well known conventional forensic methods. The application of forensic methods based on the detection of the polymorphisms comprised by the polynucleotides of this invention in the genome of a subject are particularly well suited in cases where a (dead) body is disfigured in a severe manner such that identification by other body characteristics such as the features of the face is not possible. This is the case, for example, for corpse found in water which are usually entirely disfigured. Advantageously methods which are based on the provision of the polynucleotides of the invention merely require a minimal amount of tissues or cells in order to be carried out. Said tissues or cells may be blood droplets, hair roots, epidermal scales, saliva droplets, sperms etc. Since only such a minimal amount of tissues or cells are required for the identification of a subject, the polymorphisms comprised by the polynucleotides of this invention can be also used as forensic markers in order to prove someone guilt of a crime, such as a violation or a ravishment. Moreover, the polymorphisms comprised by the polynucleotides of this invention can be used to proof paternity. In accordance with the forensic methods referred to herein the presence or absence of the polynucleotides of the invention is determined and compared with a reference sample which is unambiguously derived from the subject to be identified. The

forensic methods which require detection of the presence or absence of the polynucleotides of the invention in a sample of a subject the polymorphisms comprised by the polynucleotides of this invention can be for example PCR-based techniques which are particularly well suited in cases where only a minimal amount of tissues or cells are available as forensic samples. On the other hand, where enough tissue or cells are available, hybridization based techniques may be performed in order to detect the presence or absence of a polynucleotide of this invention. These techniques are well known by the person skilled in the art and can be adopted to the individual purposes referred to herein without further ado. In conclusion, thanks to the present invention forensic means which allow improved and reliable predictions as regards the aforementioned aspects are now available.

In line with the foregoing, preferably, the polynucleotide of the present invention is associated with cancer or diseases including cardiovascular diseases, diabetes and AIDS.

The term "cancer" used herein is very well known and characterized in the art. Several variants of cancer exist and are comprised by said term as meant in accordance with the invention. For a detailed list of symptoms which are indicative for cancer it is referred to text book knowledge, e.g. Pschyrembel.

In a further embodiment the present invention relates to a polynucleotide which is DNA or RNA.

The polynucleotide of the invention may be, e.g., DNA, cDNA, genomic DNA, RNA or synthetically produced DNA or RNA or a recombinantly produced chimeric nucleic acid molecule comprising any of those polynucleotides either alone or in combination. Preferably said polynucleotide is part of a vector, particularly plasmids, cosmids, viruses and bacteriophages used conventionally in genetic engineering that comprise a polynucleotide of the invention. Such vectors may comprise further genes such as marker genes which allow for the selection of said vector in a suitable host cell and under suitable conditions.

The invention furthermore relates to a gene comprising the polynucleotide of the invention.

It is well known in the art that genes comprise structural elements which encode an amino acid sequence as well as regulatory elements which are involved in the regulation of the expression of said genes. Structural elements are represented by exons which may either encode an amino acid sequence or which may encode for RNA which is not encoding an amino acid sequence but is nevertheless involved in RNA function, e.g. by regulating the stability of the RNA or the nuclear export of the RNA.

Regulatory elements of a gene may comprise promoter elements or enhancer elements both of which could be involved in transcriptional control of gene expression. It is very well known in the art that a promoter is to be found upstream of the structural elements of a gene. Regulatory elements such as enhancer elements, however, may be found distributed over the entire locus of the gene. Said elements could be reside, e.g., in introns, regions of genomic DNA which separate the exons of a gene. Said introns may comprise further regulatory elements which are required for proper gene expression. Introns are usually transcribed together with the exons of a gene resulting in a nascent RNA transcript which contains both, exon and intron sequences. The intron encoded RNA sequences are usually removed by a process known as RNA splicing. However, said process also requires regulatory sequences present on a RNA transcript, said regulatory sequences may be encoded by the introns.

In addition, besides their function in transcriptional control and control of proper RNA processing and/or stability, regulatory elements of a gene could be also involved in the control of genetic stability of a gene locus. Said elements control, e.g., recombination events or serve to maintain a certain structure of the DNA or the arrangement of DNA in a chromosome.

Therefore, polymorphisms can occur in exons of a gene which encode an amino acid sequence as discussed supra as well as in regulatory regions which are involved in the above discussed process. The analysis of the nucleotide sequence of a gene locus in its entirety including, e.g., introns is in light of the above desirable. It has been found based on the polymorphisms comprised by the polynucleotides of the present invention that the mechanism of the increased expression of CYP3A5 protein in most Caucasians livers described in the examples below may involve enhanced transcription and stabilisation of the gene's transcripts.

Therefore, in a furthermore preferred embodiment of the gene of the invention a nucleotide deletion, addition and/or substitution results in altered expression of the variant gene compared to the corresponding wild type gene.

In another embodiment the present invention relates to a vector comprising the polynucleotide of the invention or the gene of the invention.

Said vector may be, for example, a phage, plasmid, viral or retroviral vector. Retroviral vectors may be replication competent or replication defective. In the latter case, viral propagation generally will occur only in complementing host/cells.

The polynucleotides or genes of the invention may be joined to a vector containing selectable markers for propagation in a host. Generally, a plasmid vector is introduced in a precipitate such as a calcium phosphate precipitate, or in a complex with a charged lipid or in carbon-based clusters. Should the vector be a virus, it may be packaged in vitro using an appropriate packaging cell line prior to application to host cells.

In a more preferred embodiment of the vector of the invention the polynucleotide is operatively linked to expression control sequences allowing expression in prokaryotic or eukaryotic cells or isolated fractions thereof.

Expression of said polynucleotide comprises transcription of the polynucleotide, preferably into a translatable mRNA. Regulatory elements ensuring expression in eukaryotic cells, preferably mammalian cells, are well known to those skilled in the art. They usually comprise regulatory sequences ensuring initiation of transcription and optionally poly-A signals ensuring termination of transcription and stabilization of the transcript. Additional regulatory elements may include transcriptional as well as translational enhancers. Possible regulatory elements permitting expression in prokaryotic host cells comprise, e.g., the *lac*, *trp* or *tac* promoter in *E. coli*, and examples for regulatory elements permitting expression in eukaryotic host cells are the *AOX1* or *GAL1* promoter in yeast or the CMV-, SV40-, RSV-promoter (Rous sarcoma virus), CMV-enhancer, SV40-enhancer or a globin intron in mammalian and other animal cells. Beside elements which are responsible for the initiation of transcription such regulatory elements may also comprise transcription termination signals, such as the SV40-poly-A site or the tk-poly-A site, downstream of the polynucleotide. In this context, suitable expression vectors are known in the art such as Okayama-Berg cDNA expression vector pcDV1 (Pharmacia), pCDM8, pRc/CMV, pcDNA1, pcDNA3 (In-vitrogene), pSPORT1 (GIBCO BRL). Preferably, said vector is an expression vector and/or a gene transfer or targeting vector. Expression vectors derived from viruses such as retroviruses, vaccinia virus, adeno-associated virus, herpes viruses, or bovine

papilloma virus, may be used for delivery of the polynucleotides or vector of the invention into targeted cell population. Methods which are well known to those skilled in the art can be used to construct recombinant viral vectors; see, for example, the techniques described in Sambrook, Molecular Cloning A Laboratory Manual, Cold Spring Harbor Laboratory (1989) N.Y. and Ausubel, Current Protocols in Molecular Biology, Green Publishing Associates and Wiley Interscience, N.Y. (1994). Alternatively, the polynucleotides and vectors of the invention can be reconstituted into liposomes for delivery to target cells.

The term "isolated fractions thereof" refers to fractions of eukaryotic or prokaryotic cells or tissues comprising said cells which are capable of transcribing or transcribing and translating RNA from the vector of the invention. Said fractions comprise proteins which are required for transcription of RNA or transcription of RNA and translation of said RNA into a polypeptide. Said isolated fractions may be, e.g., nuclear and cytoplasmic fractions of eukaryotic cells such as of reticulocytes.

The present invention furthermore relates to a host cell genetically engineered with the polynucleotide of the invention, the gene of the invention or the vector of the invention.

Said host cell may be a prokaryotic or eukaryotic cell; see supra. The polynucleotide or vector of the invention which is present in the host cell may either be integrated into the genome of the host cell or it may be maintained extrachromosomally. In this respect, it is also to be understood that the recombinant DNA molecule of the invention can be used for "gene targeting" and/or "gene replacement", for restoring a mutant gene or for creating a mutant gene via homologous recombination; see for example Mouellic, Proc. Natl. Acad. Sci. USA, 87 (1990), 4712-4716; Joyner, Gene Targeting, A Practical Approach, Oxford University Press.

The host cell can be any prokaryotic or eukaryotic cell, such as a bacterial, insect, fungal, plant, animal or human cell. Preferred fungal cells are, for example, those of the genus *Saccharomyces*, in particular those of the species *S. cerevisiae*. The term "prokaryotic" is meant to include all bacteria which can be transformed or transfected with a polynucleotide for the expression of a variant polypeptide of the invention. Prokaryotic hosts may include gram negative as well as gram positive bacteria such as, for example, *E. coli*, *S. typhimurium*, *Serratia marcescens* and *Bacillus subtilis*. A polynucleotide coding for a mutant form of variant polypeptides of the invention can be used to transform or transfect the host using any of the techniques commonly known to those of ordinary skill in the art.

Methods for preparing fused, operably linked genes and expressing them in bacteria or animal cells are well-known in the art (Sambrook, *supra*). The genetic constructs and methods described therein can be utilized for expression of variant polypeptides of the invention in, e.g., prokaryotic hosts. In general, expression vectors containing promoter sequences which facilitate the efficient transcription of the inserted polynucleotide are used in connection with the host. The expression vector typically contains an origin of replication, a promoter, and a terminator, as well as specific genes which are capable of providing phenotypic selection of the transformed cells. The transformed prokaryotic hosts can be grown in fermentors and cultured according to techniques known in the art to achieve optimal cell growth. The proteins of the invention can then be isolated from the grown medium, cellular lysates, or cellular membrane fractions. The isolation and purification of the microbially or otherwise expressed polypeptides of the invention may be by any conventional means such as, for example, preparative chromatographic separations and immunological separations such as those involving the use of monoclonal or polyclonal antibodies.

Thus, in a further embodiment the invention relates to a method for producing a molecular variant polypeptide or fragment thereof comprising culturing the above described host cell; and recovering said protein or fragment from the culture.

In another embodiment the present invention relates to a method for producing cells capable of expressing a molecular variant polypeptide comprising genetically engineering cells with the polynucleotide of the invention, the gene of the invention or the vector of the invention.

The cells obtainable by the method of the invention can be used, for example, to test drugs according to the methods described in D. L. Spector, R. D. Goldman, L. A. Leinwand, *Cells, a Lab manual*, CSH Press 1998. Furthermore, the cells can be used to study known drugs and unknown derivatives thereof for their ability to complement the deficiency caused by mutations in the CYP3A5 gene. For these embodiments the host cells preferably lack a wild type allele, preferably both alleles of the CYP3A5 gene and/or have at least one mutated from thereof. Ideally, the gene comprising an allele as comprised by the polynucleotides of the invention could be introduced into the wild type locus by homologous replacement. Alternatively, strong overexpression of a mutated allele over the normal allele and comparison with a recombinant cell line overexpressing the normal

allele at a similar level may be used as a screening and analysis system. The cells obtainable by the above-described method may also be used for the screening methods referred to herein below.

Furthermore, the invention relates to a polypeptide or fragment thereof encoded by the polynucleotide of the invention, the gene of the invention or obtainable by the method described above or from cells produced by the method described above.

In this context it is also understood that the variant polypeptide of the invention can be further modified by conventional methods known in the art. By providing said variant proteins according to the present invention it is also possible to determine the portions relevant for their biological activity or inhibition of the same. The terms "polypeptide" and "protein" as used herein are exchangeable. Moreover, what is comprised by said terms is standard textbook knowledge.

The present invention furthermore relates to an antibody which binds specifically to the polypeptide of the invention.

Advantageously, the antibody specifically recognizes or binds an epitope containing one or more amino acid substitution(s) as defined above. Antibodies against the variant polypeptides of the invention can be prepared by well known methods using a purified protein according to the invention or a (synthetic) fragment derived therefrom as an antigen. Monoclonal antibodies can be prepared, for example, by the techniques as originally described in Köhler and Milstein, *Nature* 256 (1975), 495, and Galfré, *Meth. Enzymol.* 73 (1981), 3, which comprise the fusion of mouse myeloma cells to spleen cells derived from immunized mammals. In a preferred embodiment of the invention, said antibody is a monoclonal antibody, a polyclonal antibody, a single chain antibody, human or humanized antibody, primatized, chimerized or fragment thereof that specifically binds said peptide or polypeptide also including bispecific antibody, synthetic antibody, antibody fragment, such as Fab, Fv or scFv fragments etc., or a chemically modified derivative of any of these. Furthermore, antibodies or fragments thereof to the aforementioned polypeptides can be obtained by using methods which are described, e.g., in Harlow and Lane "Antibodies, A Laboratory Manual", CSH Press, Cold Spring Harbor, 1988. These antibodies can be used, for example, for the immunoprecipitation and immunolocalization of the variant polypeptides of the invention as well as for the monitoring of the presence of

said variant polypeptides, for example, in recombinant organisms, and for the identification of compounds interacting with the proteins according to the invention. For example, surface plasmon resonance as employed in the BIAcore system can be used to increase the efficiency of phage antibodies which bind to an epitope of the protein of the invention (Schier, Human Antibodies Hybridomas 7 (1996), 97-105; Malmborg, J. Immunol. Methods 183 (1995), 7-13).

In a preferred embodiment the antibody of the present invention specifically recognizes an epitope containing one or more amino acid substitution(s) resulting from a nucleotide exchange as defined supra.

Antibodies which specifically recognize modified amino acids such as phospho-Tyrosine residues are well known in the art. Similarly, in accordance with the present invention antibodies which specifically recognize even a single amino acid exchange in an epitope may be generated by the well known methods described supra.

In light of the foregoing, in a more preferred embodiment the antibody of the present invention is monoclonal or polyclonal.

The invention also relates to a transgenic non-human animal comprising at least one polynucleotide of the invention, the gene of the invention or the vector of the invention as described supra.

The present invention also encompasses a method for the production of a transgenic non-human animal comprising introduction of a polynucleotide or vector of the invention into a germ cell, an embryonic cell, stem cell or an egg or a cell derived therefrom. The non-human animal can be used in accordance with the method of the invention described below and may be a non-transgenic healthy animal, or may have a disease or disorder, preferably a disease caused by at least one mutation in the gene of the invention. Such transgenic animals are well suited for, e.g., pharmacological studies of drugs in connection with variant forms of the above described variant polypeptides since these polypeptides or at least their functional domains are conserved between species in higher eukaryotes, particularly in mammals. Production of transgenic embryos and screening of those can be performed, e.g., as described by A. L. Joyner Ed., Gene Targeting, A Practical Approach

(1993), Oxford University Press. The DNA of the embryos can be analyzed using, e.g., Southern blots with an appropriate probe or based on PCR techniques.

A transgenic non-human animal in accordance with the invention may be a transgenic mouse, rat, hamster, dog, monkey, rabbit, pig, frog, nematode such as *Caenorhabditis elegans*, fruitfly such as *Drosophila melanogaster* or fish such as torpedo fish or zebrafish comprising a polynucleotide or vector of the invention or obtained by the method described above, preferably wherein said polynucleotide or vector is stably integrated into the genome of said non-human animal, preferably such that the presence of said polynucleotide or vector leads to the expression of the variant polypeptide of the invention. It may comprise one or several copies of the same or different polynucleotides or genes of the invention. This animal has numerous utilities, including as a research model for cancer or diseases including cardiovascular diseases, diabetes and AIDS or any other disease caused by as dysfunction or dysregulation of the polynucleotides or polypeptides of the invention research and therefore, presents a novel and valuable animal in the development of therapies, treatment, etc. for cancer diseases or diseases including cardiovascular diseases, diabetes and AIDS or any other disease caused by as dysfunction or dysregulation of the polynucleotides or polypeptides of the invention. Accordingly, in this instance, the mammal is preferably a laboratory animal such as a mouse or rat.

Thus, in a preferred embodiment the transgenic non-human animal of the invention is a mouse, a rat or a zebrafish.

Numerous reports revealed that said animals are particularly well suited as model organisms for the investigation of the drug metabolism and its deficiencies or cancer. Advantageously, transgenic animals can be easily created using said model organisms, due to the availability of various suitable techniques well known in the art.

The invention also relates to a solid support comprising one or a plurality of the polynucleotide, the gene, the vector, the polypeptide, the antibody or the host cell of the invention in immobilized form.

The term "solid support" as used herein refers to a flexible or non-flexible support that is suitable for carrying said immobilized targets. Said solid support may be homogenous or

inhomogeneous. For example, said solid support may consist of different materials having the same or different properties with respect to flexibility and immobilization, for instance, or said solid support may consist of one material exhibiting a plurality of properties also comprising flexibility and immobilization properties. Said solid support may comprise glass-, polypropylene- or silicon-chips, membranes, oligonucleotide-conjugated beads or bead arrays.

The term "immobilized" means that the molecular species of interest is fixed to a solid support, preferably covalently linked thereto. This covalent linkage can be achieved by different means depending on the molecular nature of the molecular species. Moreover, the molecular species may be also fixed on the solid support by electrostatic forces, hydrophobic or hydrophilic interactions or Van-der-Waals forces. The above described physico-chemical interactions typically occur in interactions between molecules. For example, biotinylated polypeptides may be fixed on a avidin-coated solid support due to interactions of the above described types. Further, polypeptides such as antibodies, may be fixed on an antibody coated solid support. Moreover, the immobilization is dependent on the chemical properties of the solid support. For example, the nucleic acid molecules can be immobilized on a membrane by standard techniques such as UV-crosslinking or heat.

In a preferred embodiment of the invention said solid support is a membrane, a glass- or polypropylene- or silicon-chip, or oligonucleotide-conjugated beads or a bead array, which is assembled on an optical filter substrate.

Moreover, the present invention relates to an in vitro method for identifying a polymorphism said method comprising the steps of:

- (a) isolating a polynucleotide or the gene of the invention from a plurality of subgroups of individuals, wherein one subgroup has no prevalence for a CYP3A5 associated disease and at least one or more further subgroup(s) do have prevalence for a CYP3A5 associated disease; and
- (b) identifying a polymorphism by comparing the nucleic acid sequence of said polynucleotide or said gene of said one subgroup having no prevalence for a CYP3A5 associated disease with said at least one or more further subgroup(s) having a prevalence for a CYP3A5 associated disease.

The term "prevalence" as used herein means that individuals are susceptible for one or more disease(s) which are associated with CYP3A5 dysfunction or dysregulation or could already have one or more of said disease(s). Thereby, one CYP3A5 associated disease can be used to determine the susceptibility for another CYP3A5 associated disease, e.g. impaired drug metabolism may be indicative for a prevalence for, e.g. cancer. Moreover, symptoms which are indicative for a prevalence for developing said diseases are very well known in the art and have been sufficiently described in standard textbooks such as Pschyrembel.

Advantageously, polymorphisms according to the present invention which are associated with CYP3A5 dysfunction or dysregulation or one or more disease(s) based thereon should be enriched in subgroups of individuals which have a prevalence for said diseases versus subgroups which have no prevalence for said diseases. Thus, the above described method allows the rapid and reliable detection of polymorphisms which are indicative for one or more CYP3A5 associated disease(s) or a susceptibility therefor. Advantageously, due to the phenotypic preselection a large number of individuals having no prevalence might be screened for polymorphisms in general. Thereby, a reference sequences comprising polymorphisms which do not correlate to one or more CYP3A5 associated disease(s) can be obtained. Based on said reference sequences it is possible to efficiently and reliably determine the relevant polymorphisms.

In a further embodiment the present invention relates to a method for identifying and obtaining a pro-drug or a drug capable of modulating the activity of a molecular variant of a CYP3A5 polypeptide comprising the steps of:

- (a) contacting the polypeptide, the solid support of the invention, a cell expressing a molecular variant gene comprising a polynucleotide of the invention, the gene or the vector of the invention in the presence of components capable of providing a detectable signal in response to drug activity with a compound to be screened for pro-drug or drug activity; and
- (b) detecting the presence or absence of a signal or increase or decrease of a signal generated from the pro-drug or the drug activity, wherein the absence, presence, increase or decrease of the signal is indicative for a putative pro-drug or drug.

The term "compound" in a method of the invention includes a single substance or a plurality of substances which may or may not be identical.

Said compound(s) may be chemically synthesized or produced via microbial fermentation but can also be comprised in, for example, samples, e.g., cell extracts from, e.g., plants, animals or microorganisms. Furthermore, said compounds may be known in the art but hitherto not known to be useful as an inhibitor, respectively. The plurality of compounds may be, e.g., added to the culture medium or injected into a cell or non-human animal of the invention.

If a sample containing (a) compound(s) is identified in the method of the invention, then it is either possible to isolate the compound from the original sample identified as containing the compound in question or one can further subdivide the original sample, for example, if it consists of a plurality of different compounds, so as to reduce the number of different substances per sample and repeat the method with the subdivisions of the original sample. It can then be determined whether said sample or compound displays the desired properties, for example, by the methods described herein or in the literature (Spector et al., Cells manual; see supra). Depending on the complexity of the samples, the steps described above can be performed several times, preferably until the sample identified according to the method of the invention only comprises a limited number of or only one substance(s). Preferably said sample comprises substances of similar chemical and/or physical properties, and most preferably said substances are identical. The methods of the present invention can be easily performed and designed by the person skilled in the art, for example in accordance with other cell based assays described in the prior art or by using and modifying the methods as described herein. Furthermore, the person skilled in the art will readily recognize which further compounds may be used in order to perform the methods of the invention, for example, enzymes, if necessary, that convert a certain compound into a precursor. Such adaptation of the method of the invention is well within the skill of the person skilled in the art and can be performed without undue experimentation.

Compounds which can be used in accordance with the present invention include peptides, proteins, nucleic acids, antibodies, small organic compounds, ligands, peptidomimetics, PNAs and the like. Said compounds may act as agonists or antagonists of the invention. Said compounds can also be functional derivatives or analogues of known drugs. Methods for the preparation of chemical derivatives and analogues are well known to those skilled in the art and are described in, for example, Beilstein, Handbook of Organic Chemistry, Springer edition New York Inc., 175 Fifth Avenue, New York, N.Y. 10010 U.S.A. and Organic Synthesis, Wiley, New York, USA. Furthermore, said derivatives and analogues

can be tested for their effects according to methods known in the art or as described. Furthermore, peptide mimetics and/or computer aided design of appropriate drug derivatives and analogues can be used, for example, according to the methods described below. Such analogs comprise molecules may have as the basis structure of known CYP3A5 substrates and/or inhibitors and/or modulators; see *infra*.

Appropriate computer programs can be used for the identification of interactive sites of a putative inhibitor and the polypeptides of the invention by computer assistant searches for complementary structural motifs (Fassina, *Immunomethods* 5 (1994), 114-120). Further appropriate computer systems for the computer aided design of protein and peptides are described in the prior art, for example, in Berry, *Biochem. Soc. Trans.* 22 (1994), 1033-1036; Wodak, *Ann. N. Y. Acad. Sci.* 501. (1987), 1-13; Pabo, *Biochemistry* 25 (1986), 5987-5991. The results obtained from the above-described computer analysis can be used in combination with the method of the invention for, e.g., optimizing known inhibitors, analogs, antagonists or agonists. Appropriate peptidomimetics and other inhibitors can also be identified by the synthesis of peptidomimetic combinatorial libraries through successive chemical modification and testing the resulting compounds, e.g., according to the methods described herein. Methods for the generation and use of peptidomimetic combinatorial libraries are described in the prior art, for example in Ostresh, *Methods in Enzymology* 267 (1996), 220-234 and Dorner, *Bioorg. Med. Chem.* 4 (1996), 709-715. Furthermore, the three-dimensional and/or crystallographic structure of said compounds and the polypeptides of the invention can be used for the design of peptidomimetic drugs (Rose, *Biochemistry* 35 (1996), 12933-12944; Rutenber, *Bioorg. Med. Chem.* 4 (1996), 1545-1558). It is very well known how to obtain said compounds, e.g. by chemical or biochemical standard techniques. Thus, also comprised by the method of the invention are means of making or producing said compounds. In summary, the present invention provides methods for identifying and obtaining compounds which can be used in specific doses for the treatment of specific forms of CYP3A5 associated diseases, e.g. dysfunctions of the drug metabolism or cancer.

The above definitions apply *mutatis mutandis* to all of the methods described in the following.

In a further embodiment the present invention relates to a method for identifying and obtaining an inhibitor of the activity of a molecular variant of a CYP3A5 polypeptide comprising the steps of:

- (a) contacting the protein, the solid support of the invention or a cell expressing a molecular variant gene comprising a polynucleotide or the gene or the vector of the invention in the presence of components capable of providing a detectable signal in response to drug activity with a compound to be screened for inhibiting activity; and
- (b) detecting the presence or absence of a signal or increase or decrease of a signal generated from the inhibiting activity, wherein the absence or decrease of the signal is indicative for a putative inhibitor.

In a preferred embodiment of the method of the invention said cell is a cell, obtained by the method of the invention or can be obtained from the transgenic non-human animal as described supra.

In a still further embodiment the present invention relates to a method of identifying and obtaining a pro-drug or drug capable of modulating the activity of a molecular variant of a CYP3A5 polypeptide comprising the steps of:

- (a) contacting the host cell, the cell obtained by the method of the invention, the polypeptide or the solid support of the invention with the first molecule known to be bound by a CYP3A5 polypeptide to form a first complex of said polypeptide and said first molecule;
- (b) contacting said first complex with a compound to be screened, and
- (c) measuring whether said compound displaces said first molecule from said first complex.

Advantageously, in said method said measuring step comprises measuring the formation of a second complex of said protein and said inhibitor candidate. Preferably, said measuring step comprises measuring the amount of said first molecule that is not bound to said protein.

In a particularly preferred embodiment of the above-described method of said first molecule is a agonist or antagonist or a substrate and/or a inhibitor and/or a modulator of the polypeptide of the invention, e.g., with a radioactive or fluorescent label.

In a still another embodiment the present invention relates to a method of identifying and obtaining an inhibitor capable of modulating the activity of a molecular variant of a CYP3A5 polypeptide comprising the steps of:

- (a) contacting the host cell or the cell obtained by the method of the invention, the protein or the solid support of the invention with the first molecule known to be bound by a CYP3A5 polypeptide to form a first complex of said protein and said first molecule;
- (b) contacting said first complex with a compound to be screened, and
- (c) measuring whether said compound displaces said first molecule from said first complex.

In a preferred embodiment of the method of the invention said measuring step comprises measuring the formation of a second complex of said protein and said compound.

In another preferred embodiment of the method of the invention said measuring step comprises measuring the amount of said first molecule that is not bound to said protein.

In a more preferred embodiment of the method of the invention said first molecule is labeled.

The invention furthermore relates to a method for the production of a pharmaceutical composition comprising the steps of the method as described supra; and the further step of formulating the compound identified and obtained or a derivative thereof in a pharmaceutically acceptable form.

The therapeutically useful compounds identified according to the methods of the invention can be formulated and administered to a patient as discussed above. For uses and therapeutic doses determined to be appropriate by one skilled in the art and for definitions of the term "pharmaceutical composition" see *infra*.

Furthermore, the present invention encompasses a method for the preparation of a pharmaceutical composition comprising the steps of the above-described methods; and formulating a drug or pro-drug in the form suitable for therapeutic application and preventing or ameliorating the disorder of the subject diagnosed in the method of the invention.

Drugs or pro-drugs after their *in vivo* administration are metabolized in order to be eliminated either by excretion or by metabolism to one or more active or inactive

metabolites (Meyer, J. Pharmacokinet. Biopharm. 24 (1996), 449-459). Thus, rather than using the actual compound or inhibitor identified and obtained in accordance with the methods of the present invention a corresponding formulation as a pro-drug can be used which is converted into its active in the patient. Precautionary measures that may be taken for the application of pro-drugs and drugs are described in the literature; see, for review, Ozama, J. Toxicol. Sci. 21 (1996), 323-329).

In a preferred embodiment of the method of the present invention said drug or prodrug is a derivative of a medicament as defined hereinafter.

The present invention also relates to a method of diagnosing a disorder related to the presence of a molecular variant of the CYP3A5 gene or susceptibility to such a disorder comprising determining the presence of a polynucleotide or the gene of the invention in a sample from a subject.

In accordance with this embodiment of the present invention, the method of testing the status of a disorder or susceptibility to such a disorder can be effected by using a polynucleotide gene or nucleic acid of the invention, e.g., in the form of a Southern or Northern blot or *in situ* analysis. Said nucleic acid sequence may hybridize to a coding region of either of the genes or to a non-coding region, e.g. intron. In the case that a complementary sequence is employed in the method of the invention, said nucleic acid molecule can again be used in Northern blots. Additionally, said testing can be done in conjunction with an actual blocking, e.g., of the transcription of the gene and thus is expected to have therapeutic relevance. Furthermore, a primer or oligonucleotide can also be used for hybridizing to one of the above mentioned CYP3A5 gene or corresponding mRNAs. The nucleic acids used for hybridization can, of course, be conveniently labeled by incorporating or attaching, e.g., a radioactive or other marker. Such markers are well known in the art. The labeling of said nucleic acid molecules can be effected by conventional methods.

Additionally, the presence or expression of variant CYP3A5 gene can be monitored by using a primer pair that specifically hybridizes to either of the corresponding nucleic acid sequences and by carrying out a PCR reaction according to standard procedures. Specific hybridization of the above mentioned probes or primers preferably occurs at stringent hybridization conditions. The term "stringent hybridization conditions" is well known in the art; see, for example, Sambrook et al., "Molecular Cloning, A Laboratory Manual" second

ed., CSH Press, Cold Spring Harbor, 1989; "Nucleic Acid Hybridisation, A Practical Approach", Hames and Higgins eds., IRL Press, Oxford, 1985. Furthermore, the mRNA, cRNA, cDNA or genomic DNA obtained from the subject may be sequenced to identify mutations which may be characteristic fingerprints of mutations in the polynucleotide or the gene of the invention. The present invention further comprises methods wherein such a fingerprint may be generated by RFLPs of DNA or RNA obtained from the subject, optionally the DNA or RNA may be amplified prior to analysis, the methods of which are well known in the art. RNA fingerprints may be performed by, for example, digesting an RNA sample obtained from the subject with a suitable RNA-Enzyme, for example RNase T₁, RNase T₂ or the like or a ribozyme and, for example, electrophoretically separating and detecting the RNA fragments as described above.

Further modifications of the above-mentioned embodiment of the invention can be easily devised by the person skilled in the art, without any undue experimentation from this disclosure; see, e.g., the examples. An additional embodiment of the present invention relates to a method wherein said determination is effected by employing an antibody of the invention or fragment thereof. The antibody used in the method of the invention may be labeled with detectable tags such as a histidine flags or a biotin molecule.

The invention relates to a method of diagnosing a disorder related to the presence of a molecular variant of a CYP3A5 gene or susceptibility to such a disorder comprising determining the presence of a polypeptide or the antibody of the invention in a sample from a subject.

In a preferred embodiment of the above described method said disorder is cancer or diseases including cardiovascular diseases, diabetes and AIDS.

In a preferred embodiment of the present invention, the above described method is comprising PCR, ligase chain reaction, restriction digestion, direct sequencing, nucleic acid amplification techniques, hybridization techniques or immunoassays.

Said techniques are very well known in the art.

Moreover, the invention relates to a method of detection of the polynucleotide or the gene of the invention in a sample comprising the steps of

- (a) contacting the solid support described supra with the sample under conditions allowing interaction of the polynucleotide or the gene of the invention with the immobilized targets on a solid support and;
- (b) determining the binding of said polynucleotide or said gene to said immobilized targets on a solid support.

The invention also relates to an in vitro method for diagnosing a disease comprising the steps of the method described supra, wherein binding of said polynucleotide or gene to said immobilized targets on said solid support is indicative for the presence or the absence of said disease or a prevalence for said disease.

The invention furthermore relates to a diagnostic composition comprising the polynucleotide, the gene, the vector, the polypeptide or the antibody of the invention.

In addition, the invention relates to a pharmaceutical composition comprising the polynucleotide, the gene, the vector, the polypeptide or the antibody of the invention.

These pharmaceutical compositions comprising, e.g., the antibody may conveniently be administered by any of the routes conventionally used for drug administration, for instance, orally, topically, parenterally or by inhalation. Acceptable salts comprise acetate, methylester, HCl, sulfate, chloride and the like. The compounds may be administered in conventional dosage forms prepared by combining the drugs with standard pharmaceutical carriers according to conventional procedures. These procedures may involve mixing, granulating and compressing or dissolving the ingredients as appropriate to the desired preparation. It will be appreciated that the form and character of the pharmaceutically acceptable character or diluent is dictated by the amount of active ingredient with which it is to be combined, the route of administration and other well-known variables. The carrier(s) must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof. The pharmaceutical carrier employed may be, for example, either a solid or liquid. Exemplary of solid carriers are lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid and the like. Exemplary of liquid carriers are phosphate buffered saline solution, syrup, oil such as peanut oil and olive oil, water, emulsions, various types of wetting agents, sterile solutions and the like. Similarly, the carrier or diluent may include time delay

material well known to the art, such as glyceryl mono-stearate or glyceryl distearate alone or with a wax.

The dosage regimen will be determined by the attending physician and other clinical factors; preferably in accordance with any one of the above described methods. As is well known in the medical arts, dosages for any one patient depends upon many factors, including the patient's size, body surface area, age, the particular compound to be administered, sex, time and route of administration, general health, and other drugs being administered concurrently. Progress can be monitored by periodic assessment.

Furthermore, the use of pharmaceutical compositions which comprise antisense-oligonucleotides which specifically hybridize to RNA encoding mutated versions of the polynucleotide or gene according to the invention or which comprise antibodies specifically recognizing a mutated polypeptide of the invention but not or not substantially the functional wild-type form is conceivable in cases in which the concentration of the mutated form in the cells should be reduced.

Thanks to the present invention the particular drug selection, dosage regimen and corresponding patients to be treated can be determined in accordance with the present invention. The dosing recommendations will be indicated in product labeling by allowing the prescriber to anticipate dose adjustments depending on the considered patient group, with information that avoids prescribing the wrong drug to the wrong patients at the wrong dose.

In another embodiment the present invention relates to the use of the polynucleotide, a polynucleotide comprising SEQ ID No: 104, a polynucleotide encoding a polypeptide comprising SEQ ID No: 145, the gene, the vector or the polypeptide of the invention, a polypeptide comprising SEQ ID No: 145 or the antibody of the invention for the preparation of a diagnostic composition for diagnosing a disease.

A gene encoding a functional and expressible polypeptide of the invention can be introduced into the cells which in turn produce the protein of interest. Gene therapy, which is based on introducing therapeutic genes into cells by *ex-vivo* or *in-vivo* techniques is one of the most important applications of gene transfer. Suitable vectors and methods for *in-vitro* or *in-vivo* gene therapy are described in the literature and are known to the person skilled in the art; see, e.g., Giordano, Nature Medicine 2 (1996), 534-539; Schaper, Circ. Res. 79 (1996), 911-919; Anderson, Science 256 (1992), 808-813; Isner, Lancet 348 (1996), 370-374; Muhlhauser, Circ. Res. 77 (1995), 1077-1086; Wang, Nature Medicine 2

(1996), 714-716; WO94/29469; WO 97/00957 or Schaper, Current Opinion in Biotechnology 7 (1996), 635-640, and references cited therein. The gene may be designed for direct introduction or for introduction via liposomes, or viral vectors (e.g. adenoviral, retroviral) into the cell. Preferably, said cell is a germ line cell, embryonic cell, or egg cell or derived therefrom, most preferably said cell is a stem cell. As is evident from the above, it is preferred that in the use of the invention the nucleic acid sequence is operatively linked to regulatory elements allowing for the expression and/or targeting of the polypeptides of the invention to specific cells. Suitable gene delivery systems that can be employed in accordance with the invention may include liposomes, receptor-mediated delivery systems, naked DNA, and viral vectors such as herpes viruses, retroviruses, adenoviruses, and adeno-associated viruses, among others. Delivery of nucleic acids to a specific site in the body for gene therapy may also be accomplished using a biolistic delivery system, such as that described by Williams (Proc. Natl. Acad. Sci. USA 88 (1991), 2726-2729). Standard methods for transfecting cells with recombinant DNA are well known to those skilled in the art of molecular biology, see, e.g., WO 94/29469; see also supra. Gene therapy may be carried out by directly administering the recombinant DNA molecule or vector of the invention to a patient or by transfecting cells with the polynucleotide or vector of the invention ex vivo and infusing the transfected cells into the patient.

A polynucleotide comprising SEQ ID No: 104 and a polypeptide comprising SEQ ID No: 145 have already been described in Jounaidi *et al.* (Jounaidi, Biochem Biophys Res Commun 221 (1996), 466-70). However, Jounaidi *et al.* have merely disclosed the respective amino acid and nucleotide sequences without making any suggestion towards the pharmaceutical and diagnostic value of said polynucleotide or polypeptide, in particular for those disorders and diseases referred to infra.

In a further embodiment the present invention relates to the use of the polynucleotide, a polynucleotide comprising SEQ ID No: 104, a polynucleotide encoding a polypeptide comprising SEQ ID No: 145, the gene, the vector, the polypeptide of the invention, a polypeptide comprising SEQ ID No.: 145 or the antibody of the invention for the preparation of a pharmaceutical composition for treating a disease.

In another embodiment the present invention encompasses the use of a polynucleotide selected from the group consisting of:

- (a) a polynucleotide having the nucleic acid sequence of SEQ ID NO: 082, 088, 104, 112, 126, 131, or 140;

- (b) a polynucleotide encoding a polypeptide having the amino acid sequence of SEQ ID No: 127, 132, 141 or 145;
- (c) a polynucleotide capable of hybridizing to a CYP3A5 gene, wherein said polynucleotide is having at least one additional nucleotide at a position corresponding to position 3709/3710 or 27131/27132 of the CYP3A5 gene (Accession No: AF280107.1, wherein position 166220 has been numbered +1 and position 174832 has been numbered +8613, and Accession No: AC005020.2, wherein position 27341 has been numbered +8614) or a nucleotide exchange at a position corresponding to position 7303 or 27289 of the CYP3A5 gene (Accession No: AF280107.1, wherein position 166220 has been numbered +1 and position 174832 has been numbered +8613, and Accession No: AC005020.2, wherein position 27341 has been numbered +8614);
- (d) a polynucleotide capable of hybridizing to a CYP3A5 gene, wherein said polynucleotide is having an additional G nucleotide at a position corresponding to position 3709/3710 of the CYP3A5 gene (Accession No: AF280107.1, wherein position 166220 has been numbered +1 and position 174832 has been numbered +8613, and Accession No: AC005020.2, wherein position 27341 has been numbered +8614), an additional T nucleotide at a position corresponding to position 27131/27132 of the CYP3A5 gene (Accession No: AF280107.1, wherein position 166220 has been numbered +1 and position 174832 has been numbered +8613, and Accession No: AC005020.2, wherein position 27341 has been numbered +8614), or an A at a position corresponding to position 7303 or 27289 of the CYP3A5 gene (Accession No: AF280107.1, wherein position 166220 has been numbered +1 and position 174832 has been numbered +8613, and Accession No: AC005020.2, wherein position 27341 has been numbered +8614);

for the preparation of a diagnostic composition for diagnosing a disease in a subject having a genome comprising a variant allele of the CYP3A5 gene, wherein said allele is having an A at a position corresponding to position 6986 of the CYP3A5 gene (Accession No: AF280107.1, wherein position 166220 has been numbered +1 and position 174832 has been numbered +8613, and Accession No: AC005020.2, wherein position 27341 has been numbered +8614).

The definitions of the terms referred to in this specification apply *mutatis mutandis* to the aforementioned use.

The term "subject" *inter alia* refers to animals. Preferably, said animals belong to the animal species referred to above. Moreover, the term "subject" encompasses humans. The humans in accordance with the use of the present invention are selected from all existing ethnical groups and subgroups, e.g. Caucasians, African Americans or Asians. However, particular well suited for the use of the invention are African Americans for which it could be demonstrated that diagnosing a disease or a prevalence for a disease based on monitoring the presence or absence of an CYP3A5 allele having at a position corresponding to position 6986 of the CYP3A5 gene (Accession No: AF280107.1, wherein position 166220 has been numbered +1 and position 174832 has been numbered +8613, and Accession No: AC005020.2, wherein position 27341 has been numbered +8614) an A results in a false positive prediction for CYP3A5 expression in a considerable number of subjects. This allele of CYP3A5 has been described in detail in Kuehl, 2001, *Nature Genetics* 27: 383-391 as CYP3A5*1 allele. The CYP3A5*1 allele is characterized by the presence of an A at position 22893 of the CYP3A5 nucleic acid sequence referred to in Kuehl, *loc.cit.* The allelic frequency of said allele is particularly high in African Americans although it is also present in other ethnical groups or subgroups. However, it was found in accordance with the present invention that the CYP3A5 expression of subjects for which a false positive result was obtained in diagnostic studies based on the CYP3A5*1 allele could be correctly predicted by further diagnosing the presence or absence of a polynucleotide as defined under (a) to (d) in accordance with the use of the present invention. For example, a polynucleotide having an additional nucleotide at a position corresponding to position 27131/27132 of the CYP3A5 gene as defined *supra* has been found in accordance with this invention to be present in approximately 10% of the African Americans resulting in a frameshift mutation in exon 11. The present invention provides means and methods to distinguish between the haplotype resulting in improved expression of CYP3A5 comprising the polymorphism(s) of the CYP3A5*1 allele and the haplotype resulting in decreased expression, wherein said haplotype as set forth above comprises in addition to the polymorphism(s) of the CYP3A5*1 allele co-segregating polymorphisms comprised by a polynucleotide referred to under (a) to (d) *supra*. Thus, based on the aforementioned use of the present invention a reliable diagnosis of the CYP3A5 activity of a subject is achieved.

The invention also relates to the use of a polynucleotide comprising a polynucleotide having an A at a position corresponding to position 14690 of the CYP3A5 gene (Accession No: AF280107.1, wherein position 166220 has been numbered +1 and position 174832 has been numbered +8613, and Accession No: AC005020.2, wherein position 27341 has been numbered +8614) for the preparation of a diagnostic composition for diagnosing a disease in a subject having a genome comprising a variant allele of the CYP3A5 gene, wherein said allele is having an A at a position corresponding to position 6986 of the CYP3A5 gene (Accession No: AF280107.1, wherein position 166220 has been numbered +1 and position 174832 has been numbered +8613, and Accession No: AC005020.2, wherein position 27341 has been numbered +8614).

The definitions of the terms referred to in this specification apply mutatis mutandis to the aforementioned use.

In accordance with the present invention it could also be shown that the polymorphism(s) constituting the CYP3A5*1 and the CYP3A5*6 allele as described in Kuehl, loc.cit., co-segregate in a considerable number of subjects and thereby constitute another haplotype resulting in decreased CYP3A5 expression. It has been shown that the CYP3A5*6 allele results in inappropriate splicing of exon 7 of CYP3A5, a frameshift and a premature termination at position 184 of the CYP3A5 protein. Consequently, false positive result as regards the expression level of CYP3A5 in a subject can be obtained in diagnostic studies based on the CYP3A5*1 allele. Said false positive results, however, can be avoided according to the use of this invention by further diagnosing the presence or absence of the polymorphism(s) of the CYP3A5*6 allele. Thus, based on the aforementioned use of the present invention a reliable diagnosis of the CYP3A5 activity of a subject is achieved.

In light with the foregoing, in a preferred embodiment of the aforementioned use said subject is an African American.

As has been discussed above, the number of subjects which are diagnosed false positive is due to the high allelic frequency of CYP3A5 alleles such as those comprising a polynucleotide as defined under (a) to (d) above resulting in a frame shift mutation or those comprised by the CYP3A5*6 allele. Said allelic frequency is particularly high within the group of African Americans. In accordance with the present invention it has been found that the CYP3A5*6 allele is present in about 13.3% of the African Americans. Thus within this ethnic group the problems emerging from a wrong prediction of CYP3A5 expression are more severe than for other ethnical groups.

In a more preferred embodiment of the use of the present invention said disease is cancer or diseases including cardiovascular diseases, diabetes and AIDS.

Finally, the present invention relates to a diagnostic kit for detection of a polymorphism comprising the polynucleotide, the gene, the vector, the polypeptide, the antibody, the host cell, the transgenic non-human animal or the solid support of the invention.

The kit of the invention may contain further ingredients such as selection markers and components for selective media suitable for the generation of transgenic cells and animals. The kit of the invention can be used for carrying out a method of the invention and could be, inter alia, employed in a variety of applications, e.g., in the diagnostic field or as research tool. The parts of the kit of the invention can be packaged individually in vials or in combination in suitable containers or multicontainer units. Manufacture of the kit follows preferably standard procedures which are known to the person skilled in the art. The kit may be used for methods for detecting expression of a mutant form of the polypeptides, genes or polynucleotides in accordance with any one of the above-described methods of the invention, employing, for example, immunoassay techniques such as radioimmunoassay or enzymeimmunoassay or preferably nucleic acid hybridization and/or amplification techniques such as those described herein before and in the Examples as well as pharmacokinetic studies when using non-human transgenic animals of the invention.

The figures illustrate the invention.

Figure 1: **A.** Western blot analysis of CYP3A5 protein expression in microsomes prepared from 6 LE (low expressing) and 6 HE (high expressing) Caucasian livers. **B.** The relative contributions of CYP3A5 and CYP3A4 to the combined CYP3A5/CYP3A4 protein pool in 17 HE livers as determined by Western blot.

Figure 2: Expression levels and the allelic source of *CYP3A5* transcripts in LE and HE Caucasian livers. **A.** TaqMan analysis of *CYP3A5* mRNA in 8 LE (low expressing, white bars) and 8 HE (high expressing, grey bars) liver samples. **B.** Sequences of a portion of the 3'-UTR of *CYP3A5* in samples heterozygous for variant ch-v-015 (Table 2A). Templates used for PCR were genomic DNA (left panel), cDNA from a LE liver (middle panel) and cDNA from an HE liver (right panel).

Figure 3: Allelic frequencies of *CYP3A5* genetic variants in Caucasians. **A.** in DNA samples derived from 8-168 LE individuals **B.** in DNA samples derived from 7-18 HE individuals. The bars at the bottom of the figure indicate schematically the localisation of the pseudoexons *PS2* exon 1 and 2 and exons 1 – 13 of the *CYP3A5* gene. The arrowhead marks the duplication boundary (Gellner, Pharmacogenetics 11 (2001), 111 - 121).

Figure 4: Genomic and peptide sequences: genomic DNA sequences containing the amplified regions in which polymorphisms were detected and polypeptide sequences with amino acid substitutions. Nucleotide sequences are listed in 5' - 3' orientation. Letters in lowercase indicate non-coding sequences, letters in uppercase indicate coding sequences. Primer regions are underlined. Variant sites are shown framed. Peptide sequences are shown in one letter code. || marks a site where a deletion has occurred. In Seq ID 198, the hybridizing site of the TaqMan® probe is shown in bold.

Figure 5: CYP3A5 cDNA insert region of the plasmid that was used as starting material for in vitro mutagenesis. Cloning sites are shown underlined. Modified 5' and 3' regions of the CYP3A5 cDNA are shown in lowercase letters. The 5' modification, a MALLLAVF amino acid sequence on protein level, has been introduced in order to increase expression in *E. coli* (Gillam, Arch Biochem Biophys 317 (1995), 374-84). The 3' modification, a His₆ tag on protein level, has been introduced in order to enhance subsequent purification. The unmodified part of the CYP3A5 insert was verified to be identical to the CYP3A5 cDNA corresponding to accession no. NM_000777.1 by sequencing, which is the underlying nucleotide sequence for NP_000768.1. Sites corresponding to ch-v-009 and ch-v-001 are shown framed.

The invention will now be described by reference to the following biological Examples which are merely illustrative and are not constructed as a limitation of the scope of the present invention.

Example 1: Isolation of genomic DNA from human blood, generation and purification of CYP3A5 gene fragments

Genomic DNA was isolated from blood or liver samples using Qiagen blood and tissue DNA isolation kits. Oligonucleotides used in the screen were designed based on the recently determined sequence and organisation of the human *CYP3A* locus (Gellner, Pharmacogenetics 11 (2001), 111 - 121). Primer sequences and PCR fragment lengths are given in Table 1A. Amplified fragments were processed through PCR purification columns (Qiagen) and sequenced on PE ABI 3700 DNA Analysers using the same primers as in PCR. The sequences were analysed for the presence of polymorphisms using the PHRED/PHRAP/POLYPHRED/CONSED software package (University of Washington, Seattle, WA, USA).

Total RNA was isolated from liver samples using the RNeasy kit (Qiagen) according to the manufacturers instructions except that an additional DNase I digestion was performed directly on the column. cDNA pools were generated from 1 µg of total RNA using random hexamer primers and Superscript reverse transcriptase (Life Technologies). The cDNA used for one TaqMan assay was derived from 40 ng total RNA. *CYP3A5* mRNA expression levels were quantified by real time quantitative PCR using the ABI 7700

Sequence Detection System (PE Biosystems). Oligonucleotides and probes were designed with the Primer Express (PE Biosystems) programme. Oligonucleotides used for the quantitative PCR were: forward 5'- TTG TTG GGA AAT GTT TTG TCC TAT C -3' (Seq ID: 237) and reverse 5'- ACA GGG AGT TGA CCT TCA TAC GTT -3' (Seq ID: 238). The TaqMan probe (5'- TCA GGG TCT CTG GAA ATT TGA CAC AGA GTG CTA-3'; Seq ID: 239) was labelled with the 5' reporter dye 6-carboxy-fluorescein (FAM) and the 3' quencher 6-carboxy-tetramethylrhodamin (TAMRA). The experiments were performed according to a standard protocol developed by PE Biosystems. The specificity of the assay for *CYP3A5* was determined using equal amounts of *CYP3A4*, *CYP3A5*, *CYP3A7* and *CYP3A43* cDNA species expressed *in vitro*. The specificity of the probe was 10^4 times higher for *CYP3A5* than for *CYP3A7* cDNA whereas *CYP3A4* and *CYP3A43* cDNAs were not detectable at all. The linear range of the *CYP3A5* assay was determined to be between 10 and 10^6 target molecules. *CYP3A5* expression levels were normalised using the expression of *18S* mRNA species determined with pre-developed TaqMan assays (PE Biosystems).

Example 2: Determination of genetic variations within the *CYP3A5* locus

Sequence diversity within the *CYP3A5* locus was determined by PCR amplification from genomic DNA (fragment size: 264 – 997 bp) and sequencing each PCR-product of 19 - 217 samples of Caucasian origin, 36 - 45 samples of African American origin, 34 - 47 samples of Chinese origin, 41 - 50 samples of Japanese origin, and 31 - 47 samples of Korean origin. The PCR-fragments encompass the entire protein-coding region of *CYP3A5*, a portion of the 3'-UTR, the entire 5'-UTR as well as 6203 bp sequence between the *CYP3A5* transcriptional start site and a L1_5'UTR_ORF repeat located upstream of the gene (Fig. 3). In addition, we genotyped two linked single nucleotide polymorphisms (SNPs, ch-v-020, ch-v-021, Table 2A-E) located in a sequence originally described as *CYP3A5* promoter that were recently reported to co-segregate with increased *CYP3A5* protein expression (Paulussen, Pharmacogenetics 10 (2000), 415-24). The results also indicate co-segregation of both variants. Using the recently determined sequence of the entire *CYP3A* locus (Gellner, Pharmacogenetics 11 (2001), 111 - 121), we place these variants approximately 20 kb upstream of the first exon of *CYP3A5*, in a sequence 5' adjacent to a *CYP3A* pseudogene (PS2 in Fig. 3). Furthermore, we additionally genotyped a single nucleotide polymorphism located in intron 3 of the *CYP3A5* gene (ch-v-048;

Kuehl, 2001, *Nature Genetics* 27: 383-391) by TaqMan® assay using the primers and probes listed in Table 1B. The analysis were performed on a Sequence Detection System (PE Biosystems).

A total of 29 variants including the two linked SNPs described by Paulussen *et al.* (Paulussen, *Pharmacogenetics* 10 (2000), 415-24) were detected in the screen of Caucasian samples and their allelic frequencies were estimated to be between 0.3 % and 11.9 % (Table 2A). 6 variants are located within the 6 kb sequence upstream of the transcriptional start site of *CYP3A5*. 14 variants are located in introns, or in the 5'-UTR or 3'-UTR, whereas 4 have been found in the protein-coding sequence. Among the latter ones, three variants result in amino acid substitutions and one in a premature termination of the *CYP3A5* protein (Table 2A). The g.7303C>A variant (ch-v-009, Table 2A) results in a S100Y amino acid exchange in exon 4. The g.3705C>T variant (ch-v-005) leads to a H30Y amino acid exchange in exon 2. Cloning and sequencing revealed a physical linkage of this variant to the g.3709-3710insG variant (ch-v-006). The latter variant results in a shift of the open reading frame leading to a truncation of the protein sequence at position 34 (K34.). The T398N variant (ch-v-001, Table 2A), originally described by Jounaidi (Jounaidi, *Biochem Biophys Res Commun* 221 (1996), 466-70), was found in 3 out of 80 individuals tested.

Neither of the four protein altering variants found in Caucasians have been found in the African-Americans, Chinese, Japanese or Korean samples (Table 2A-E). However, among others we have found 4 new variants in these samples that result in an altered *CYP3A5* amino acid sequence (ch-v-017, ch-v-043, ch-v-045, ch-v-068, Table 2B-E). The g.27131-27132insT (ch-v-017) variant in exon 11 (ch-v-017, Table 2B, 2D) has been found in 9 out of 45 African-American samples and in one out of 50 Japanese samples. The variant results in a shift of the open reading frame which leads to a truncation of the protein sequence at position 348 (D348.). Variants ch-v-043, ch-v-045 and ch-v-068 lead to amino acid exchanges.

Example 3: Identification of genetic determinants of *CYP3A5* protein expression

In the following, the frequencies of Caucasian *CYP3A5* gene variants have been analyzed as a function of *CYP3A5* protein expression. For this purpose, allelic frequencies of

variants shown in Table 2A were calculated separately for HE and LE livers (Fig. 3). The frequencies of 9 variants (ch-v-020, ch-v-021, ch-v-026, ch-v-034, ch-v-007, ch-v-008, ch-v-011, ch-v-014 and ch-v-015) were significantly increased in HE livers (all $\chi^2 > 13.3$, df = 1, $p < 0.01$, Bonferroni corrected). Except one, all tested HE livers (17/18, 94 %) were heterozygous for three variants (ch-v-021, ch-v-026 and ch-v-015). 16 of those samples were heterozygous for ch-v-020 as well. One HE sample could not be genotyped for this variant. In contrast, LE livers were either wildtype (155/168, 92.3 %), heterozygous for variants ch-v-021 and ch-v-26 (9/168, 5.4 %) or heterozygous for the variant ch-v-015 (4/168, 2.4 %) only. However, in LE livers all three variants never occurred simultaneously (Table 3). These results defined either of the three variants as a useful but imperfect marker of increased CYP3A5 expression. The variants ch-v-034, ch-v-008, ch-v-011 and ch-v-14 only occurred in a subset of the samples heterozygous for the above three variants (ch-v-021, ch-v-026 and ch-v-015).

The distribution of variants ch-v-021, ch-v-026 and ch-v-015 in the samples screened strongly suggest that they constitute a haplotype. In the following, the hypotheses whether these three variants recombine independently or not has been tested. Assuming their independent inheritance, the expected 3-loci-genotype frequencies for all combinations of variants and compared them with the observed frequencies have been calculated. The difference is highly significant ($\chi^2 = 93.6$; classes 'all wildtype', 'single variant hetero- or homozygous', 'two or three variants hetero- or homozygous'; df = 1; $p < 0.001$). There were more individuals with two or three of the variants than expected and less individuals with only one of the variants. This result suggests linkage among the three variants. The degree of linkage with the linkage disequilibrium parameter D for the three pairs of variants was estimated. Using maximum likelihood estimates for haplotype frequencies, D was calculated to be 0.041 for the variant pairs ch-v-021/ch-v-015 and ch-v-026/ch-v-015, which is 80 % of its theoretical maximum, and 0.065 for variants ch-v-021 and ch-v-026 which corresponds to 100 % of its theoretical maximum.

The probability that individuals showing the respective variant genotype are HE (positive predictive value) is estimated to be 65 % for variants ch-v-021 and ch-v-026, respectively, and 81 % for the ch-v-015 variant. For the combination of all three variants the positive predictive value is 100 % in our sample set. However, assuming that these variants need to be located in *cis* for increased protein expression, it is clear that there is some probability for individuals showing all three variants to be LE. The results show that at least the allele ch-v-021/ch-v-026 and the allele ch-v-015 actually exist (see genotype 2 and 3,

Table 3) and therefore the existence of a genotype with a combination of these two alleles has to be postulated. The maximum likelihood estimate for the frequency of these 3-fold heterozygotes having not all three variants in *cis* is 0.05 % of all samples screened or 0.61 % of samples hetero- or homozygote for all three variants. In other words, of 100 Caucasians screened statistically about 9 of them will be hetero- or homozygous for all three variants and about 0.05 of these will have not all three variants in *cis*. Therefore, it can be expected that the positive predictive power of the 3-variant genotype to be about 99.95 %. Of course, the same values would be achieved for a combination of only two variants, either ch-v-021/ch-v-015 or ch-v-26/ch-v-15.

In a single HE liver none of the above 9 variants that were found in the other 17 HE samples could be detected. A closer examination of variants found in this sample revealed a variant within intron 4 (ch-v-018) and one within intron 5 (ch-v-019), respectively. These variants were unique to this sample, since they were not found in any other of the samples screened. Neither were they found in any of the other ethnic groups screened. It remains to be shown whether these variants are themselves causative for transcriptional activation or whether they are linked to another, so far undetected variant.

Example 4: Determination of CYP3A5 protein expression

Protein expression of CYP3A4 and CYP3A5 in Caucasian liver samples was determined by Western blotting using CYP3A4- and CYP3A5-specific antibodies (Gentest). Liver microsomes were prepared as previously described (Zanger, Biochemistry 27 (1988), 5447-54). To obtain total protein homogenate, powdered liver tissue was homogenised in 0.1 M Tris-Cl pH 7.4, 1 mM EDTA, 1 mM Pefa Bloc SC, 1 µg/ml leupeptin, 1 µg/ml pepstatin with a Potter Elvehjem homogenisator (glass/Teflon) for 2 min at 1000 rpm. Homogenates were then sonified with a Bandelin Sonoplus HD 200 and stored at -80°C. For Western blotting, 12.5 µg microsomal protein homogenate or 40 µg total protein homogenate were separated in a 10 % SDS-polyacrylamide gel. Electrophoretic transfer onto PVDF membranes was carried out in a TankBlot Cell (BioRad) for 1.5 hours at constant voltage (100 V) and at 10 °C. Following the transfer, the membranes were incubated for 60 min in 5 % milk, TBS, 0.1 % Tween 20 to reduce the unspecific antibody binding. Incubations with either primary antibody (Gentest, dilution 1:500) were performed in 1 % milk, TBS, 0.1 % Tween 20 for 60 min, those with the secondary antibody (anti-

rabbit IgG-POD Fab-fragments, Dianova, dilution 1:10000 in the same solution for 30 min. CYP3A4 or CYP3A5 protein bands were detected with Supersignal Dura (Pierce) and a digital CCD-camera (LAS-1000, Fuji). Signal quantification was performed with AIDA (Raytest). Protein expression levels were calculated based on calibration curves obtained with microsomes expressing recombinant CYP3A4 and CYP3A5 proteins (Gentest).

Homogenates or microsomal fractions were prepared from 186 human livers and investigated by Western blotting using a CYP3A5-specific antibody. CYP3A5 protein was detected in all samples analysed and its expression showed a clear bimodality (Fig. 1A). 168 livers (~ 90 %), further referred to as LE (low-expressing), showed expression close to or below the lower limit of quantification (LLOQ) of the assay (0.3 pmol/mg homogenate protein and 1.0 pmol/mg microsomal protein). Eighteen samples (~ 10 %), further referred to as HE (high-expressing), exhibited much higher CYP3A5 expression levels. The expression was in the range between 1.6 and 2.9 pmol/mg homogenate protein (2.3 ± 0.5 ; $n = 6$) and between 3.9 and 15.5 pmol/mg microsomal protein (9.7 ± 4.1 ; $n = 12$). Taking the LLOQ of the assay as the expression level of CYP3A5 in LE livers, HE livers express on average 8 to 10 times more CYP3A5 protein than LE livers.

In the following, the contribution of CYP3A5 to the combined CYP3A5 and CYP3A4 protein expression in HE livers was investigated. CYP3A4 expression in these livers was between 0.9 and 82.6 pmol/mg homogenate protein ($n = 6$) and between 4.5 and 295 pmol/mg microsomal protein ($n = 11$). The levels and the range of CYP3A4 variability in HE livers were similar to those in LE livers (not shown). Fig. 1B shows the share of CYP3A5 in the combined CYP3A5 and CYP3A4 protein pool in 17 HE livers. CYP3A5 contribution varies between 3 % and 74 %. In an average HE liver, the share of CYP3A5 in the combined pool of both proteins is 24 %. Taking the LLOQ of the CYP3A5 assay as the actual expression level of the protein in LE livers, the corresponding value in these livers is approximately 1.6 %.

Example 5: Determination of CYP3A5 mRNA expression

The expression of *CYP3A5* mRNA in 8 Caucasian HE and 8 LE livers was investigated using a CYP3A5-specific TaqMan probe. As illustrated in Fig. 2A, the distribution of *CYP3A5* mRNA levels exhibited a bimodality which was in complete agreement with that

observed in the expression of CYP3A5 protein (Fisher's exact test, $p = < 0.001$). The number of 3A5 transcripts per ng of total RNA in HE livers ($n = 8$) was on average 8.5 times higher than those in LE livers ($n = 8$).

In the following, the allelic origin of *CYP3A5* transcripts in HE and LE livers was investigated. To this end, by PCR a portion of the 3'-UTR (untranslated region) of the gene was amplified and sequenced using genomic or cDNA samples as templates which were heterozygous for a T>C variant located in this region (variant ch-v-015 in Table 2A;). As expected, both alleles are represented in the sequence using genomic DNAs as template (Fig. 2B). Both alleles were also equally represented in a sequence of PCR-amplified cDNA from a LE (homozygous wildtype for ch-v-021 and ch-v-26, heterozygous for ch-v-015) liver. In contrast, only the C allele was found in the same portion of *CYP3A5* 3'-UTR cDNA from a HE liver. This indicates an overrepresentation of transcripts derived from the chromosome harbouring the C allele in the total pool of *CYP3A5* transcripts in HE livers.

Example 6: In vitro mutagenesis and expression of recombinant CYP3A5 proteins

Five polymorphisms in Caucasians have been detected that lead to changes in the protein sequence. Two of them, ch-v-006 and ch-v-017, lead to a truncation of the protein and therefore are unlikely to code for a functional protein. As ch-v-005 has only been found physically linked to ch-v-006, the resulting protein variant is not likely to be functional as well. To determine the effect of the protein variants ch-v-009 and ch-v-001 these variants were analysed in a heterologous bacterial expression system.

A modified *CYP3A5* cDNA in the prokaryotic expression vector pKK233-2 (Pharmacia) was used as starting material for in vitro mutagenesis (Fig. 5). Variants ch-v-009 and ch-v-001, respectively, were introduced into the plasmid by in vitro mutagenesis using the QuikChange mutagenesis kit (Stratagene). The successful introduction of the mutations and the absence of other, undesired mutations was confirmed by sequencing. The original plasmid as well as the two mutagenised plasmids were used to transform *E. coli* TOPP3 cells, a strain in which optimal expression of CYP3A proteins has previously been obtained. A total of 8 separate colonies of each mutant plasmid were chosen for expression studies. The bacteria were grown and induced as described in Eiselt *et al.* (Eiselt, Pharmacogenetics 11 (2001), 447-58.). Expression was analysed 48 h and 72 h after induction with IPTG/ δ -ALA. Cells were harvested as described in Domanski *et al.*

(Domanski, Arch Biochem Biophys 350 (1998), 223-32). The final P450 content was measured by reduced carbon monoxide (CO) difference spectra (Omura, J. Biol. Chem. 239 (1964), 2370-2378).

Whereas 30 to 50 nmol solubilised CYP3A5 could be recovered per litre culture of the non-mutagenised CYP3A5, expression in the two CYP3A5 variants S100Y and T398N was determined to be lower than 3 nmol P450 protein per litre culture. In many instances, the "P450" peak was shifted to 454 - 458 nm rather than the typical 448 - 450 nm peak expected. The low level of expression in mutagenised colonies made any attempts at protein purification futile. Previous experiments suggest that expression levels as low as those demonstrated by these CYP3A5 variants can not be significantly improved by utilising other bacterial strains or adjusting growth temperature. Therefore, the results strongly suggest that the CYP3A5 protein variants comprising the S100Y or the T398N substitutions are unstable in an *E. coli* expression system and that the variants comprising ch-v-009 or ch-v-001 may not code for functional proteins. The result of negative expression for variant ch-v-001 (T398N) is in agreement with the study in which this polymorphism was initially detected in two of five CYP3A5 deficient individuals (Jounaidi, Biochem Biophys Res Commun 221 (1996), 466-70).

Example 7: Prediction of expected drug metabolism by CYP3A5 genotypes

The CYP3A5 protein degrades many drugs by oxidation so that they are not therapeutically active anymore. Therefore, drugs that are CYP3A5 substrates might not reach therapeutically active plasma concentrations for an adequate time span in patients with enhanced CYP3A5 activity. In these patients these drugs have to be dosed higher. On the other side, in patients with reduced CYP3A5 activity, these drugs have to be administered at lower dosage in order to avoid toxic drug levels. Table 4 gives an assignment for CYP3A5 genotypes and recommended dosages.

In cases in which CYP3A5 metabolism leads to the formation of pharmacologically active substance, enhanced enzyme activity has to be counteracted by reduced dosage whereas reduced CYP3A5 activity has to be met by increased dosage.

Table 1A: Primers used to screen for polymorphisms within the *CYP3A5* upstream regions and the *CYP3A5* gene.

Ref.	Primer			Position (nt)	(bp)
	ID	Name	Sequence (5'-3')		
chzk	001	694	ACAGGCACAGAAACCCACAAG	145448-145468 ¹	630
	002	711	ATCGCCACTTGCCTTCTTC	146077-146059 ¹	
chzl	003	794	CCCTGCTTCGGCTTGTGCA	159915-159933 ¹	575
	004	750	CACAGCCTGCTTTATTTGTCATGA	160489-160466 ¹	
chzj	005	751	GATCCTTGGTAGGACAAGCCT	160351-160371 ¹	844
	006	754	CAAGCACTGATTGGTCACTTCCT	161194-161171 ¹	
chzb	007	819	GGGATGGGACCGTAAGTGGAAAC	160951-160972 ¹	618
	008	820	TAATCACATTGGAGTTCTGACAAATG	161568-161543 ¹	
chzi	009	736	AAAAACCTCTTACAAAAGTATCATCGGATA	161419-161448 ¹	910
	010	737	CCTACTAGGTCTCTGACTTGGAAACCAT	162328-162302 ¹	
chzh	011	784	GCCGAGACGCACCATTACACT	161876-161896 ¹	637
	012	785	CACCCATCCCTTCCCACTCAT	162512-162492 ¹	
chzg	013	740	TGATGGTTCCAAGTCAGAGACCTAGTAG	162300-162327 ¹	997
	014	741	AATGTAGACATCTTCTCTTAAGTTAATTCCAG	163296-163262 ¹	
chzf	015	786	TCTGCATGCCAACAGTGAACAATCT	163182-163206 ¹	824
	016	789	GGCACGCACCAGCATGTCC	164005-163987 ¹	
chze	017	790	CTGGCTGAGTGCCGTGGCT	163845-163863 ¹	591
	018	791	TGAGCGCTTCATGTATTCTGGCTAT	164435-164411 ¹	
chza	019	824	AAATATTTTCAAAGTCACACTCTGACAACAG	164376-164406 ¹	617
	020	822	TAACAGGATCTCATGCTTTTTCATGGCT	164992-164964 ¹	
chzd	021	747	CACTCCAATATTACAATAGCCACTATTCA	164843-164872 ¹	926
	022	748	ACTCCTACGTATCCTTCCAAGCCC	165768-165745 ¹	
chzc	023	728	GCTAAGGGAAACAGGCATAGAACTTAC	165586-165613 ¹	557
	024	729	GGAGCTTCCCTGCCCTGC	166142-166125 ¹	
chzy	025	323	TCCTTCTCCAGCACATAAATC	166076-166096 ¹	424
	026	325	AAATTAGAAGGTGGATGGGAG	166499-166479 ¹	
chzx	027	335	GAGTAACTCACCAGCCCTCTG	169838-169858 ¹	264
	028	336	AAACCTCAGAATCCCTCCCA	170101-170081 ¹	
chzw	029	338	GACATCTCTGAATAGCTTCCTTC	171392-171414 ¹	402
	030	341	GCACATAGTTTATAACGGCAA	171793-171773 ¹	
chzv	031	346	AGAACCTAAGGTTGCTGTGTGTC	173303-173325 ¹	394
	032	348	TGCAAGATGTTACCCTGGGC	173696-173676 ¹	
chzu	033	354	CGCCCCACATACACTCAGAA	31376-31395 ²	426
	034	357	AGACCATTTTATAGGAAGCTCG	31801-31781 ²	
chzt	035	379	CAAGGGGTAGTCCACTGAGTTC	31760-31781 ²	403
	036	381	CTCTTTGGAGTTGCAGCG	32162-32145 ²	
chzs	037	362	AGGTGAGTCTAACTCAGCTTG	33081-33101 ²	578
	038	365	GACAGCTAAAGTGTGTGAGGG	33658-33638 ²	
chzr	039	371	AATGGGTTCCAGTTGAGAATC	34411-34431 ²	470
	040	373	ATTGTTGTGCCTGATTTCAAG	34880-34860 ²	
chzq	041	387	AGAAGCCATAGGGAGGTTG	35627-35645 ²	423
	042	389	GACTGTCTCTCAAGCATTCT	36049-36030 ²	
chzp	043	394	GATGCCATGATGAGGAGTGTG	37724-37744 ²	626
	044	397	ACCAGGGCCAGCAATATTG	38349-38331 ²	
chzm	045	403	AAATACTTCACGAATACTATGATCA	45711-45735 ²	595
	046	405	CAGGGACATAATTGATTATCTTTG	46305-46282 ²	
chzo	047	411	TACTGGTTGGGAGGTGGAG	48290-48308 ²	456
	048	412	CATGATGTTCTTAATGCTACAGG	48745-48723 ²	
chzn	049	419	GAAGAGTTCAAGATACATGGTGTTA	50088-50112 ²	416
	050	420	TGCACAACACTCTACACAGACTC	50503-50481 ²	

Ref.: Reference sequence. The positions of primers refer to GenBank sequences with accession numbers (1) AF280107.1 and (2) AC005020.2.

Table 1B: Primers (Seq IDs 202 and 203) and probes (Seq IDs 204 and 205) used determine the nucleotide status at the polymorphic site ch-v-048 (g.6986G>A) by TaqMan assay.

Ref.	Primer			Position (nt)	(bp)
	ID	Name	Sequence (5'-3')		
chyu	202	TQPi_ch-v-048_F	GCTCTACTGTCATTTCTAACCATAATCTCTTTA	173152-173184	99
	204	TQPo_ch-v-048_AI1_G_VIC	VIC-TGTCTTTCAGTATCTCTT-MGB-DQ	173196-173213	
	205	TQPo_ch-v-048_AI2_A_FAM	FAM-TGTCTTTCATATCTCTTC-MGB-DQ	173196-173214	
	203	TQPi_ch-v-048_R	GCTTCATATGATGAAGGTAATGTGGT	173250-173224	

Ref.: Reference sequence. The positions of the primers refer to the GenBank sequence with accession number AF280107.1. Probes are labelled with a fluorescent dye at the 5' end and labelled with a dark quencher (DQ) and using a minor groove binder (MGB).

Table 2A: CYP3A5 polymorphisms detected in samples of Caucasian origin.

Variant ID	Reference sequence	Variant position on		Sequence context		Genetic element	Predicted effect	Caucasian	
		Reference sequence	gDNA	Seq ID	Reference seq. Variant seq.			N	Variant allele frequency (%)
ch-v-020	chzk	254T>G	g.-20619T>G	051 052	TGGGCTTGCAAG.....	5' of PS2		211	6.6
ch-v-031	chzk	318G>A	g.-20555G>A	053 054	GCATGGGTAAAA.....	5' of PS2		189	0.3
ch-v-032	chzk	544G>A	g.-20329G>A	055 056	GGGTGTGTGCA.....	5' of PS2		186	0.3
ch-v-033	chzk	550G>A	g.-20323G>A	057 058	TGTGCGATTCTA.....	5' of PS2		186	0.3
ch-v-021	chzk	582A>G	g.-20291A>G	059 060	GCCCCACCTCCG.....	5' of PS2		215	6.7
ch-v-026	chzi	229A>G	g.-6177A>G	061 062	CTCACACTGGGG.....	5' of Exon 1		208	7.0
ch-v-027	chzi	566G>A	g.-4336G>A	063 064	GAGACGCACCAA.....	5' of Exon 1		19	2.7
ch-v-028	chzh	601G>A	g.-3844G>A	065 066	TGTGTGTGGGAA.....	5' of Exon 1		20	10.0
ch-v-029	chzg	464T>C	g.-3557T>C	067 068	ATCCATGTATAC.....	5' of Exon 1		20	2.5
ch-v-034	chza	328T>C	g.-1617T>C	069 070	CATCTTACCCC.....	5' of Exon 1		93	2.2
ch-v-030	chzd	683T>A	g.-795T>A	071 072	TCTATTGCTATA.....	5' of Exon 1		20	5.0
ch-v-002	chzy	159G>A	g.-86G>A	073 074	GGCAGGGAAGCA.....	Exon 1 (5' UTR)		106	0.5
ch-v-003	chzy	171C>T	g.-74C>T	075 076	CCAGGCAACAT.....	Exon 1 (5' UTR)		106	4.3
ch-v-004	chzy	418-420delGAG	g.174-176delGAG	077 078	TCAAGGAGAAGT.....	Intron 1		106	0.5
ch-v-005	chzx	187C>T	g.3705C>T	079 080	GTACACATGGAT.....	Exon 2	H30Y	104	1.4
ch-v-006	chzx	191-192insG	g.3709-3710insG	081 082	CATGG-ACCTTG.....	Exon 2	(K34.) ¹	104	1.4
ch-v-007	chzw	143C>T	g.5215C>T	083 084	GATAGCAGGCCT.....	Intron 2		105	6.7

ch-v-048	chyu	206G>A		g.6986G>A	147A.....	Intron 3	splice defect	217	4.6
ch-v-008	chzv	199C>A		g.7182C>A	085	AGAAATCGGGCT	Intron 3		107	1.9
ch-v-009	chzv	320C>A		g.7303C>A	086A.....	Exon 4	S100Y	107	0.5
ch-v-018	chzv	441- 444insCTAAAAAAT		g.7424- 7427insCTAAAAAAT	087	TTATTCTGTCT	Intron 4		107	0.5
ch-v-016	chzt	145T>G		g.13077T>G	088A.....	Intron 5		105	0.5
ch-v-019	chzt	241T>C		g.13173T>C	089	C--AG-----G	Intron 5		105	0.5
ch-v-010	chzq	132-133insGTC		g.16931- 16932insGTC	090	CCTAAAAAATG	Intron 8		95	0.5
ch-v-011	chzq	384G>T		g.17163G>T	091	TCTTTTATCTT	Intron 9		95	3.2
ch-v-012	chzp	269G>A		g.19165G>A	092G.....	Intron 9		106	0.5
ch-v-013	chzm	167A>G		g.27050A>G	093	GAGTCTGCACA	Intron 10		80	11.9
ch-v-001	chzm	406C>A		g.27289C>A	094C.....	Exon 11	T398N	80	1.9
ch-v-014	chzm	643C>T		g.27526C>T	095	AGTC---AAGA	Intron 11		80	3.8
ch-v-015	chzn	351T>C		g.31611T>C	096GTC....	Exon 13 (3' UTR)		197	5.6

All variants were detected in the heterozygous state except for 1 homozygous individual for variant ch-v-013. ¹ variant results in a frame shift which ultimately leads to a premature termination.

Table 2B: CYP3A5 polymorphisms detected in samples of African-American origin.

Variant ID	Reference sequence	Variant position on		Sequence context		Genetic element	Predicted effect	N	Variant allele frequency (%)
		Reference sequence	gDNA	Seq ID	reference seq. variant seq.				
ch-v-037	chzk	230T>C	g.-20643T>C	148 149	TTTAATAGAAGC.....	5' of PS2		42	3.6
ch-v-020	chzk	254T>G	g.-20619T>G	051 052	TGGGCTTGCAAG.....	5' of PS2		41	69.5
ch-v-038	chzk	506C>T	g.-20367C>T	150 151	ATTCCCCCATAGT.....	5' of PS2		44	1.1
ch-v-039	chzk	514T>C	g.-20359T>C	152 153	TAGAAATATGAAC.....	5' of PS2		44	1.1
ch-v-021	chzk	582A>G	g.-20291A>G	059 060	GCCCCCACCTCCG.....	5' of PS2		45	66.7
ch-v-026	chzl	229A>G	g.-6177A>G	061 062	CTCACACTGGGG.....	5' of Exon 1		43	65.1
ch-v-051	chzh	455T>G	g.-3990T>G	154 155	GTAACCTTATCCG.....	5' of Exon 1		44	2.3
ch-v-052	chzh	577G>A	g.-3868G>A	156 157	TTCACGTGGAGA.....	5' of Exon 1		44	3.4
ch-v-028	chzh	601G>A	g.-3844G>A	065 066	TGTGTGTGGGAA.....	5' of Exon 1		44	17.1
ch-v-034	chyz	328T>C	g.-1617T>C	069 070	CATCTTACCCCC.....	5' of Exon 1		45	42.2
ch-v-002	chzy	159G>A	g.-86G>A	073 074	GGCAGGGAAGCA.....	Exon 1 (5' UTR)		45	1.1
ch-v-003	chzy	171C>T	g.-74C>T	075 076	CCAGGCAACAT.....	Exon 1 (5' UTR)		45	1.1
ch-v-007	chzw	143C>T	g.5215C>T	083 084	GATAGCAGGCCT.....	Intron 2		44	3.4
ch-v-053	chzw	163G>A	g.5235G>A	158 159	TGGACGCAACTA.....	Intron 2		45	2.2
ch-v-054	chzw	444T>A	g.5516T>A	160 161	GAGGATAATTAA.....	Intron 3		43	3.5
ch-v-048	chyu	206G>A	g.6986G>A	146 147	TTTCAGTATCTA.....	Intron 3		45	73.3

ch-v-025	chzv	224C>T		g.7207C>T	109 110	AGCTCCGTTGTT.....	Intron 3		43	7.0
ch-v-043	chzt	294T>C		g.13226T>C	162 163	CATCAATGCCC.....	Exon 6	1149T	45	1.1
ch-v-055	chzt	444G>A		g.13376G>A	164 165	CAGTCGCACTGA.....	Intron 6		45	1.1
ch-v-050	chzs	437G>A		g.14690G>A	166 167	ACTAAGAAGTTA.....	Exon 7	splice defect	45	13.3
ch-v-056	chzs	467A>G		g.14720A>G	168 169	GATCCATTATTG.....	Exon 7	P218P	45	6.7
ch-v-057	chzs	583C>T		g.14836C>T	170 171	CAATTCCAATTGT.....	Intron 7		45	1.1
ch-v-058	chzs	650A>G		g.14903A>G	172 173	TGTCAAATCTAGG.....	Intron 7		45	6.7
ch-v-059	chzr	205T>C		g.15788T>C	174 175	TTGTTTGTGTTTC.....	Intron 7		44	3.4
ch-v-060	chzr	496A>C		g.16079A>C	176 177	AAATAAAGAAGC.....	Intron 8		44	1.1
ch-v-011	chzq	364G>T		g.17163G>T	097 098	AGGAAGTATTCT.....	Intron 9		43	7.0
ch-v-062	chzp	173G>A		g.19069G>A	178 179	TTTGCCTCATCA.....	Intron 9		45	1.1
ch-v-063	chzp	312C>T		g.19208C>T	180 181	TTGACCTGATTT.....	Intron 9		45	2.2
ch-v-013	chzm	167A>G		g.27050A>G	101 102	CTTCAATAGTAG.....	Intron 10		36	1.4
ch-v-017	chzm	248-249insT		g.27131-27132insT	111 112	CACCT-ACCTAT.....	Exon 11	(D348.) ¹	45	10.0
ch-v-014	chzm	643C>T		g.27526C>T	105 106	CGAAACTACATT.....	Intron 11		42	11.9
ch-v-044	chzn	239T>C		g.31499T>C	182 183	TATTGTAGATCC.....	Intron 12		45	5.6
ch-v-015	chzn	351T>C		g.31611T>C	107 108	AAGGATTTCTAC.....	Exon 13 (3' UTR)		44	68.2

¹ variant results in a frame shift which ultimately leads to premature termination.

Table 2C: CYP3A5 polymorphisms detected in samples of Chinese origin.

Variant ID	Reference sequence	Variant position on		Sequence context		Genetic element	Predicted effect	N	Variant allele frequency (%)
		Reference sequence	gDNA	Seq ID	reference seq. variant seq.				
ch-v-020	chzk	254T>G	g.-20619T>G	051 052	TGGGCTTGCAAG.....	5' of PS2		42	23.8
ch-v-021	chzk	582A>G	g.-20291A>G	059 060	GCCCCACCTCCG.....	5' of PS2		45	26.7
ch-v-026	chzl	229A>G	g.-6177A>G	061 062	CTCACACTGGGG.....	5' of Exon 1		47	26.6
ch-v-034	chyz	328T>C	g.-1617T>C	069 070	CATCTTACCCCC.....	5' of Exon 1		47	21.3
ch-v-066	chzy	380T>C	g.136T>C	184 185	CCTTTTCCCTTC.....	Intron 1		45	1.1
ch-v-067	chzy	474G>A	g.230G>A	186 187	CTTATGCAGATA.....	Intron 1		44	1.14
ch-v-048	chyu	206G>A	g.6986G>A	146 147	TTTCAGTATCTA.....	Intron 3		47	26.6
ch-v-018	chzv	441- 444InsCTAAAAAAT	g.7424- 7427InsCTAAAAAAT	089 090	C--AG-----G CCTAAAAAATG	Intron 4		47	2.1
ch-v-068	chzu	359G>A	g.12907G>A	188 189	AATACGGTCATA.....	Exon 5	R130Q	45	3.3
ch-v-047	chzu	404T>C	g.12952T>C	190 191	GGAGGTATGAAC.....	Intron 5	splice defect	44	1.1
ch-v-069	chzu	480G>A	g.13028G>A	192 193	AGTCCGTTTCCA.....	Intron 5		44	1.1
ch-v-011	chzq	364G>T	g.17163G>T	097 098	AGGAAGTATTCT.....	Intron 9		40	21.3
ch-v-014	chzm	643C>T	g.27526C>T	105 106	CGAAACTACATT.....	Intron 11		47	5.3
ch-v-015	chzn	351T>C	g.31611T>C	107 108	AAGGATTTCTAC.....	Exon 13 (3' UTR)		47	26.6

Table 2D: CYP3A5 polymorphisms detected in samples of Japanese origin.

Variant ID	Reference sequence	Variant position on		Sequence context		Genetic element	Predicted effect	N	Variant allele frequency (%)
		Reference sequence	gDNA	Seq ID	reference seq. variant seq.				
ch-v-020	chzk	254T>G	g.-20619T>G	051 052	TGGGCTTGCAAG.....	5' of PS2		42	29.8
ch-v-021	chzk	582A>G	g.-20291A>G	059 060	GCCCCACCTCCG.....	5' of PS2		49	28.6
ch-v-026	chzl	229A>G	g.-6177A>G	061 062	CTCACACTGGGG.....	5' of Exon 1		46	28.3
ch-v-028	chzh	601G>A	g.-3844G>A	065 066	TGTGTGTGGGAA.....	5' of Exon 1		50	2.0
ch-v-034	chyz	328T>C	g.-1617T>C	069 070	CATCTTACCCCC.....	5' of Exon 1		50	26.0
ch-v-007	chzw	143C>T	g.5215C>T	083 084	GATAGCAGGCCT.....	Intron 2		48	3.1
ch-v-048	chyu	206G>A	g.6986G>A	146 147	TTTCAGTATCTA.....	Intron 3		50	29.0
ch-v-047	chzu	404T>C	g.12952T>C	190 191	GGAGGTATCAAC.....	Intron 5	splice defect	50	1.0
ch-v-061	chzq	194C>G	g.16993C>G	194 195	TCTGCCAAAGAG.....	Intron 8		49	1.0
ch-v-011	chzq	364G>T	g.17163G>T	097 098	AGGAAGTATTCT.....	Intron 9		49	26.5
ch-v-017	chzm	248-249insT	g.27131-27132insT	111 112	CACCT-ACCTAT.....	Exon 11	(D348.) ¹	48	1.0
ch-v-014	chzm	643C>T	g.27526C>T	105 106	CGAAACTACATT.....	Intron 11		49	3.1
ch-v-045	chzn	291T>C	g.31551T>C	196 197	ACCCATTGTTTCC.....	Exon 13	1488T	50	3.0
ch-v-015	chzn	351T>C	g.31611T>C	107 108	AAGGATTCTTAC.....	Exon 13 (3' UTR)		50	31.0

Table 2E: CYP3A5 polymorphisms detected in samples of Korean origin.

Variant ID	Reference sequence	Variant position on		Sequence context		Genetic element	Predicted effect	N	Variant allele frequency (%)
		Reference sequence	gDNA	Seq ID	reference seq. variant seq.				
ch-v-020	chzk	254T>G	g.-20619T>G	051 052	TGGGCTTGCAAG.....	5' of PS2		47	29.8
ch-v-065	chzk	563T>C	g.-20310T>C	198 199	GCTACTGGCTGC.....	5' of PS2		47	1.1
ch-v-021	chzk	582A>G	g.-20291A>G	059 060	GCCCCACCTCCG.....	5' of PS2		47	29.8
ch-v-040	chzl	206C>T	g.-6200C>T	200 201	GAAATCACCCGT.....	5' of Exon 1		43	1.2
ch-v-026	chzl	229A>G	g.-6177A>G	061 062	CTCACACTGGGG.....	5' of Exon 1		43	31.4
ch-v-034	chyz	328T>C	g.-1617T>C	069 070	CATCTTACCCCC.....	5' of Exon 1		47	27.7
ch-v-007	chzw	143C>T	g.-5215C>T	083 084	GATAGCAGGCCT.....	Intron 2		47	2.1
ch-v-048	chyu	206G>A	g.-6986G>A	146 147	TTTCAGTATCTA.....	Intron 3		47	29.8
ch-v-061	chzq	194C>G	g.-16993C>G	194 195	TCTGCCAAAGAG.....	Intron 8		47	2.1
ch-v-011	chzq	364G>T	g.-17163G>T	097 098	AGGAAGTATTCT.....	Intron 9		47	27.7
ch-v-014	chzm	643C>T	g.-27526C>T	105 106	CGAAACTACATT.....	Intron 11		47	2.1
ch-v-015	chzn	351T>C	g.-31611T>C	107 108	AAGGATTCTCAC.....	Exon 13 (3' UTR)		43	36.1

Table 2A-E: Variants are listed according to their localisation along the gene, separately for each ethnic group. Polymorphism nomenclature is based on Antiochakis *et al.* (Antiochakis, Hum Mutat 11 (1998), 1-3) using the joined sequences AF280107.1 and AC005020.2 as genomic reference sequences wherein the A of the ATG at position 166220 in AF280107.1 is +1. Sequence context: local alignment at the polymorphic site with the reference allele sequence given at the top and the variant sequence given below. Dots indicate nucleotide identity at the respective position. N: number of samples analysed.

Table 3: CYP3A5 genotypes and phenotypes.

	ch-v-021	ch-v-026	ch-v-015	Phenotype	Livers
Genotype 1	A/A	A/A	T/T	LE	155
Genotype 2	A/G	A/G	T/T	LE	9
Genotype 3	A/A	A/A	T/C	LE	4
Genotype 4	A/G	A/G	T/C	HE	17
Genotype 5	A/A	A/A	T/T	HE	1

All three variants were observed only in the heterozygous state. HE = high expressing livers, LE = low expressing livers. Numbers indicate LE and HE livers with each particular genotype. The increased CYP3A5 expression co-segregates with a distinct genotype.

Table 4: Expected drug metabolism by CYP3A5

Geno- type No.	Allelic combination	Enzyme Activity	Dose Adjustment	
			drug degradation	drug activation
I	high expressor allele/ high expressor allele	190 %	1.90	0.53
II, III	low expressor allele/ high expressor allele	100 %	1.00	1.00
IV - VII	null allele/ high expressor allele	95 %	0.95	1.05
VIII, IX, X	low expressor allele/ low expressor allele	10 %	0.10	10
XI - XVIII	null allele/ low expressor allele	5 %	0.05	20
XIX - XXV	null allele/ null allele	0 %	< 0.05	> 20
Geno- type No.	Genotype (SeqID) at Locus 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8	Enzyme Activity	Dose Adjustment	
			drug degradation	drug activation
I	060-062-079-081-087-111-103-108 / 060-062-079-081-087-111-103-108	190 %	1.90	0.53
II	0xx-06x-079-081-087-111-103-107 / 060-062-079-081-087-111-103-108	100 %	1.00	1.00
III	059-061-079-081-087-111-103-10x / 060-062-079-081-087-111-103-108	100 %	1.00	1.00
IV	0xx-06x-080-082-08x-11x-10x-10x / 060-062-079-081-087-111-103-108	95 %	0.95	1.05
V	0xx-06x-0xx-08x-088-11x-10x-10x / 060-062-079-081-087-111-103-108	95 %	0.95	1.05
VI	0xx-06x-0xx-08x-08x-112-10x-10x / 060-062-079-081-087-111-103-108	95 %	0.95	1.05
VII	0xx-06x-0xx-08x-08x-11x-104-10x / 060-062-079-081-087-111-103-108	95 %	0.95	1.05
VIII	060-062-079-081-087-111-103-107 / 059-061-079-081-087-111-103-108	10 %	0.10	10
IX	0xx-06x-079-081-087-111-103-107 / 0xx-06x-079-081-087-111-103-107	10 %	0.10	10
X	059-061-079-081-087-111-103-10x / 059-061-079-081-087-111-103-10x	10 %	0.10	10
XI	059-061-079-081-087-111-103-10x / 0xx-06x-080-082-08x-11x-10x-10x	5 %	0.05	20
XII	0xx-06x-079-081-087-111-103-107 / 0xx-06x-080-082-08x-11x-10x-10x	5 %	0.05	20
XIII	059-061-079-081-087-111-103-10x / 0xx-06x-0xx-08x-088-11x-10x-10x	5 %	0.05	20
XIV	0xx-06x-079-081-087-111-103-107 / 0xx-06x-0xx-08x-088-11x-10x-10x	5 %	0.05	20
XV	059-061-079-081-087-111-103-10x / 0xx-06x-0xx-08x-08x-112-10x-10x	5 %	0.05	20
XVI	0xx-06x-079-081-087-111-103-107 /	5 %	0.05	20

	0xx-06x-0xx-08x-08x-112-10x-10x			
XVII	059-061-079-081-087-111-103-10x / 0xx-06x-0xx-08x-08x-11x-104-10x	5 %	0.05	20
XVIII	0xx-06x-079-081-087-111-103-107 / 0xx-06x-0xx-08x-08x-11x-104-10x	5 %	0.05	20
XIX	0xx-06x-080-082-08x-11x-10x-10x / 0xx-06x-0xx-08x-088-11x-10x-10x	0 %	< 0.05	> 20
XX	0xx-06x-080-082-08x-11x-10x-10x / 0xx-06x-0xx-08x-08x-112-10x-10x	0 %	< 0.05	> 20
XXI	0xx-06x-080-082-08x-11x-10x-10x / 0xx-06x-0xx-08x-08x-11x-104-10x	0 %	< 0.05	> 20
XXII	0xx-06x-080-082-08x-11x-10x-10x / 0xx-06x-080-082-08x-11x-10x-10x	0 %	< 0.05	> 20
XXIII	0xx-06x-0xx-08x-088-11x-10x-10x / 0xx-06x-0xx-08x-088-11x-10x-10x	0 %	< 0.05	> 20
XXIV	0xx-06x-0xx-08x-08x-112-10x-10x / 0xx-06x-0xx-08x-08x-112-10x-10x	0 %	< 0.05	> 20
XXV	0xx-06x-0xx-08x-08x-11x-104-10x / 0xx-06x-0xx-08x-08x-11x-104-10x	0 %	< 0.05	> 20

No.: running genotype number.

Genotype: Possible CYP3A5 genotypes that result from combinations of alleles. At the top of the table concise allele names have been used to indicate the principle. The lower table lists the alleles in greater detail, giving all combinations of variants at 8 loci in the two homologous chromosomes (loci 1 -8 refer to positions corresponding to positions -20291, -6177, 3705, 3709/3710, 7303, 27131/27132, 27289 and 31611, respectively, of the CYP3A5 gene (Accession No: AF280107.1, wherein position 166220 has been numbered +1 and position 174832 has been numbered +8613), respectively. Each variant is defined by a 3-digit Seq ID as listed in Table 2A-E. A wildcard (x) in Seq IDs indicates that the phenotype is independent from the variant at this locus in this chromosome. The possible variants for each locus that can be substituted for x can be extracted from Table 2A-E. For example, 08x at locus 4 stands for Seq IDs 081 or 082, whereas 08x at locus 5 indicates either Seq ID 087 or 088.

Enzyme Activity: enzyme activity as calculated from protein concentration whereby the average protein concentration of genotype 059-061-079-081-111-107/060-062-079-081-111-108 was defined as 100 %.

Dose Adjustment: dose adjustment factors for drugs that are degraded/activated by CYP3A5 relative to the dosis required for genotype 059-061-079-081-111-107/060-062-079-081-111-108. Factors may need to be weighted according to the activity share of the CYP3A5 enzyme for drugs which are not exclusively metabolised by CYP3A5.

CLAIMS

1. A polynucleotide comprising a polynucleotide selected from the group consisting of:
 - (a) a polynucleotide having the nucleic acid sequence of SEQ ID NO: 54, 56, 58, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 106, 108, 110, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 128, 129, 130, 131, 133, 134, 135, 136, 137, 138, 139, 140, 142, 143, 149, 151, 153, 155, 157, 159, 161, 163, 165, 169, 171, 173, 175, 177, 179, 181, 183, 185, 187, 189, 193, 195, 197, 199, 201, 207, 208, 209, 210, 211, 212, 213, 214, 216, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 231, 232, 233, 235, or 236;
 - (b) a polynucleotide encoding a polypeptide having the amino acid sequence of SEQ ID NO: 127, 132, 141, 215, 229, or 234;
 - (c) a polynucleotide capable of hybridizing to a CYP3A5 gene, wherein said polynucleotide is having a nucleotide exchange, a nucleotide deletion of at least one nucleotide, or at least one additional nucleotide at a position corresponding to position -20643, -20555, -20359, -20367, -20329, -20323, -20310, -6200, -6177, -4336, -3990, -3868, -3844, -3557, -1617, -795, -86, -74, 136, 174 to 176, 230, 3705, 3709/3710, 5215, 5235, 5516, 7182, 7207, 7303, 7424/7427, 12907, 13028, 13077, 13173, 13226, 13376, 14720, 14836, 14903, 15788, 16079, 16931/16932, 16993, 17163, 19069, 19165, 19208, 27050, 27131/27132, 27526, 31499, 31551 or 31611;
 - (d) a polynucleotide capable of hybridizing to a CYP3A5 gene, wherein said polynucleotide is having an A at a position corresponding to position -20555, -20329, -20323, -4336, -3868, -3844, -795, -86, 230, 5235, 5516, 7182, 7303, 12907, 13028, 13376, 19069 or 19165 of the CYP3A5 gene (Accession No: AF280107.1, wherein position 166220 has been numbered +1 and position 174832 has been numbered +8613, and Accession No: AC005020.2, wherein position 27341 has been numbered +8614), a T at a position corresponding to position -20367, -6200, -74, 3705, 5215, 7207, 14836, 17163, 19208 or 27526 of

the CYP3A5 gene (Accession No: AF280107.1, wherein position 166220 has been numbered +1 and position 174832 has been numbered +8613, and Accession No: AC005020.2, wherein position 27341 has been numbered +8614), a G at a position corresponding to position -6177, -3990, 13077, 14720, 14903, 16993 or 27050 of the CYP3A5 gene (Accession No: AF280107.1, wherein position 166220 has been numbered +1 and position 174832 has been numbered +8613, and Accession No: AC005020.2, wherein position 27341 has been numbered +8614), a C at a position corresponding to position -20643, -20310, -3557, -1617, 136, 13173, 13226, 15788, 16079, 31499, 31551 or 31611 of the CYP3A5 gene (Accession No: AF280107.1, wherein position 166220 has been numbered +1 and position 174832 has been numbered +8613, and Accession No: AC005020.2, wherein position 27341 has been numbered +8614), nucleotide deletions at positions corresponding to positions 174 to 176 of the CYP3A5 gene (Accession No: AF280107.1, wherein position 166220 has been numbered +1 and position 174832 has been numbered +8613), an additional nucleotide at a position corresponding to position 3709/3710 or 27131/27132 of the CYP3A5 gene (Accession No: AF280107.1, wherein position 166220 has been numbered +1 and position 174832 has been numbered +8613, and Accession No: AC005020.2, wherein position 27341 has been numbered +8614), three additional nucleotides at a position corresponding to position 16931/16932 of the CYP3A5 gene (Accession No: AF280107.1, wherein position 166220 has been numbered +1 and position 174832 has been numbered +8613, and Accession No: AC005020.2, wherein position 27341 has been numbered +8614), or a deletion of two nucleotides and nine additional nucleotides inserted at a position corresponding to position 7424 to 7427 of the CYP3A5 gene (Accession No: AF280107.1, wherein position 166220 has been numbered +1 and position 174832 has been numbered +8613);

- (e) a polynucleotide encoding a CYP3A5 polypeptide or fragment thereof, wherein said polypeptide comprises an amino acid substitution at a position corresponding to position 30, 100, 130, 149 or 488 of the

CYP3A5 polypeptide (Accession No: NP_000768.1), or at least one amino acid exchange or a stop codon at a position corresponding to position 30 to 34 or 346 to 348 of the CYP3A5 polypeptide (Accession No: NP_000768.1); and

- (f) a polynucleotide encoding a CYP3A5 polypeptide or fragment thereof, wherein said polypeptide comprises amino acid substitutions of HGLFK to YGTF. (with the period meaning termination) at a position corresponding to position 30 to 34 of the CYP3A5 polypeptide (Accession No: NP_000768.1), an amino acid substitution of S to Y at a position corresponding to position 100 of the CYP3A5 polypeptide (Accession No: NP_000768.1), an amino acid substitution of R to Q at a position corresponding to position 130 of the CYP3A5 polypeptide (Accession No: NP_000768.1), an amino acid substitution of I to T at a position corresponding to position 149 of the CYP3A5 polypeptide (Accession No: NP_000768.1), an amino acid substitutions of TYD to YL. (with the period meaning termination) at position corresponding to position 346 to 348 of the CYP3A5 polypeptide (Accession No: NP_000768.1), or an amino acid substitution of I to T at a position corresponding to position 488 of the CYP3A5 polypeptide (Accession No: NP_000768.1).
- 2. A polynucleotide of claim 1, wherein said polynucleotide is associated with cancer or diseases including cardiovascular diseases, diabetes and AIDS.
 - 3. A polynucleotide of any one of claims 1 to 2 which is DNA or RNA.
 - 4. A gene comprising the polynucleotide of any one of claims 1 to 2.
 - 5. The gene of claim 4 wherein a nucleotide deletion, addition and/or substitution results in altered expression of the variant gene compared to the corresponding wild type gene.
 - 6. A vector comprising a polynucleotide of any one of claims 1 to 3 or the gene of claim 4 or 5.

7. The vector of claim 6, wherein the polynucleotide is operatively linked to expression control sequences allowing expression in prokaryotic or eukaryotic cells or isolated fractions thereof.
8. A host cell genetically engineered with the polynucleotide of any one of claims 1 to 3, the gene of claim 4 or 5 or the vector of claim 6 or 7.
9. A method for producing a molecular variant CYP3A5 polypeptide or fragment thereof comprising
 - (a) culturing the host cell of claim 8; and
 - (b) recovering said protein or fragment from the culture.
10. A method for producing cells capable of expressing a molecular variant CYP3A5 polypeptide comprising genetically engineering cells with the polynucleotide of any one of claims 1 to 3, the gene of claim 4 or 5 or the vector of claim 6 or 7.
11. A polypeptide or fragment thereof encoded by the polynucleotide of any one of claims 1 to 3, the gene of claim 4 or 5 or obtainable by the method of claim 9 or from cells produced by the method of claim 10.
12. An antibody which binds specifically to the polypeptide of claim 11.
13. The antibody of claim 12 which specifically recognizes an epitope containing one or more amino acid substitution(s) resulting from a nucleotide exchange as defined in claim 1 or 5.
14. The antibody of claim 12 or 13 which is monoclonal or polyclonal.
15. A transgenic non-human animal comprising at least one polynucleotide of any one of claims 1 to 4, the gene of claim 5 or 6 or the vector of claim 7 or 8.

16. The transgenic non-human animal of claim 15 which is a mouse, a rat or a zebrafish.
17. A solid support comprising one or a plurality of the polynucleotide of any one of claims 1 to 3, the gene of claim 4 or 5, the vector of claim 6 or 7, the polypeptide of claim 11, the antibody of claim 12 or 13 or the host cell of claim 8 in immobilized form.
18. The solid support of claim 17, wherein said solid support is a membrane, a glass-, polypropylene- or silicon-chip, are oligonucleotide conjugated beads or bead array, which is assembled on an optical filter substrate.
19. An in vitro method for identifying a polymorphism said method comprising the steps of:
 - (a) isolating a polynucleotide of any one claims 1 to 3 or the gene of claim 4 or 5 from a plurality of subgroups of individuals, wherein one subgroup has no prevalence for a CYP3A5 associated disease and at least one or more further subgroup(s) do have prevalence for a CYP3A5 associated disease; and
 - (b) identifying a polymorphism by comparing the nucleic acid sequence of said polynucleotide or said gene of said one subgroup having no prevalence for a CYP3A5 associated disease with said at least one or more further subgroup(s) having a prevalence CYP3A5 associated disease.
20. A method for identifying and obtaining a pro-drug or a drug capable of modulating the activity of a molecular variant of a CYP3A5 polypeptide comprising the steps of:
 - (a) contacting the polypeptide of claim 11, the solid support of claim 17 or 18, a cell expressing a molecular variant gene comprising a polynucleotide of any one of claims 1 to 3, the gene of claim 4 or 5 or the vector of claim 6 or 7 in the presence of components capable of providing a detectable signal in response to drug activity with a compound to be screened for pro-drug or drug activity; and

- (c) detecting the presence or absence of a signal or increase or decrease of a signal generated from the pro-drug or the drug activity, wherein the absence, presence, increase or decrease of the signal is indicative for a putative pro-drug or drug.
21. A method for identifying and obtaining an inhibitor of the activity of a molecular variant of a CYP3A5 polypeptide comprising the steps of:
- (d) contacting the protein of claim 11, the solid support of claim 17 or 18 or a cell expressing a molecular variant gene comprising a polynucleotide of any one of claims 1 to 3 or the gene of claim 4 or 5 or the vector of claim 6 or 7 in the presence of components capable of providing a detectable signal in response to drug activity with a compound to be screened for inhibiting activity; and
 - (e) detecting the presence or absence of a signal or increase or decrease of a signal generated from the inhibiting activity, wherein the absence or decrease of the signal is indicative for a putative inhibitor.
22. The method of claim 20 or 21, wherein said cell is a cell of claim 9, obtained by the method of claim 10 or can be obtained by the transgenic non-human animal of claim 15 or 16.
23. A method of identifying and obtaining a pro-drug or drug capable of modulating the activity of a molecular variant of a CYP3A5 polypeptide comprising the steps of:
- (a) contacting the host cell of claim 8, the cell obtained by the method of claim 10, the polypeptide of claim 11 or the solid support of claim 17 or 18 with the first molecule known to be bound by a CYP3A5 polypeptide to form a first complex of said polypeptide and said first molecule;
 - (b) contacting said first complex with a compound to be screened, and
 - (c) measuring whether said compound displaces said first molecule from said first complex.

24. A method of identifying and obtaining an inhibitor capable of the activity of a molecular variant of a CYP3A5 polypeptide or its gene product comprising the steps of:
- (a) contacting the host cell of claim 8, the cell obtained by the method of claim 10, the protein of claim 11 or the solid support of claim 17 or 18 with the first molecule known to be bound by a CYP3A5 polypeptide to form a first complex of said protein and said first molecule;
 - (b) contacting said first complex with a compound to be screened, and
 - (c) measuring whether said compound displaces said first molecule from said first complex.
25. The method of claim 23 or 24, wherein said measuring step comprises measuring the formation of a second complex of said protein and said compound.
26. The method of any one of claim 23 to 25, wherein said measuring step comprises measuring the amount of said first molecule that is not bound to said protein.
27. The method of any one of claims 23 to 26, wherein said first molecule is labeled.
28. A method for the production of a pharmaceutical composition comprising the steps of the method of any one of claims 20 to 27; and the further step of formulating the compound identified and obtained or a derivative thereof in a pharmaceutically acceptable form.
29. A method of diagnosing a disorder related to the presence of a molecular variant of a CYP3A5 gene or susceptibility to such a disorder comprising determining the presence of a polynucleotide of any one of claims 1 to 3 or the gene of claim 4 or 5 in a sample from a subject.
30. The method of claim 29 further comprising determining the presence of a polypeptide of claim 11 or the antibody of any one of claims 12 to 14.

31. A method of diagnosing a disorder related to the presence of a molecular variant of a CYP3A5 gene or susceptibility to such a disorder comprising determining the presence of a polypeptide of claim 11 or the antibody of any one of claims 12 to 14 in a sample from a subject.
32. The method of any one of claims 29 to 31, wherein said disorder is cancer or diseases including cardiovascular diseases, diabetes and AIDS.
33. The method of any one of claims 29 to 32 comprising PCR, ligase chain reaction, restriction digestion, direct sequencing, nucleic acid amplification techniques, hybridization techniques mass spectroscopy or immunoassays.
34. A method of detection of the polynucleotide of any one of claims 1 to 3 or the gene of claim 4 or 5 in a sample comprising the steps of
 - (a) contacting the solid support of claim 17 or 18 with the sample under conditions allowing interaction of the polynucleotide of claim 1 to 3 or the gene of claim 4 or 5 with the immobilized targets on a solid support and;
 - (b) determining the binding of said polynucleotide or said gene to said immobilized targets on a solid support.
35. An in vitro method for diagnosing a disease comprising the steps of the method of claim 34, wherein binding of said polynucleotide or gene to said immobilized targets on said solid support is indicative for the presence or the absence of said disease or a prevalence for said disease.
36. A diagnostic composition comprising the polynucleotide of any one of claims 1 to 4, the gene of claim 3 or 4, the vector of claim 6 or 7, the polypeptide of claim 11 or the antibody of claim 12 or 13.
37. A pharmaceutical composition comprising the polynucleotide of any one of claims 1 to 3, the gene of claim 4 or 5, the vector of claim 6 or 7, the polypeptide of claim 11 or the antibody of claim 12 or 13.

38. Use of the polynucleotide of any one of claims 1 to 3, a polynucleotide comprising SEQ ID No: 104, a polynucleotide encoding a polypeptide comprising SEQ ID No: 145, the gene of claim 4 or 5, the vector of claim 6 or 7, the polypeptide of claim 11, a polypeptide comprising SEQ ID No: 145 or the antibody of claim 12 or 13 for the preparation of a diagnostic composition for diagnosing a disease.
39. Use of the polynucleotide of any one of claims 1 to 3, a polynucleotide comprising SEQ ID No: 104, a polynucleotide encoding a polypeptide comprising SEQ ID No: 145, the gene of claim 4 or 5, the vector of claim 6 or 7, the polypeptide of claim 11, a polypeptide comprising SEQ ID No: 145 or the antibody of claim 12 or 13 for the preparation of a pharmaceutical composition for treating a disease.
40. Use of a polynucleotide selected from the group consisting of:
- (a) a polynucleotide having the nucleic acid sequence of SEQ ID NO: 82, 88, 104 or 112;
 - (b) a polynucleotide encoding a polypeptide having the amino acid sequence of SEQ ID No: 127, 132, 141 or 145;
 - (c) a polynucleotide capable of hybridizing to a CYP3A5 gene, wherein said polynucleotide is having at least one additional nucleotide at a position corresponding to position 3709/3710 or 27131/27132 of the CYP3A5 gene (Accession No: AF280107.1, wherein position 166220 has been numbered +1 and position 174832 has been numbered +8613, and Accession No: AC005020.2, wherein position 27341 has been numbered +8614) or a nucleotide exchange at a position corresponding to position 7303 or 27289 of the CYP3A5 gene (Accession No: AF280107.1, wherein position 166220 has been numbered +1 and position 174832 has been numbered +8613, and Accession No: AC005020.2, wherein position 27341 has been numbered +8614);
 - (d) a polynucleotide capable of hybridizing to a CYP3A5 gene, wherein said polynucleotide is having an additional G nucleotide at a position

corresponding to position 3709/3710 of the CYP3A5 gene (Accession No: AF280107.1, wherein position 166220 has been numbered +1 and position 174832 has been numbered +8613, and Accession No: AC005020.2, wherein position 27341 has been numbered +8614), an additional T nucleotide at a position corresponding to position 27131/27132 of the CYP3A5 gene (Accession No: AF280107.1, wherein position 166220 has been numbered +1 and position 174832 has been numbered +8613, and Accession No: AC005020.2, wherein position 27341 has been numbered +8614), or an A at a position corresponding to position 7303 or 27289 of the CYP3A5 gene (Accession No: AF280107.1, wherein position 166220 has been numbered +1 and position 174832 has been numbered +8613, and Accession No: AC005020.2, wherein position 27341 has been numbered +8614);

for the preparation of a diagnostic composition for diagnosing a disease in a subject having a genome comprising a variant allele of the CYP3A5 gene, wherein said allele is having an A at a position corresponding to position 6986 of the CYP3A5 gene (Accession No: AF280107.1, wherein position 166220 has been numbered +1 and position 174832 has been numbered +8613, and Accession No: AC005020.2, wherein position 27341 has been numbered +8614).

41. Use of a polynucleotide comprising a polynucleotide having an A at a position corresponding to position 14690 of the CYP3A5 gene (Accession No: AF280107.1, wherein position 166220 has been numbered +1 and position 174832 has been numbered +8613, and Accession No: AC005020.2, wherein position 27341 has been numbered +8614) for the preparation of a diagnostic composition for diagnosing a disease in a subject having a genome comprising a variant allele of the CYP3A5 gene, wherein said allele is having an A at a position corresponding to position 6986 of the CYP3A5 gene (Accession No: AF280107.1, wherein position 166220 has been numbered +1 and position 174832 has been numbered +8613, and Accession No: AC005020.2, wherein position 27341 has been numbered +8614).

42. The use of claim 40 or 41, wherein said subject is an African American.
43. The use of any one of claims 38 to 41, wherein said disease is cancer or diseases including cardiovascular diseases, diabetes and AIDS.
44. A diagnostic kit for detection of a single nucleotide polymorphism comprising the polynucleotide of any one of claims 1 to 3, the gene of claim 4 or 5, the vector of claim 6 or 7, the polypeptide of claim 11, the antibody of claim 12 or 13, the host cell of claim 8, the transgenic non-human animal of claim 15 or 16 or the solid support of claim 17 or 18.





Fig. 1

2/21
Figure 2





Figure 3



4/21

Figure 4

Seq ID: 113

>chzk_ch-v-020_254T>G_ch-v-021_582A>G

```

1  tggtcaccca ccatgtgtac agtaccctgc taggggccag ggtcatgaaa gtaaataata
61 ccagactgtg cccttgagga actcacctct gctaagggaa acaggcacag aaaccacaaa
121 gggtaggtaga gaggaatag gacaatagga ctgtgtgagg gggataggag gcaccagag
181 gaggaatgg ttacatctgt gtgaggaggt tggtaaggaa agactttaat agaaggggtc
241 tgtctggctg ggcttgcaag gatgtgtagg agtcatctag ggggcacaag tacactccag
301 gcagagggaa ttgcatgggt aaagatctgc agttgtggct tgtggggatg gatttcaagt
361 attctggaat gaagacagcc atggaaacaa gggcaggtga gaggatattt aagaggcttc
421 atgccaatgg ctccacttca gtttctgata agaactcagg ttccgtggac tccctgataa
481 aactgattaa gttgtttatg attccccata gaatatgaac tcaaaggagg taagcaaagg
541 ggtgtgtgcg attccttctg actggctgca gctgcagccc ccctccttc tccagcacat
601 aaacatttca gcagcttgac ctaagactgc tgtgcagggc agggatgctc caggcagaca
661 gccagcaaaa caacagcaca cagctgaaag taagactcag aggagacagt tgaagaaggc
721 aagtggcgat ggacctcatc ccaaatttgg cgggtgaaac ctggcttctc ctggctgtca
781 gcctgggtgct cctctatctg tcagtaactg tccagattcc tctcctctgt

```

Seq ID: 114

>chzk_ch-v-031_318G>A

```

1  tggtcaccca ccatgtgtac agtaccctgc taggggccag ggtcatgaaa gtaaataata
61 ccagactgtg cccttgagga actcacctct gctaagggaa acaggcacag aaaccacaaa
121 gggtaggtaga gaggaatag gacaatagga ctgtgtgagg gggataggag gcaccagag
181 gaggaatgg ttacatctgt gtgaggaggt tggtaaggaa agactttaat agaaggggtc
241 tgtctggctg ggcttgcaag gatgtgtagg agtcatctag ggggcacaag tacactccag
301 gcagagggaa ttgcatgagt aaagatctgc agttgtggct tgtggggatg gatttcaagt
361 attctggaat gaagacagcc atggaaacaa gggcaggtga gaggatattt aagaggcttc
421 atgccaatgg ctccacttca gtttctgata agaactcagg ttccgtggac tccctgataa
481 aactgattaa gttgtttatg attccccata gaatatgaac tcaaaggagg taagcaaagg
541 ggtgtgtgcg attccttctg actggctgca gctgcagccc cacctccttc tccagcacat
601 aaacatttca gcagcttgac ctaagactgc tgtgcagggc agggatgctc caggcagaca
661 gccagcaaaa caacagcaca cagctgaaag taagactcag aggagacagt tgaagaaggc
721 aagtggcgat ggacctcatc ccaaatttgg cgggtgaaac ctggcttctc ctggctgtca
781 gcctgggtgct cctctatctg tcagtaactg tccagattcc tctcctctgt

```

Seq ID: 115

>chzk_ch-v-032_544G>A

```

1  tggtcaccca ccatgtgtac agtaccctgc taggggccag ggtcatgaaa gtaaataata
61 ccagactgtg cccttgagga actcacctct gctaagggaa acaggcacag aaaccacaaa
121 gggtaggtaga gaggaatag gacaatagga ctgtgtgagg gggataggag gcaccagag
181 gaggaatgg ttacatctgt gtgaggaggt tggtaaggaa agactttaat agaaggggtc
241 tgtctggctg ggcttgcaag gatgtgtagg agtcatctag ggggcacaag tacactccag
301 gcagagggaa ttgcatgggt aaagatctgc agttgtggct tgtggggatg gatttcaagt
361 attctggaat gaagacagcc atggaaacaa gggcaggtga gaggatattt aagaggcttc
421 atgccaatgg ctccacttca gtttctgata agaactcagg ttccgtggac tccctgataa
481 aactgattaa gttgtttatg attccccata gaatatgaac tcaaaggagg taagcaaagg
541 ggtatgtgcg attccttctg actggctgca gctgcagccc cacctccttc tccagcacat
601 aaacatttca gcagcttgac ctaagactgc tgtgcagggc agggatgctc caggcagaca
661 gccagcaaaa caacagcaca cagctgaaag taagactcag aggagacagt tgaagaaggc
721 aagtggcgat ggacctcatc ccaaatttgg cgggtgaaac ctggcttctc ctggctgtca
781 gcctgggtgct cctctatctg tcagtaactg tccagattcc tctcctctgt

```

5/21

Figure 4 continued

Seq ID: 116

>chzk_ch-v-033_550G>A

```

1  tggtcaccca ccatgtgtac agtaccctgc taggggtccag ggtcatgaaa gtaaataata
61  ccagactgtg cccttgagga actcacctct gctaagggaa acaggcacag aaacccacaa
121 gggtggtaga gaggaatatag gacaatagga ctgtgtgagg gggataggag gcaccagag
181 gaggaaatgg ttacatctgt gtgaggaggt tggttaaggaa agactttaat agaaggggtc
241 tgtctggctg ggcttgcaag gatgtgtagg agtcatctag ggggcacaag tacactccag
301 gcagagggaa ttgcatgggt aaagatctgc agttgtggct tgtggggatg gatttcaagt
361 attctggaat gaagacagcc atggaaacaa gggcagggtga gaggatattt aagaggcttc
421 atgccaatgg ctccacttca gtttctgata agaactcagg ttccgtggac tccctgataa
481 aactgattaa gttgtttatg attccccata gaatatgaac tcaaaggagg taagcaaagg
541 gggtgtgtgc attctttgct actggctgca gctgcagccc cacctccttc tccagcacat
601 aaacatttca gcagcttgac ctaagactgc tgtgcagggc agggatgctc caggcagaca
661 gccagcaaaa caacagcaca cagctgaaag taagactcag aggagacagt tgaagaaggc
721 aagtggcgat ggacctcatc ccaaatttgg cggtggaaac ctggcttctc ctggctgtca
781 gcctggtgct cctctatctg tcagtaactg tccagattcc tctcctctgt

```

Seq ID: 117

>chzl_ch-v-026_229A>G

```

1  ggagtgcact gattttccag gtgctgtctg tcaccocctt ctttgactag gaaagggaaac
61  tccttgaccc ctgctgcttc tcaagtggag caatgcctcg ccctgcttcg gctgtgacac
121 agcacgctgc acccactgtc ctgcacccac tgtctggcac tccctagtga gatgaacccg
181 gtacctcaga tgaaaatgca gaaatcaccg gtcttctgtg tcaactcacg tgggagctgt
241 agaccggagc tgttccattt cggccatctt ggctccaccc cccgagtttt ggcttttaat
301 tgaaagtgtg ttgatgtggg aaggagataa tgccatgcat ttatgagcac atattagagg
361 gtctgagaca atgcatgtga taaaagggtc cctaagggaag aaaaaaagaa caagggaaga
421 cactggaaag aacgtgatgc tgggagtcct tgggccacca aagtctggag aaaagtggta
481 accacaaggg tcccagccta gtttcaactga agacctcgac actagggtgac ttatgggatac
541 cttggttagg caagccttga aaagttttac aatagcaaat gtggacgttg tcagaaccaa
601 atgatgtcac gtgtgtatct gtgtgtgtgt gtcagtgtgt gtgtttaaaa atcatgacaa
661 ataaagcagg ctgtgaagag gggattocca tgctcgtgtg cctgataaca caactatcac
721 aaacgccttt cgaaaccaca agtttgcaca aaggcaatcc caaccttaca caaaa

```

Seq ID: 118

>chzi_ch-v-027_566G>A

```

1  taatgaaat aagaattatt ttgatggctc taacagtgc atttatatca tctgttttat
61  ctggagcatt ctataataag tttatatata gcaaatcaat aaaaacctct tacaaaagta
121 tcatcggata ctttccctgaa cattaaggag aaatctatag aactgaatga atgagaacca
181 acaagtaaat atatgtgatac attgtaacca ttgttggtgt ggggcatttg tcagaactcc
241 aatgtgatta ttaacatagg tgagaattaa tccactgtga ctttgcccat tgcttagaaa
301 gaacattcat agtttaatta tgcctttttt gaccaagcac agtggctcat gcctgtaate
361 ccagcacttt gggaggccga ggtgggtgga tcacctgagg tcaggagttc gagaccagcc
421 tgaccaacat ggtgaaaccc catctctact aaaaatacaa aaattagcta ggtgtgggtg
481 tatgcaccta taatctcagc taccaggag gctgaggcag gagaatcact tgaacctgga
541 ggcagagggt gcagtgcagc gagacacacc attacactcc agcctgggtg acagagtgcg
601 attccatctc aaaaaaaaaa aaaaaaaatt atgccttttt gaagcacata cattttataa
661 catacaactg aatcccttat tatattatta gttttgattt aatgttttca aaccatctcc
721 cctgatatct ctgggagatg ggaacatgt tttcttacac ctcttgcatc ccattctcaa
781 ctcccaactg tcttactgca atgaacactt aataagaaac agtcaattgg tcaattgatt
841 gggcaacagg ctaaacacac tcatccttgc tctgttccca cttctttctt tactttccct
901 tcctgagtaa cttatcctaa agtcattagg tgggtggcag ccagatgggt gccacacatt
961 aaggtagaaa agagagtgtc atgatgggtc caagtcagag acctagtagg gtgaggatca
1021 agtaggtgtt cacgtggaga aacagcccgg cctgtgtgtg ggagtccaag caagcagaga
1081 aaatgtcgac acagaggggt ggcctgaaaa

```

6/21

Figure 4 continued

Seq ID: 119

>chzh_ch-v-028_601G>A

```

1  caaaaatttag ctaggtgtgg tggtagtcac ctataatctc agctaccag gaggtgagg
61  caggagaatc acttgaacct ggaggcagag gttgcagtga gccgagacgc accattacac
121 tccagcctgg gtgacagagt gagattccat ctcaaaaaaa aaaaaaaaaa attatgcctt
181 tttgaagcac atacatttta taacatacaa ctgaatccct tattatatta ttagttttga
241 tttaatgttt tcaaacatc tccctgata tttctgggag atgggaaaca tgttttctta
301 cacctcttgc attccattct caactcccaa ctgtcttact gcaatgaaca cttaataaga
361 aacagtcaat tgggtcaattg attgggcaac aggctaaaca cactcattcc ttgtctgttc
421 ccacttcttt ctttactttc ccttcctgag taacttatcc taaagtcat aggtgggtgg
481 cagccagatg gtggccacac attaaggtag aaaagagagt gtcatgatgg ttccaagtca
541 gagacctagt aggggtgagga tcaagtaggt gttcacgtgg agaaacagcc cggcctgtgt
601 atggggatgcc aagcaagcag agaaaatgtc gacacagagg ggtggcctga aaaagcagcc
661 agagcctaaa cagggcatgg agaacatatt tagggcatga ggtgaggagg gcataatga
721 gtgggaaggg atgggtgagg tttcactaca taaaggggat tgatgaaata agtaataaaa
781 gtatactgga agccaggtgt gtcacttttg cagaaaagag tcatggattc agaaagg

```

Seq ID: 120

>chzg_ch-v-029_464T>C

```

1  ttctttcttt actttccctt cctgagtaac ttatcctaaa gtcattaggt ggggtggcagc
61  cagatggtgg ccacacatta aggtagaaaa gagagtgtca tgatggttcc aagtcagaga
121 cctagtaggg tgaggatcaa gtaggtgttc acgtggagaa acagcccgcc ctgtgtgtgg
181 gagtccaagc aagcagagaa aatgtcgaca cagaggggtg gcctgaaaaa gcagccagag
241 cctaaacagg gcatggagaa catatttagg gcatgaggtg aggagggcat ccatgagtgg
301 gaaggatgg gtgaggtttc actacataaa ggggattgat gaaataagta aataaagtat
361 actggaagcc aggtgtgtca cttttgcaga aaagagtcac ggattcagaa agggagaaaa
421 ctagcaggaa tcctatgaaa ttagattaaa atggatgtat ccaggtatat tcataccctt
481 ctagatagat aaatggtttag ataggtgata aaaagataac aagaggacaa gataattaga
541 tagacataaa tgtatgtatg tgtttgtgtg tgtgtacaaa aaaacatata ctccctactt
601 ctctccactg atagggctag gtaacaatgg catttcaata gcaatgagca cacttagtgg
661 ccagatcttg gcttattaat accattttcc actgaaagga accagagctt tttagagaaa
721 tggctgattc cagggccagg attaagaatg ttcaagataa gcctaggata cathttgtgc
781 caggaagcaa gaagatgttc aaatgatttc caagtaatgt ttggaaatga tatttgaaaa
841 tgatttccaa atgatatttc caaatgattt ccaaatgata tatggaaaca cttaaagact
901 ccactaaaga actatttagat ctgataaaca aattcagtaa tgttgctgga tacaaaatca
961 acatacaaaa accagtagca tttctgcatg ccaacagtga acaatctggc aaaaataaaa
1021 aatgtaatcc catttacaat aaccccaaat aaaactaaat acctgggaat taacttaaga
1081 gaaagatgtc tacaattaat attgtaaaac actgatgaag gaaattgaag aagacacaaa
1141 aaagaaggat attccatgtt tatatatgtt aagcattaat attgttaaaa atgtcca

```

Seq ID: 121

>chza_ch-v-034_328T>C

```

1  caaagcaaaa atggacaaat ggatcagatc aagttaaaaa gcttctgtac cacaaagaaa
61  gcaatcaaca aagtgaagac acaaacacac gaatgggaga aaatattttc aaagtcacac
121 tctgacaaca gattaatagc cagaatacat gaagcgctca aacaactctg taaggaaaaa
181 tctaataatc caatcaaaaa atgggcaaaa tttgaataga catttttcaa agaagacat
241 acaaatgcc cataggcata tgataaggtg ctcaacatca ctggtcatta gagaaatgca
301 aatcaaaaac acaatgagat atcatctgac cccagctaaa atgggtttta tccaaaagac
361 aggcaacaac aaatgccagc gagaatgtgg agaaaaggga accctgttac actgttgggtg
421 taaattagtg caaccactat agagaacaat ttggaggttc ctcaaaacat taaaattaac
481 attaaataga gctaccacaa tatccagaaa tccccatgct gggatatata ctggaagaaa
541 ggaaatcata tattgaagag ataacatcac tccaatatc acaatagcca ctattcacia
601 atgccaaag ttggaagcaa cctaagtgtc catcaacaga tgaatggata aagaaagtac
661 tccaattata cacaatggag cacaattcag ccatgaaaaa agcatgagat cctgttatct
721 gtaataatat ggatggaact ggaggtcatc atgttaagtg aaataagcca ggcacagaaa
781 cacagatatt gcaagttctc acatactgtg gggatct

```

7/21

Figure 4 continued

Seq ID: 122

>chzd_ch-v-030_683T>A

```
1 cattaataatt aacattaaat agagctacca caatatccag aaatccccat gctgggtata
61 tacctggaag aaaggaaatc atatattgaa gagataacat cactccaata ttcacaatag
121 ccactattca caaatgccaa gatttggaag caacctaatg gtccatcaac agatgaatgg
181 ataaagaaag tactccaatt atacacaatg gagcacaatt cagccatgaa aaaagcatga
241 gatcctgtta tctgtaataa tatggatgga actggaggtc atcatgttaa gtgaaataag
301 ccaggcacag aaacacagat attgcaagtt ctcacatact tgtgggatct acaaatcaaa
361 acaactgagc taatgtctgg gccttagtca gtgtgtgacc caagtactgg gagcacagct
421 tttaaaatac atcatgaatg ctttaataca ggaatgaata gatgagaggc acaaactggg
481 tgggtgttct tctgatacac agtatcttcc ttgacagatt cagtacaact ctcaacaggt
541 aagtctcttc atgttatgtt accttatgag gaattaagtg gcagaacatg atttctatta
601 ttttcctttg cagaacaaga ccaactttat tagttgggac acagtgtggc tgcatttgag
661 tcccaagcaa ccattagtct atagctatca ccacagagtc agaggggatg agacgccag
721 caatctcacc caagacaact ccaccaacat tcctgggtac ccaccatgtg tacagtacc
781 tgctaggaac cagggtcatg aaagtaaata ataccagact gtgcccttga ggagctcacc
841 tctgctaagg gaaacaggca tagaaactta caatggtggt agagagaaaa gaggacaata
901 ggactgtgtg agggggatag gaggcaccca gaggaggaaa tggttacatt tgtgtgagga
961 ggttggttaag gaaaaatttt agcagaaggg gtctgtctgg ctgggcttgg aaggatagct
1021 aggagtcac tagagggcac aggtacactc caggcagagg gaatttcgtg ggtaaagatg
1081 tgtagggtgtg gcttgtgagg atggatttca attattctag aatgaa
```

Seq ID: 123

>chzy_ch-v-002_159G>A

```
1 gattaagctt ttcatgattc ctcatagaac atgaactcaa aagagggtcag caaaggggtg
61 tgtgcgattc tttgctattg gctgcagcta tagccctgcc tccttctcca gcacataaat
121 ctttcagcag cttggctgaa gactgctgtg cagggcagag ag aagctccagg caaacagccc
181 agcaaacagc agcactcagc taaaaggaag actcacagaa cacagttgaa gaaggaaagt
241 ggcgATGGAC CTCATCCCAA ATTTGGCGGT GGAAACCTGG CTTCTCCTGG CTGTCAGCCT
301 GGTGCTCCTC TATCTgtgag taactgtcca aactcctctc tttgtttcct tggacttggg
361 gtgctaactg ggcccccttt cccttatctg ttttgaagat caaaagagat gttcaaggag
421 aagtagctga agtgttggac gctacaaaac catagaagtt attattatct tatgcagatc
481 tatgaatgaa taaataagca tttctcccat ccaccttcta attttgggtga ctaggagggt
541 ttagggacag catttggtag tgggaatgat ttgattagct tagatctgac gaagactaat
601 caatgaaaac atggcagcgg caga
```

Seq ID: 124

>chzy_ch-v-003_171C>T

```
1 gattaagctt ttcatgattc ctcatagaac atgaactcaa aagagggtcag caaaggggtg
61 tgtgcgattc tttgctattg gctgcagcta tagccctgcc tccttctcca gcacataaat
121 ctttcagcag cttggctgaa gactgctgtg cagggcaggg aagctccagg taaaacagccc
181 agcaaacagc agcactcagc taaaaggaag actcacagaa cacagttgaa gaaggaaagt
241 ggcgATGGAC CTCATCCCAA ATTTGGCGGT GGAAACCTGG CTTCTCCTGG CTGTCAGCCT
301 GGTGCTCCTC TATCTgtgag taactgtcca aactcctctc tttgtttcct tggacttggg
361 gtgctaactg ggcccccttt cccttatctg ttttgaagat caaaagagat gttcaaggag
421 aagtagctga agtgttggac gctacaaaac catagaagtt attattatct tatgcagatc
481 tatgaatgaa taaataagca tttctcccat ccaccttcta attttgggtga ctaggagggt
541 ttagggacag catttggtag tgggaatgat ttgattagct tagatctgac gaagactaat
601 caatgaaaac atggcagcgg caga
```

8/21

Figure 4 continued

Seq ID: 125

>chzy_ch-v-004_418-420delGAG

```

1 gattaagctt ttcattgattc ctcataagaac atgaactcaa aagagggtcag caaaggggtg
61 tgtgcgattc tttgctattg gctgcagcta tagccctgcc tccttctcca gcacataaat
121 ctttcagcag cttggctgaa gactgctgtg cagggcaggg aagctccagg caaacagccc
181 agcaaacagc agcactcagc taaaaggaag actcacagaa cacagttgaa gaaggaaagt
241 ggcgATGGAC CTCATCCCAA ATTTGGCGGT GGAAACCTGG CTTCCTCTGG CTGTCAGCCT
301 GGTGCTCCTC TATCTgtgag taactgtcca aactcctctc tttgtttcct tggacttggg
361 gtgctaactg ggcccctttt cccttatctg ttttgaagat caaaagagat gttcaag||aag
421 tagctgaagt gttggacgct acaaacgcat agaagttatt attatcttat gcagatctat
481 gaatgaataa ataagcattt ctcccatcca ccttctaatt ttggtgacta ggagggttta
541 gggacagcat ttggtagtgg gaatgatttg attagcttag atctgacgaa gactaatcaa
601 tgaaaacatg gcagcggcag a

```

Seq ID: 126

>chzx_ch-v-005_187C>T_ch-v-006_191-192insG

```

1 aggaaaggac ctgatgagtg aatgcaatta ctgatgttgg agttgctgtt attatttattc
61 gtgtacatat tacctccctc tcttgaccat tccagttcct gagtaactca ccagccctct
121 gatctataaa gtcacaatcc ctgtgacctg atttctgttt cactttgtag ATATGGGACC
181 CGTACATATG GGACTTTTA AGAGACTGGG AATTCCAGGG CCCACACCTC TGCCTTTGTG
241 GGGAAATGTT TTGTCTATC GTCAGgtgag ttgcttgagc ttcctctttt gcttcttatg
301 gttgcaaaaca tcagcttagt tccatcagta aaaaatgcccc tccttgggag ggagttctga
361 ggtttcacat tttcagaaat ggtgggactg ggtgcagtggt atcatgcctg taatctcagc
421 ctctgtgagg ccaagactgg caaattgctt gagcccagga gtttg

```

Seq ID: 127

>peptide of ch-v-005_ch-v-006

1 MDLIPNLAVE TWLLLA^{VSLV} LLYLYGTRTY GTF.

Seq ID: 128

>chzw_ch-v-007_143C>T

```

1 catagacaag ggtgagtcct tcagtactta gagaaaatc aagagtgact ttaaattccc
61 cacttcaaat atattctctg ttttcttgtc tttcccttaa gacatctctg aatagcttcc
121 ttcaactgcc agtgaaagat aggaggcctg atttcattgg acgcaactgt tttcagcccc
181 aattagaggt agggtttatt ctatttaaaa taataatcaa cttgtatttt gtttctctc
241 ccagGGTCTC TGGAAATTTG ACACAGAGTG CTATAAAAAG TATGGAAAAA TGTGGGGgtg
301 agtattctga aaacctccat tggatagacc tgctactgtg aggaggttac cccactgcag
361 gatagtctct gccaggtct tcatgggatg aagctcttgt caacctaaat acaaacagag
421 agaggttctc tgaaagaaga ggataattac ttgggagtag aatattgcaa tgggaatctg
481 cttgcctgta taaactatgt gcaaattcag ggaggtaaac aagacaaaga tgctccatag
541 aaaatatgag aagaatctca taactgtttt gagataatta ttgttagcta caaagatcaa
601 ta

```

Seq ID: 129

>chzv_ch-v-008_199C>A

```

1 cagtatctct tccctgtttg gaccacatta cccttcatca tatgaagcct tgggtggctc
61 ctgtgtgaga ctcttgctgt gtgtcacacc ctaatgaact agaacctaag gttgctgtgt
121 gtcgtacaac taggggtatg gattacataa cataatgac aaagtctggc ttcctgggtg
181 tggctccagc tgcagaatag ggctagtga gtttaatcag ctccgttgtc cccacacagA
241 ACCTATGAAG GTCAACTCCC TGTGCTGGCC ATCACAGATC CCGACGTGAT CAGAACAGTG
301 CTAGTGAAAG AATGTTATTC TGTCTTCACA AATCGAAGGg taagcatcca ttttttgaaa
361 tttaaataat gattgatcca ctgattaaat ttttattttt aaaaaaacat atattcacag
421 aagggttacct aaaaaatgta caggaaggtt ccatgtactc ttcactcctgt cccgcccagt
481 ggtaacatct tgcaatcttg tatattgcaa tatatatcta gtatattcat attatcaggt
541 tggcacaaaa gttaaaatgg caaactacag gctgggcata atgggtcatg cctg

```

9/21
Figure 4 continued

Seq ID: 130

>chzv_ch-v-025_224C>T

```

1  cagtatctct tccctgtttg gaccacatta cccttcatca tatgaagcct tgggtggctc
61  ctgtgtgaga ctcttgctgt gtgtcacacc ctaatgaact agaacctaag gttgctgtgt
121 gtcgtacaac taggggtatg gattacataa cataatgac aaagtctggc ttcctgggtg
181 tggctccagc tgcagaatcg ggctagtga gtttaatcag ctccgttgtc cccacacagA
241 ACGTATGAAG GTCAACTCCC TGTGCTGGCC ATCACAGATC CCGACGTGAT CAGAACAGTG
301 CTAGTGAAAG AATGTTATTC TGTCTTCACA AATCGAAGGg taagcatcca ttttttgaaa
361 tttaaataat gattgatcca ctgattaaat ttttattttg aaaaaaacat atattcacag
421 aaggttacct aaaaaatgta caggaagggt ccatgtactc ttcacctgt cccgcccagt
481 ggtaacatct tgcaatcttg tatattgcaa tataatctta gtatattcat attatcaggT
541 tggcacaaaa gttaaaatgg caaactacag gctgggcata atggctcatg cctg

```

Seq ID: 131

>chzv_ch-v-009_320C>A

```

1  cagtatctct tccctgtttg gaccacatta cccttcatca tatgaagcct tgggtggctc
61  ctgtgtgaga ctcttgctgt gtgtcacacc ctaatgaact agaacctaag gttgctgtgt
121 gtcgtacaac taggggtatg gattacataa cataatgac aaagtctggc ttcctgggtg
181 tggctccagc tgcagaatcg ggctagtga gtttaatcag ctccgttgtc cccacacagA
241 ACGTATGAAG GTCAACTCCC TGTGCTGGCC ATCACAGATC CCGACGTGAT CAGAACAGTG
301 CTAGTGAAAG AATGTTATTC TGTCTTCACA AATCGAAGGg taagcatcca ttttttgaaa
361 tttaaataat gattgatcca ctgattaaat ttttattttg aaaaaaacat atattcacag
421 aaggttacct aaaaaatgta caggaagggt ccatgtactc ttcacctgt cccgcccagt
481 ggtaacatct tgcaatcttg tatattgcaa tataatctta gtatattcat attatcaggT
541 tggcacaaaa gttaaaatgg caaactacag gctgggcata atggctcatg cctg

```

Seq ID: 132

>peptide of ch-v-009_320C>A

1 MWGTYEGQLP VLATDPDVI RTVLVKECYV VFTNRRSLGP VGFMKSAISL AEDEEWKRIR

Seq ID: 133

>chzv_ch-v-018_441-444insCTAAAAAAT

```

1  cagtatctct tccctgtttg gaccacatta cccttcatca tatgaagcct tgggtggctc
61  ctgtgtgaga ctcttgctgt gtgtcacacc ctaatgaact agaacctaag gttgctgtgt
121 gtcgtacaac taggggtatg gattacataa cataatgac aaagtctggc ttcctgggtg
181 tggctccagc tgcagaatcg ggctagtga gtttaatcag ctccgttgtc cccacacagA
241 ACGTATGAAG GTCAACTCCC TGTGCTGGCC ATCACAGATC CCGACGTGAT CAGAACAGTG
301 CTAGTGAAAG AATGTTATTC TGTCTTCACA AATCGAAGGg taagcatcca ttttttgaaa
361 tttaaataat gattgatcca ctgattaaat ttttattttg aaaaaaacat atattcacag
421 aaggttacct aaaaaatgta ctaaaaaat gaagggtcca tgtactcttc atcctgtccc
481 gcccagtggt aacatcttgc aatcttgtat attgcaatat atatctagta tattcatatt
541 atcaggttgg cacaaaagtt aaaatggcaa actacaggct gggcataatg gctcatgcct
601 g

```

Seq ID: 134

>chzt_ch-v-016_145T>G

```

1  agcggaaaac tcaaggaggT atgaaaataa gatgagtctt aattagaaat gtaaagaatg
61  aatctgggga caggtagaaa gtaagatcac agtccgtttc caaggggtag tccactgagt
121 tcgagcttcc taaaaatggT ctttctatctt tatgtacaga aaagacatca caaaattcat
181 taaaaaatgt cacttactgc tccatgctgg agaaagccat atccttctgg gacttgagtc
241 tgcacattta actacaggta ctgatctgtt ttgtgcttag ATGTTCCCCA TCATTGCCCCA
301 GTATGGAGAT GTATTGGTGA GAAACTTGAG GCGGGAAGCA GAGAAAGGCA AGCCTGTCAC
361 CTTGAAAGAg taagtaggag cacagccatg gggttctgag ctgtcatgag ccctccagc
421 tgcctgccat ggagtcgaca gtcgactgt tgggttactc cagtgaccag acaaaagcag
481 ggcagcgctg caactccaaa gagccaccta agagggagtg gctcccatga ggcggcaagt
541 cagcaaggga aaagggcctt ctctcctgtg cacaggagcc aggatttact tatctgttaa
601 ctt

```

10/21
Figure 4 continued

Seq ID: 135

>chzt_ch-v-019_241T>C

```

1 agcggaaaac tcaaggaggt atgaaaataa gatgagtctt aattagaaat gtaagaatg
61 aatctgggga caggtagaaa gtaagatcac agtccgtttc caaggggtag tccactgagt
121 tcgagcttcc taaaaatggt cttttatctt tatgtacaga aaagacatca caaaattcat
181 taaaaaatgt cacttactgc tccatgctgg agaaagccat atccttctgg gacttgagtc
241 Ggcacattta actacaggta ctgatctggt ttgtgcttag ATGTTCCCA TCATTGCCCA
301 GTATGGAGAT GTATTGGTGA GAACTTGAG GCGGGAAGCA GAGAAAGGCA AGCCTGTCAC
361 CTTGAAAGAg taagtaggag cacagccatg gggttctgag ctgtcatgag cccttccagc
421 tgcctgccat ggagtcgaca gtcgactgt tgggttactc cagtgaccag acaaaagcag
481 ggcagcgctg caactccaaa gagccaccta agagggagtg gctcccata ggcggcaagt
541 cagcaaggga aaagggcctt ctctcctgtg cacaggagcc aggatttact tatctgttaa
601 ctt

```

Seq ID: 136

>chzq_ch-v-010_132-133insGTC

```

1 attggacatg atagctagat ttgtttcagg aaaacatcct gctttccaag gatttagatg
61 aatgtttttg ttcactggtg actcaggtaa cagctcttca agaagccata gggagggtga
121 gggaggggaag tcgtcaagaa gggagggtga ggactgcact ttgtatttac ttctgaattc
181 acgagtcact ttctgccaaa gaaatctctc cttttgcttc tagCACCGAC TAGATTCTCT
241 TCAGCTGATG ATTGACTCCC AGAATTCGAA AGAACTGAG TCCACAAAG gtaaccaagg
301 agtgcttctg agggctactg gcggggacac taagagggag ggccttgctc tgaaaatgtg
361 caggaagtat tccaggaaga tgagaatttt tgccacatag cagaacaaca cacatttaga
421 tgttataaat ggtagctgga ggcactttcc agaagccac aggtatagcc atgttccagg
481 ctgaaagggc aaccctaagc aaacctagaa tgcttggagg acagtcagtg gtttgtggat
541 cacctacatg agatcaaatg ccagttctca gcctcctcca gatccacca gtgagaacct
601 ctacttgga atttatatca aacata

```

Seq ID: 137

>chzq_ch-v-011_364G>T

```

1 attggacatg atagctagat ttgtttcagg aaaacatcct gctttccaag gatttagatg
61 aatgtttttg ttcactggtg actcaggtaa cagctcttca agaagccata gggagggtga
121 gggaggggaag tcaagaaggg aggttgagga ctgcactttt gatttacttc tgacttcacg
181 agtcactttc tgccaaagaa atctctcctt ttgcttctag CACCGACTAG ATTTCTCTCA
241 GCTGATGATT GACTCCCAGA ATTCGAAAGA AACTGAGTCC CACAAAGgta accaaggagt
301 gcttctgagg gctactggcg gggacactaa gagggaggcg cttgttctga aaatgtgcag
361 gaacttattcc aggaagatga gaatttttgc cacatagcag aacaacacac atttagatgt
421 tataaatggt agctggaggc actttccaga agcccacag tatagccatg ttccaggctg
481 aaagggcaac cctaagcaaa cctagaatgc ttggaggaca gtcagtggtt tgtggatcac
541 ctacatgaga tcaaatgcca gttctcagcc tcttccagat ccaccaagtg agaacctcta
601 cttggaaatt tatatcaaac ata

```

Seq ID: 138

>chzp_ch-v-012_269G>A

```

1 agataaagta ctttttaggat cattcaaggc acacacccat aacactgagt atgtaagaca
61 gaaatgctct ctctggaaat tacagcagtg ctgggtgctgg gatgccatga tgaggagtgt
121 gtggcccaca atcatgtaga ccttgggaaa acctggatta aaatgatttt ggcgtatcct
181 ggcctgtat aagatacata tcagaatgaa aaccactccc agtgtgactt tgaattgctt
241 ttccattttt tcttcttggg attagagatc ttcacttaga ttcatctaa gctgtgatgt
301 tgtacgttga cctgatttac ctaaaatgtc tttcctctcc tttcagCTCT GTCTGATCTG
361 GAGCTCGCAG CCCAGTCAAT AATCTTCATT TTTGCTGGCT ATGAAACCAC CAGCAGTGT
421 CTTTCCTTCA CTTTATATGA ACTGGCCACT CACCCTGATG TCCAGCAGAA ACTGCAAAAG
481 GAGATTGATG CAGTTTGGCC CAATAAGgtg aggggatgac ccctggagat gaaggggaaga
541 ggtgaagcct tagcaaaaat gcctcctcac cactcccag gagaattttt ataaaaagca
601 taatcactga ttcttctact gacataatgt aggaagcctc tgaggagaaa acaaaagga
661 gaaacataga gaacggttgc tactggcaga agcataagat ctttgtacaa tattgctggc
721 cctgggttcac ctgtttactg ttatcacaat aatgctaagt aaaaaaaaaa aaaaaaaaaa

```

11/21
Figure 4 continued

781 aaaaaaaaaa aggagtgtgg cgagaagatg gccaaacagg aacagc

Seq ID: 139

>chzm_ch-v-013_167A>G

```

1  gtccctgggg tgaggatggt cttgaatata tcctacattc ataactcctc cacacatctc
61  agtaggtcac tgagcacatc aatggacatg ccagttatta aaatacttca cgaatactat
121 gatcatcttac cagtatgagt tattctctgg agcttctaata acttcaatag tactgcatgg
181 actcagttga gagttaattc aaaatctcag attatccaat tctgtttctt tccttccagG
241 CACCACCTAC CTATGATGCC GTGGTACAGA TGGAGTACCT TGACATGGTG GTGAATGAAA
301 CACTCAGATT ATTCCCAGTT GCTATTAGAC TTGAGAGGAC TTGCAAGAAA GATGTTGAAA
361 TCAATGGGGT ATTCAATCCC AAAGGGTCAA TGGTGGTGAT TCCAACCTAT GCTCTTCACC
421 ATGACCCAAA GACTGGGACA GAGCCTGAGG AGTTCCGCCC TGAAAGgtac aagtctccag
481 ggaaatggag ctccacctga cccaggctgg ttcaagcata ttctgcctct cttaactctac
541 atgacaatcg tgtggttgta caatcatttg cttgtaagtc tttttatcac aaaaaagtga
601 taattatcaa actttacaaa ccacagacta gaaaaaacga aactacatcc atccacagtc
661 ccagcacaag acaaagataa tcaattatgt ccctgtgggc atttttctac gcctatatag
721 atttttaaaa attagaatgg tatcactttt tatttggttt gaattgctgc ttacttgatt
781 taacaggaaa ctatc

```

Seq ID: 140

>chzm_ch-v-017_248-249inst

```

1  gtccctgggg tgaggatggt cttgaatata tcctacattc ataactcctc cacacatctc
61  agtaggtcac tgagcacatc aatggacatg ccagttatta aaatacttca cgaatactat
121 gatcatcttac cagtatgagt tattctctgg agcttctaata acttcaatag tactgcatgg
181 actcagttga gagttaattc aaaatctcag attatccaat tctgtttctt tccttccagG
241 CACCACCTTA CTATGATGC CGTGGTACAG ATGGAGTACC TTGACATGGT GGTGAATGAA
301 AACTCAGAT TATTCAGAGT TGCTATTAGA CTTGAGAGGA CTTGCAAGAA AGATGTTGAA
361 ATCAATGGGG TATTCATTCC CAAAGGGTCA ATGGTGGTGA TTCCAACCTA TGCTCTTCAC
421 CATGACCCAA AGTACTGGAC AGAGCCTGAG GAGTTCCGCC CTGAAAGgta caagtctcca
481 gggaaatgga gctccacctg acccaggctg gttcaagcat attctgcctc tcttaactcta
541 catgacaatc gtgtggttgta acaatcattt gcttgaagtc ctttttatca caaaaaagtg
601 ataattatca aactttacaa accacagact agaaaaaacg aaactacatc catccacagt
661 cccagcaca gacaaagata atcaattatg tccctgtggg catttttcta cgcctatata
721 gattttttaa aattagaatg gtatcaactt ttatttggtt tgaattgctg cttacttgat
781 ttaacaggaa actatc

```

Seq ID: 141

>peptide of ch-v-017_248-249inst

1 ALSDLELAQ SIIFIFAGYE TTSSVLSFTL YELATHPDVQ QKLQKEIDAV LPNKAPFYL.

Seq ID: 142

>chzm_ch-v-014_643C>T

```

1  gtccctgggg tgaggatggt cttgaatata tcctacattc ataactcctc cacacatctc
61  agtaggtcac tgagcacatc aatggacatg ccagttatta aaatacttca cgaatactat
121 gatcatcttac cagtatgagt tattctctgg agcttctaata acttcaatag tactgcatgg
181 actcagttga gagttaattc aaaatctcag attatccaat tctgtttctt tccttccagG
241 CACCACCTAC CTATGATGCC GTGGTACAGA TGGAGTACCT TGACATGGTG GTGAATGAAA
301 CACTCAGATT ATTCCCAGTT GCTATTAGAC TTGAGAGGAC TTGCAAGAAA GATGTTGAAA
361 TCAATGGGGT ATTCAATCCC AAAGGGTCAA TGGTGGTGAT TCCAACCTAT GCTCTTCACC
421 ATGACCCAAA GACTGGGACA GAGCCTGAGG AGTTCCGCCC TGAAAGgtac aagtctccag
481 ggaaatggag ctccacctga cccaggctgg ttcaagcata ttctgcctct cttaactctac
541 atgacaatcg tgtggttgta caatcatttg cttgtaagtc tttttatcac aaaaaagtga
601 taattatcaa actttacaaa ccacagacta gaaaaaacga aaatcacatcc atccacagtc
661 ccagcacaag acaaagataa tcaattatgt ccctgtgggc atttttctac gcctatatag
721 atttttaaaa attagaatgg tatcactttt tatttggttt gaattgctgc ttacttgatt
781 taacaggaaa ctatc

```


12/21
Figure 4 continued

Seq ID: 143

>chzn_ch-v-015_351T>C

```

1 caggcctggc acagagtcag tgctccataa atattttgtt aaacgatgga tggtagtg
61 ttttactatc cagtatttac ccagcttata gattaagtat gaagagttca agatacatgg
121 tggttaagagt cgtttttata tgcttgcaaa gcatttttgt catatttttt ctactttgct
181 tccatctttt cttctttcac ttcatttatt aattctccat atgcttggtt aactattgta
241 gATCCCCCTG AAATTAGACA CGCAAGGACT TCTTCAACCA GAAAAACCCA TTGTTCTAAA
301 GGTGGATTCA AGAGATGGAA CCCTAAGTGG AGAATGAgtt attctaagga cttctacttt
361 ggtcttcaag aaagctgtgc cccagaacac cagagatttc aacttagtca ataaaacctt
421 gaaataaaga tgggcttaat ctaatgtact gcatgagtag ttggtgattt tgtacattca
481 ttgagctctc ccagagtcctg tgtagagtgt tgtgcattat gtagtataaa ggaggtgacc
541 aggtaagtga cagataggtga gactcagctt ctctgcttct cataggacta cctctacca
601 cctctagtta gcatta

```

Seq ID: 145

>peptide of ch-v-001_406C>A

```

..1 PVAIRLERTC KKDVEINGVF IPKGSMMVIP NYALHHDPKY WTEPEEFRPE RFSKKKDSID

```

Seq ID: 206

>chyu_ch-v-048_206G>A

```

1 catttagtcc ttgtgagcac ttgatgattt acctgccttc aatttttcac tgacctata
61 ttctttttga taatgaagta ttttaaacat ataaaacatt atggagagtg gcataggaga
121 taccacagta tgtaccaccc agcttaacga atgctctact gtcatttcta accataatct
181 cttttaagag ctcttttgtc tttca tatc tcttccctgt ttggaccaca ttacccttca
241 tcatatgaag ccttggtggtg ctctgtgtg agactcttgc tgtgtgtcac accctaata
301 actagaacct aaggttgctg tgtgtcgtac aactaggggt atggattaca taacataatg
361 atcaaagtct ggcttccctg gtgtggctcc agctgcagaa tcgggctagt gaagtttaat
421 cagctccgtt gtccccacac agAA

```

Seq ID: 207

>chzk_ch-v-037_230T>C

```

1 tggtcaccca ccatgtgtac agtaccctgc tagggccag ggtcatgaaa gtaaataata
61 ccagactgtg cccttgagga actcacctct gctaaggga acaggcacag aaaccacaa
121 gggtggtaga gaggaatag gacaatagga ctgtgtgagg gggataggag gcaccagag
181 gaggaatgg ttacatctgt gtgaggaggt tggtaaggaa agactttaac agaaggggtc
241 tgtctggctg ggcttgcaag gatgtgtagg agtcatctag ggggcacaag tacactcag
301 gcagagggaa ttgcatgggt aaagatctgc agttgtggct tgtggggatg gatttcaagt
361 attctggaat gaagacagcc atggaaacaa gggcaggtga gaggatattt aagaggcttc
421 atgccaatgg ctccacttca gtttctgata agaactcagg ttccgtggac tccctgataa
481 aactgattaa gttgtttatg attccccata gaatatgaac tcaaaggagg taagcaaagg
541 ggtgtgtgct attctttgct actggctgca gctgcagccc cactccttc tccagcacat
601 aaacatttca gcagcttgac ctaagactgc tgtgcagggc agggatgctc caggcagaca
661 gccagcaaaa caacagcaca cagctgaaag taagactcag aggagacagt tgaagaaggc
721 aagtggcgat ggacctcatc ccaaatttgg cgggtgaaac ctggcttctc ctggtgtgca
781 gcctgggtgt cctctatctg tcagtaactg tccagattcc tctcctctgt

```

13/21

Figure 4 continued

Seq ID: 208

>chzk_ch-v-038_506C>T

```

1  tggtcaccca ccatgtgtac agtaccctgc taggggtccag ggatcatgaaa gtaaataata
61  ccagactgtg cccttgagga actcacctct gctaagggaa acaggcacag aaacccacaa
121 gggtggtaga gaggaatatag gacaatatga ctgtgtgagg gggataggag gcacccagag
181 gaggaatatg ttacatctgt gtgaggaggt tggtaaggaa agactttaat agaaggggtc
241 tgtctggctg ggcttgcaag gatgtgtagg agtcatctag ggggcacaag tacactccag
301 gcagagggaa ttgcatgggt aaagatctgc agtttgtggc tgtggggatg gatttcaagt
361 attctggaat gaagacagcc atggaaacaa gggcaggtga gaggatattt aagaggcttc
421 atgccaatgg ctccacttca gtttctgata agaactcagg ttccgtggag tccctgataa
481 aactgattaa gttgtttatg attctctata gaatatgaac tcaaaggagg taagcaaagg
541 ggtgtgtgctg attctttgct actggctgca gctgcagccc cacctccttc tccagcacat
601 aaacatttca gcagcttgac ctaagactgc tgtgcagggc agggatgctc caggcagaca
661 gccagcaaaa caacagcaca cagctgaaag taagactcag agggagacagt tgaagaaggc
721 aagtggcgat ggacctcatc ccaaatttgg cggtggaac ctggcttctc ctggctgtca
781 gcctggtgct cctctatctg tcagtaactg tccagattcc tctcctctgt

```

Seq ID: 209

>chzk_ch-v-039_514T>C

```

1  tggtcaccca ccatgtgtac agtaccctgc taggggtccag ggatcatgaaa gtaaataata
61  ccagactgtg cccttgagga actcacctct gctaagggaa acaggcacag aaacccacaa
121 gggtggtaga gaggaatatag gacaatatga ctgtgtgagg gggataggag gcacccagag
181 gaggaatatg ttacatctgt gtgaggaggt tggtaaggaa agactttaat agaaggggtc
241 tgtctggctg ggcttgcaag gatgtgtagg agtcatctag ggggcacaag tacactccag
301 gcagagggaa ttgcatgggt aaagatctgc agtttgtggc tgtggggatg gatttcaagt
361 attctggaat gaagacagcc atggaaacaa gggcaggtga gaggatattt aagaggcttc
421 atgccaatgg ctccacttca gtttctgata agaactcagg ttccgtggag tccctgataa
481 aactgattaa gttgtttatg attccccata gaaatgaac tcaaaggagg taagcaaagg
541 ggtgtgtgctg attctttgct actggctgca gctgcagccc cacctccttc tccagcacat
601 aaacatttca gcagcttgac ctaagactgc tgtgcagggc agggatgctc caggcagaca
661 gccagcaaaa caacagcaca cagctgaaag taagactcag agggagacagt tgaagaaggc
721 aagtggcgat ggacctcatc ccaaatttgg cggtggaac ctggcttctc ctggctgtca
781 gcctggtgct cctctatctg tcagtaactg tccagattcc tctcctctgt

```

Seq ID: 210

>chzh_ch-v-051_455T>G

```

1  caaaaattag ctagggtgtg tggatgcac ctataatctc agctaccag gaggtgagg
61  caggagaatc acttgaacct ggaggcagag gttgcagtga gccgagacgc accattacac
121 tccagcctgg gtgacagagt gagattccat ctcaaaaaaa aaaaaaaaaa attatgcctt
181 tttgaagcac atacatttta taacatacaa ctgaatccct tattatatta ttagttttga
241 tttaatgttt tcaaaccatc tcccctgata tttctgggag atgggaaaca tgttttctta
301 cacctcttgc attccattct caactcccaa ctgtcttact gcaatgaaca cttaataaga
361 aacagtcaat tgggtcaattg attgggcaac aggtctaaaca cactcattcc ttgtctgttc
421 ccacttcttt ctttactttc cttcctctg taacttatcc taaagtcatt aggtgggtgg
481 cagccagatg gtggccacac attaaggtag aaaagagagt gtcattgatg ttccaagtca
541 gagacctagt aggggtgagga tcaagtaggt gttcacgtgg agaaacagcc cggcctgtgt
601 gtgggagtcc aagcaagcag agaaaatgtc gacacagagg ggtggcctga aaaagcagcc
661 agagcctaaa cagggcatgg agaacaatatt tagggcatga ggtgaggagg gcatccatga
721 gtgggaagg atgggtgagg tttcactaca taaaggggat tgatgaaata agtaataaa
781 gtatactgga agccaggtgt gtcacttttg cagaaaagag tcatggattc agaaagg

```

14/21

Figure 4 continued

Seq ID: 211

>chzh_ch-v-052_577G>A

```

1  caaaaattag ctagggtgtgg tggatatgcac ctataatctc agctaccag gaggtgagg
61  caggagaatc acttgaacct ggaggcagag gttgcagtga gccgagacgc accattacac
121 tccagcctgg gtgacagagt gagattccat ctcaaaaaaa aaaaaaaaaa attatgcctt
181 tttgaagcac atacatttta taacatacaa ctgaatccct tattatatta ttagttttga
241 tttaatgttt tcaaaccatc tccctgata tttctgggag atgggaaaca tgttttctta
301 cacctcttgc attccattct caactcccaa ctgtcttact gcaatgaaca ctttaataaga
361 aacagtcaat tgggtcaattg attgggcaac aggctaaaca cactcattcc ttgtctgttc
421 ccacttcttt ctttactttc cttcctgag taacttatcc taaagtcatt aggtgggtgg
481 cagccagatg gtggccacac attaaggtag aaaagagagt gtcattgatg ttccaagtca
541 gagacctagt aggttgagga tcaagtaggt gttcacatgg agaaacagcc cggcctgtgt
601 gtgggagtcc aagcaagcag agaaaatgtc gacacagagg ggtggcctga aaaagcagcc
661 agagcctaaa cagggcatgg agaacaatatt tagggcatga ggtgaggagg gcatccatga
721 gtgggaaggg atgggtgagg ttctactaca taaaggggat tgatgaaata agtaataaaa
781 gtatactgga agccaggtgt gtcacttttg cagaaaagag tcatggattc agaaagg

```

Seq ID: 212

>chzw_ch-v-053_163G>A

```

1  catagacaag ggtgagtcct tcagtactta gagaaaattc aagagtgact ttaaattccc
61  cacttcaaat atattctctg ttttcttgtc tttcccttaa gacatctctg aatagcttcc
121 ttcaactgcc agtgaaagat agcaggcctg atttcattgg acacaaactgt tttagcctcc
181 aattagaggt aggttttatt ctatttaaaa taataatcaa cttgtatttt gtttctctc
241 ccagGGTCTC TGGAAATTTG ACACAGAGTG CTATAAAAAG TATGGAAAAA TGTGGGGgtg
301 agtattctga aaacctccat tggatagacc tgctactgtg aggagggttac cccactgcag
361 gatagtctct gccaggtctt tcatgggatg aagctcttgt caacctaaat acaaacagag
421 agaggttctc tgaaagaaga ggataattac ttgggagtag aatattgcaa tgggaatctg
481 cttgccgtta taaactatgt gcaaattcag ggaggtaaac aagacaaaga tgctccatag
541 aaaatatgag aagaatctca taactgtttt gagataatta ttgttagcta caaagatcaa
601 ta

```

Seq ID: 213

>chzw_ch-v-054_444T>A

```

1  catagacaag ggtgagtcct tcagtactta gagaaaattc aagagtgact ttaaattccc
61  cacttcaaat atattctctg ttttcttgtc tttcccttaa gacatctctg aatagcttcc
121 ttcaactgcc agtgaaagat agcaggcctg atttcattgg acgcaactgt tttagcctcc
181 aattagaggt aggttttatt ctatttaaaa taataatcaa cttgtatttt gtttctctc
241 ccagGGTCTC TGGAAATTTG ACACAGAGTG CTATAAAAAG TATGGAAAAA TGTGGGGgtg
301 agtattctga aaacctccat tggatagacc tgctactgtg aggagggttac cccactgcag
361 gatagtctct gccaggtctt tcatgggatg aagctcttgt caacctaaat acaaacagag
421 agaggttctc tgaaagaaga ggaatattac ttgggagtag aatattgcaa tgggaatctg
481 cttgccgtta taaactatgt gcaaattcag ggaggtaaac aagacaaaga tgctccatag
541 aaaatatgag aagaatctca taactgtttt gagataatta ttgttagcta caaagatcaa
601 ta

```

Seq ID: 214

>chzt_ch-v-043_294T>C

```

1  agcggaaaaac tcaaggaggt atgaaaataa gatgagtctt aattagaaat gtaaagaatg
61  aatctgggga caggtagaaa gtaagatcac agtccgtttc caaggggtag tccactgagt
121 tcgagcttcc taaaaatggt cttttatctt tatgtacaga aaagacatca caaaattcat
181 tacaaaatgt cacttactgc tccatgctgg agaaaagccat atccttctgg gacttgagtc
241 tgcacattta actacaggta ctgatctgtt ttgtgcttag ATGTTCCCCA TCAATGCCCA
301 GTATGGAGAT GTATTGGTGA GAACTTGAG GCGGGAAGCA GAGAAAGGCA AGCCTGTCAC
361 CTTGAAAGAg taagtaggag cacagccatg gggttctgag ctgtcatgag cccttcagc
421 tgcctgccat ggagtcgaca gtcgcaactgt tgggttactc cagtgaccag acaaaagcag
481 ggcagcgctg caactccaaa gagccaccta agagggagtg gctcccatga ggcggcaagt
541 cagcaagggg aaagggcctt ctctcctgtg cacaggagcc aggatttact tatctgtta

```

15/21

Figure 4 continued

601 ctt

Seq ID: 215

>peptide of ch-v-043_294T>C

1 SLAEDEEWKR IRSLLSPTFT SGKLKEMFPI TAQYGDVLVR NLRREAEGK PVTLKDIFGA

Seq ID: 216

>chzt_ch-v-055_444G>A

1 agcggaaaac tcaaggaggt atgaaaataa gatgagtctt aattagaaat gtaaagaatg
 61 aatctgggga caggtagaaa gtaagatcac agtccgtttc caaggggtag tccactgagt
 121 tcgagcttcc taaaaatggt cttttatctt tatgtacaga aaagacatca caaaattcat
 181 taaaaaatgt cacttactgc tccatgctgg agaaagccat atccttctgg gacttgagtc
 241 tgcacattta actacaggta ctgatctgtt ttgtgcttag ATGTTCCCCA TCATTGCCCA
 301 GTATGGAGAT GTATTGGTGA GAAACTTGAG GCGGGAAGCA GAGAAAGGCA AGCCTGTCAC
 361 CTTGAAAGAg taagtaggag cacagccatg gggttctgag ctgtcatgag cccttccagc
 421 tgcttgccat ggagtcgaca gtcacactgt tgggttactc cagtgaccag acaaaagcag
 481 ggcagcgctg caactccaaa gagccaccta agagggagtg gctcccatga ggcggaagt
 541 cagcaaggga aaagggcctt ctctcctgtg cacaggagcc aggatttact tatctgttaa
 601 ctt

Seq ID: 217

>chzs_ch-v-050_437G>A

1 cagagcttac atatcttata tcatccacac tcaacacatg ctactgtagt tgtctgataa
 61 tgggtctctg tcttcctatg actgggctcc ttgacctcag aggtgagtct aactcagctt
 121 ggtgtctcca tcacccccag catagggcca gctccatcac tggcaccaga taaccacctt
 181 ctgagggaggt agatggaaga tgattcagca gatagttctg aaagtctgtg gctctttatg
 241 tgtcttgact ggatatgtgg gtttcttgct gcatgtatag tgggaaggacg gtaagaggtg
 301 ctgattttaa ttttccatat ctttctccac tcagCATCTT TGGGGCCTAC AGCATGGATG
 361 TGATTACTGG CACATCATTT GGAGTGAACA TCGACTCTCT CAACAATCCA CAAGACCCCT
 421 TTGTGGAGAG CACTAAAAG TTCCTAAAAT TTGGTTTCTT AGATCCATTA TTTCTCTCAA
 481 TAAgtatgtg ggctattatt tctttctctc tttttaaaaa taactgcttt cttgacatat
 541 aattcacata tcgtataatt catccactta aaaggtacaa ttccattggt ttttaagataa
 601 tcaaaaatat gtatgaccat tactattgta aactaaaatg tttttgtcaa tctagagccc
 661 tcacacactt tagctgtcaa caccccacca caaaccaccac tgccctaagc atccaataat
 721 caactttctg cctctataga tttgcctatt ctggacactt catagaaata atatcatt

Seq ID: 218

>chzs_ch-v-056_467A>G

1 cagagcttac atatcttata tcatccacac tcaacacatg ctactgtagt tgtctgataa
 61 tgggtctctg tcttcctatg actgggctcc ttgacctcag aggtgagtct aactcagctt
 121 ggtgtctcca tcacccccag catagggcca gctccatcac tggcaccaga taaccacctt
 181 ctgagggaggt agatggaaga tgattcagca gatagttctg aaagtctgtg gctctttatg
 241 tgtcttgact ggatatgtgg gtttcttgct gcatgtatag tgggaaggacg gtaagaggtg
 301 ctgattttaa ttttccatat ctttctccac tcagCATCTT TGGGGCCTAC AGCATGGATG
 361 TGATTACTGG CACATCATTT GGAGTGAACA TCGACTCTCT CAACAATCCA CAAGACCCCT
 421 TTGTGGAGAG CACTAAGAAG TTCCTAAAAT TTGGTTTCTT AGATCCGTTA TTTCTCTCAA
 481 TAAgtatgtg ggctattatt tctttctctc tttttaaaaa taactgcttt cttgacatat
 541 aattcacata tcgtataatt catccactta aaaggtacaa ttccattggt ttttaagataa
 601 tcaaaaatat gtatgaccat tactattgta aactaaaatg tttttgtcaa tctagagccc
 661 tcacacactt tagctgtcaa caccccacca caaaccaccac tgccctaagc atccaataat
 721 caactttctg cctctataga tttgcctatt ctggacactt catagaaata atatcatt

16/21

Figure 4 continued

Seq ID: 219

>chzs_ch-v-057_583C>T

```

1  cagagcttac atattcttata tcatccacac tcaacacatg ctactgtagt tgtctgataa
61  tgggtctctg tcttctctatg actgggctcc ttgacctcag aggtagtct aactcagctt
121 ggtgtctcca tcacccccag catagggcca gctccatcac tggcaccaga taaccacctt
181 ctgagggagt agatggaaga tgattcagca gatagtcttg aaagtctgtg gctctttatg
241 tgtcttgact ggatatgtgg gtttcttgct gcatgtatag tggaggagcg gtaagagggtg
301 ctgattttta ttttccatat ctttctccac tcagCATCTT TGGGGCCTAC AGCATGGATG
361 TGATTACTGG CACATCATTT GGAGTGAACA TCGACTCTCT CAACAATCCA CAAGACCCCT
421 TTGTGGAGAG CACTAAGAAG TTCCTAAAAT TTGGTTTCTT AGATCCATTA TTTCTCTCAA
481 TAAgtatgtg ggctattatt tctttctctc tttttaaaaa taactgcttt cttgacatat
541 aattcacata tcgtataatt catccactta aaaggtacaa ttccattggt ttttaagataa
601 tcaaaaaatat gtatgaccat tactattgta aactaaaatg tttttgtcaa tctagagccc
661 tcacacactt tagctgtcaa caccaccaca caaacccac tgccctaagc atccaataat
721 caactttctg cctctataga tttgcctatt ctggacactt catagaaata atatcatt

```

Seq ID: 220

>chzs_ch-v-058_650A>G

```

1  cagagcttac atattcttata tcatccacac tcaacacatg ctactgtagt tgtctgataa
61  tgggtctctg tcttctctatg actgggctcc ttgacctcag aggtagtct aactcagctt
121 ggtgtctcca tcacccccag catagggcca gctccatcac tggcaccaga taaccacctt
181 ctgagggagt agatggaaga tgattcagca gatagtcttg aaagtctgtg gctctttatg
241 tgtcttgact ggatatgtgg gtttcttgct gcatgtatag tggaggagcg gtaagagggtg
301 ctgattttta ttttccatat ctttctccac tcagCATCTT TGGGGCCTAC AGCATGGATG
361 TGATTACTGG CACATCATTT GGAGTGAACA TCGACTCTCT CAACAATCCA CAAGACCCCT
421 TTGTGGAGAG CACTAAGAAG TTCCTAAAAT TTGGTTTCTT AGATCCATTA TTTCTCTCAA
481 TAAgtatgtg ggctattatt tctttctctc tttttaaaaa taactgcttt cttgacatat
541 aattcacata tcgtataatt catccactta aaaggtacaa ttccattggt ttttaagataa
601 tcaaaaaatat gtatgaccat tactattgta aactaaaatg tttttgtcag tctagagccc
661 tcacacactt tagctgtcaa caccaccaca caaacccac tgccctaagc atccaataat
721 caactttctg cctctataga tttgcctatt ctggacactt catagaaata atatcatt

```

Seq ID: 221

>chzr_ch-v-059_205T>C

```

1  agaagggtgcc attgatctca ctgctgtagt ggtgtttcct atgtatagac ctgcccttgc
61  tcagtgcgag gctgaaaga agggcaaaca tgataaaagg aatgggttcc agttgagaat
121 catgatgttc ttattcttat tactggtaga gaaaattata attgctccag gtaaagtttg
181 cattttcaat gatttccctt tgttctgttt gtttttccca cagTACTCTT TCCATTCCTT
241 ACCCCAGTTT TTGAAGCATT AAATGTCTCT CTGTTTCCAA AAGATACCAT AAATTTTTTA
301 AGTAAATCTG TAAACAGAAT GAAGAAAAGT CGCCTCAACG ACAACAAAA Ggtaaaatct
361 gatgggtggtt aaatgacgat gtttaggttt tgataaattt agattttata cacatgatag
421 agcatgtatc tgtattttta aaaaataaga cagagaactt atgttttaga caagagaagc
481 catttggtag aaataaagaa ggagattggg gaaggagatg agaatgagtc agagagatag
541 catttaaaac ttgaaatcag gcacaacaat tagtatgtca tgatataaac agtattgaga
601 taaaatttta ccacttctct tccctttaat aaattgtcaa aggataaagt ttctgtttg
661 aaaaatatatt

```

17/21

Figure 4 continued

Seq ID: 222

>chzr_ch-v-060_496A>C

```

1  agaaggtgcc attgatctca ctgctgtagt ggtgtttcct atgtatagac ctgcccttgc
61  tcagtcgccg gcctgaaaga agggcaaaca tgataaaagg aatgggttcc agttgagaat
121 catgatgttc ttattcttat tactggtaga gaaaattata attgctccag gtaaagtttg
181 cattttcaat gatttccttt tgttgtttt gtttttccca cagTACTCTT TCCATTCTTT
241 ACCCAGTTT TTGAAGCATT AAATGTCTCT CTGTTTCCAA AAGATACCAT AAATTTTTTA
301 AGTAAATCTG TAAACAGAAT GAAGAAAAGT CGCCTCAACG ACAAACAAA Ggtaaaatct
361 gatggtggtt aaatgacgat gtttaggttt tgataaattt agattttata cacatgatag
421 agcatgtatc tgtattttta aaaataaaga cagagaactt atgttttaga caagagaagc
481 catttggtag aaatacagaa ggagattggg gaaggagatg agaatgagtc agagagatag
541 catttaaaac ttgaaatcag gcacaacaat tagtatgtca tgatataaac agtattgaga
601 taaaatttta ccacttctct tccttttaat aaattgtcaa aggataaagt ttctgtttg
661 aaaatatatt

```

Seq ID: 223

>chzp_ch-v-062_173G>A

```

1  agataaagta cttttaggat cattcaaggc acacacccat aacactgagt atgtaagaca
61  gaaatgctct ctctggaaat tacagcagtg ctggtgctgg gatgccatga tgaggagtgt
121 gtggcccaca atcatgtaga ccttgggaaa acctggatta aaatgatttt gcctcatcct
181 ggccctgtat aagatacata tcagaatgaa aaccactccc agtgtgactt tgaattgctt
241 ttccattttt tcttcttggg attagagagc ttcacttaga tttcatctaa gctgtgatgt
301 tgtacgttga cctgatttac ctaaaatgtc tttcctctcc tttcagCTCT GTCTGATCTG
361 GAGCTCGCAG CCCAGTCAAT AATCTTCATT TTTGCTGGCT ATGAAACCAC CAGCAGTGTT
421 CTTTCCTTCA CTTTATATGA ACTGGCCACT CACCCTGATG TCCAGCAGAA ACTGCAAAAG
481 GAGATTGATG CAGTTTGGCC CAATAAGgtg aggggatgac ccctggagat gaagggaaga
541 ggtgaagcct tagcaaaaat gcctcctcac cactccccag gagaattttt ataaaaagca
601 taatcactga ttccttcact gacataatgt aggaagcctc tgaggagaaa acaaaaggga
661 gaaacataga gaacggttgc tactggcaga agcataagat ctttgtacaa tattgctggc
721 cctgggttcac ctgtttactg ttatcacaa aatgctaagt aaaaaaaaaa aaaaaaaaaa
781 aaaaaaaaaa aggagtgtgg cgagaagatg gccaaacagg aacagc

```

Seq ID: 224

>chzp_ch-v-063_312C>T

```

1  agataaagta cttttaggat cattcaaggc acacacccat aacactgagt atgtaagaca
61  gaaatgctct ctctggaaat tacagcagtg ctggtgctgg gatgccatga tgaggagtgt
121 gtggcccaca atcatgtaga ccttgggaaa acctggatta aaatgatttt gcgtcatcct
181 ggccctgtat aagatacata tcagaatgaa aaccactccc agtgtgactt tgaattgctt
241 ttccattttt tcttcttggg attagagagc ttcacttaga tttcatctaa gctgtgatgt
301 tgtacgttga cctgatttac ctaaaatgtc tttcctctcc tttcagCTCT GTCTGATCTG
361 GAGCTCGCAG CCCAGTCAAT AATCTTCATT TTTGCTGGCT ATGAAACCAC CAGCAGTGTT
421 CTTTCCTTCA CTTTATATGA ACTGGCCACT CACCCTGATG TCCAGCAGAA ACTGCAAAAG
481 GAGATTGATG CAGTTTGGCC CAATAAGgtg aggggatgac ccctggagat gaagggaaga
541 ggtgaagcct tagcaaaaat gcctcctcac cactccccag gagaattttt ataaaaagca
601 taatcactga ttccttcact gacataatgt aggaagcctc tgaggagaaa acaaaaggga
661 gaaacataga gaacggttgc tactggcaga agcataagat ctttgtacaa tattgctggc
721 cctgggttcac ctgtttactg ttatcacaa aatgctaagt aaaaaaaaaa aaaaaaaaaa
781 aaaaaaaaaa aggagtgtgg cgagaagatg gccaaacagg aacagc

```

18/21

Figure 4 continued

Seq ID: 225

>chzn_ch-v-044_239T>C

```

1  caggcctggc acagagtcag tgctccataa atatthttgtt aaacgatgga tgggtgagtgc
61  ttttactatc cagtattttac ccagcttata gattaagtat gaagagttca agatacatgg
121 tgttaagagt cgthttttata tgcttgcaaa gcattthttgt catatthtttt ctactthtgct
181 tccatctthtt ctctthttcac ttcattttatt aattctccat atgcttgthtt aactattgca
241 gATCCCTTG AAATTAGACA CGCAAGGACT TCTTCAACCA GAAAAACCCA TTGTTCTAAA
301 GGTGGATTCA AGAGATGGAA CCCTAAGTGG AGAATGAgtt attctaagga tthctacttt
361 ggtcttcaag aaagctgtgc cccagaacac cagagatttc aacttagtca ataaaaacctt
421 gaaataaaga tgggcttaat ctaatgtact gcagtagtag ttgggtgattt tgtacattca
481 ttgagctctc ccagagctctg tgtagagtgt tgtgcattat gtagtataaa ggaggtgacc
541 aggtaagtga cagataggta gactcagctt ctctgcttct cataggacta cctctacca
601 cctctagtta gcatta

```

Seq ID: 226

>chzy_ch-v-066_380T>C

```

1  gattaagctt ttcattgattc ctcatagaac atgaactcaa aagaggtcag caaaggggtg
61  tgtgcgattc tttgctattg gctgcagcta tagccctgcc tccttctcca gcacataaat
121 ctttcagcag cttggctgaa gactgctgtg cagggcaggg aagctccagg caaacagccc
181 agcaaacagc agcactcagc taaaaggaag actcacagaa cacagttgaa gaaggaagt
241 ggcgATGGAC CTCATCCCAA ATTTGGCGGT GGAAACCTGG CTTCCTCTGG CTGTCAGCCT
301 GGTGCTCTCT TATCTgtgag taactgtcca aactcctctc tttgtttcct tggacttggg
361 gtgctaactc ggcccccttt cccttatctg ttttgaagat caaaagagat gttcaaggag
421 aagtagctga agtgttggac gctacaaaag catagaagtt attattatct tatgcagatc
481 tatgaatgaa taaataagca tttctcccat ccaccttcta attttggtga ctaggagggt
541 ttagggacag catttggttag tgggaatgat ttgattagct tagatctgac gaagactaat
601 caatgaaaac atggcagcgg caga

```

Seq ID: 227

>chzy_ch-v-067_474G>A

```

1  gattaagctt ttcattgattc ctcatagaac atgaactcaa aagaggtcag caaaggggtg
61  tgtgcgattc tttgctattg gctgcagcta tagccctgcc tccttctcca gcacataaat
121 ctttcagcag cttggctgaa gactgctgtg cagggcaggg aagctccagg caaacagccc
181 agcaaacagc agcactcagc taaaaggaag actcacagaa cacagttgaa gaaggaagt
241 ggcgATGGAC CTCATCCCAA ATTTGGCGGT GGAAACCTGG CTTCCTCTGG CTGTCAGCCT
301 GGTGCTCTCT TATCTgtgag taactgtcca aactcctctc tttgtttcct tggacttggg
361 gtgctaactc ggcccccttt cccttatctg ttttgaagat caaaagagat gttcaaggag
421 aagtagctga agtgttggac gctacaaaag catagaagtt attattatct tatgcagatc
481 tatgaatgaa taaataagca tttctcccat ccaccttcta attttggtga ctaggagggt
541 ttagggacag catttggttag tgggaatgat ttgattagct tagatctgac gaagactaat
601 caatgaaaac atggcagcgg caga

```

Seq ID: 228

>chzu_ch-v-068_359G>A

```

1  gaacagttcc ctaccacgtg gagcatttgc aattaaaagg agactgagat atagaggcag
61  gagaccacac cagatggctg ggtctcccca ctcccacccc cgccccacat acactcagaa
121 gaggctaggc atctaggatc tccattgagc atcttgaata tggcttgcca taatatcata
181 tacagtcatt aaatatttgt taaataagga tgctcttcca atataattttg tgcaaccatg
241 aagatcacca caactaatgt gagaaaaaat gtttctgttg aactctagTC TTAGGCCCA
301 GTGGGATTTA TGAAAAGTGC CATCTCTTTA GCTGAGGATG AAGAATGGAA GAGAATACAG
361 TCATTGCTGT CTCCAACCTT CACCAGCGGA AACTCAAGG AGgtatgaaa ataagatgag
421 tcttaattag aaatgtaaag aatgaatctg gggacaggta gaaagtgaaga tcacagtccg
481 tttccaaggg gtagtccact gagttcgagc ttcctaaaaa tgggtctttta tctttatgta
541 cagaaaagac atcacaaaat tcattacaaa atgtcactta ctgctccatg ctggagaaag
601 ccatactcct ctgggacttg agtctg

```

19/21

Figure 4 continued

Seq ID: 229

>peptide of ch-v-068_359G>A

1 SVFTNRRSLG PVGFMKSAIS LAEDEEWKRI Q₁SLLSPTFTS GKLEKEMFPII AQYGDVLVRN

Seq ID: 230

>chzu_ch-v-047_404T>C

1 gaacagttcc ctaccacgtg gagcatttgc aattaaaagg agactgagat atagaggcag
 61 gagaccacac cagatggctg ggtctcccca ctcccacccc cgccccacat acactcagaa
 121 gaggctaggc atctaggatc tccattgagc atcttgaata tggcttgcca taatatcata
 181 tacagtcaat aaatatttgc taaataagga tgccctcttca atatatatttgc tgcaaccatg
 241 aagatcacca caactaatgt gagaaaaaat gtttctgttg aactctagTC TTTAGGCCCA
 301 GTGGGATTTA TGAAAAGTGC CATCTCTTTA GCTGAGGATG AAGAATGGAA GAGAATACGG
 361 TCATTGCTGT CTCCAACCTT CACCAGCGGA AAACCTCAAGG AGg₁atgaaa ataagatgag
 421 tcttaattag aaatgtaaag aatgaatctg gggacaggta gaaagtaaga tcacagtccg
 481 tttccaaggg gtagtcact gagttcgagc ttcctaaaaa tggctcttta tctttatgta
 541 cagaaaagac atcacaaaat tcattacaaa atgtcactta ctgctccatg ctggagaaag
 601 ccatatcctt ctgggacttg agtctg

Seq ID: 231

>chzu_ch-v-069_480G>A

1 gaacagttcc ctaccacgtg gagcatttgc aattaaaagg agactgagat atagaggcag
 61 gagaccacac cagatggctg ggtctcccca ctcccacccc cgccccacat acactcagaa
 121 gaggctaggc atctaggatc tccattgagc atcttgaata tggcttgcca taatatcata
 181 tacagtcaat aaatatttgc taaataagga tgccctcttca atatatatttgc tgcaaccatg
 241 aagatcacca caactaatgt gagaaaaaat gtttctgttg aactctagTC TTTAGGCCCA
 301 GTGGGATTTA TGAAAAGTGC CATCTCTTTA GCTGAGGATG AAGAATGGAA GAGAATACGG
 361 TCATTGCTGT CTCCAACCTT CACCAGCGGA AAACCTCAAGG AGgtatgaaa ataagatgag
 421 tcttaattag aaatgtaaag aatgaatctg gggacaggta gaaagtaaga tcacagtcc₁
 481 tttccaaggg gtagtcact gagttcgagc ttcctaaaaa tggctcttta tctttatgta
 541 cagaaaagac atcacaaaat tcattacaaa atgtcactta ctgctccatg ctggagaaag
 601 ccatatcctt ctgggacttg agtctg

Seq ID: 232

>chzq_ch-v-061_194C>G

1 attggacatg atagctagat ttgtttcagg aaaacatcct gctttccaag gatttagatg
 61 aatgtttttg ttcactgggtg actcaggtaa cagctcttca agaagccata gggaggttga
 121 gggaggggaag tcaagaaggg aggttgagga ctgcactttt gatttacttc tgacttcacg
 181 agtcactttc tgc₁aaagaa atctctcctt ttgcttctag CACCGACTAG ATTTCTTCA
 241 GCTGATGATT GACTCCCGA ATTGGAAGA AACTGAGTCC CACAAAGgta accaaggagt
 301 gcttctgagg gctactggcg gggacactaa gagggagggc cttgttctga aaatgtgcag
 361 gaagtattcc aggaagatga gaatttttgc cacatagcag aacaacacac atttagatgt
 421 tataaatggt agctggaggc actttccaga agcccacagg tatagccatg ttccaggctg
 481 aaagggcaac cctaagcaaa cctagaatgc ttggaggaca gtcagtggtt tgtggatcac
 541 ctacatgaga tcaaatgccg gttctcagcc tcttcagat ccaccaagtg agaacctcta
 601 cttggaaatt tatatcaaac ata

Seq ID: 233

>chzn_ch-v-045_291T>C

1 caggcctggc acagagtcag tgctccataa atattttgtt aaacgatgga tggtagatgc
 61 ttttactatc cagtatttac ccagcttata gattaagtat gaagagttca agatacatgg
 121 tggttaagagt cgtttttata tgcttgcaaa gcatttttgc catattttt ctactttgct
 181 tccatctttt cttctttcac ttcatttatt aattctccat atgcttgttt aactattgta
 241 gATCCCCTTG AAATTAGACA CGCAAGGACT TCTTCAACCA GAAAAACCCA CTGTCTTAAA
 301 GGTGGATTCA AGAGATGGAA CCCTAAGTGG AGAATGAgtt attctaagga tttctacttt
 361 ggtcttcaag aaagctgtgc ccagaacac cagagatttc aacttagtca ataaaacctt

20/21

Figure 4 continued

```

421 gaaataaaga tgggcttaat ctaatgtact gcatgagtag ttggtgattt tgtacattca
481 ttgagctctc ccagagtctg tgtagagtgt tgtgcattat gtagtataaa ggaggtgacc
541 aggtaagtga cagataggta gactcagctt ctctgcttct cataggacta cctctaccca
601 cctctagtta gcatta

```

Seq ID: 234

>peptide of ch-v-045_291T>C

```

1 MRFALNMNKL ALIRVLQNFS FKPKETQIP LKLDYQGLLQ PEKPTVLKVD SRDGTLSGE.

```

Seq ID: 235

>chzk_ch-v-065_563T>C

```

1 tggtcaccca ccatgtgtac agtaccctgc taggggccag ggcatgaaa gtaaataata
61 ccagactgtg cccttgagga actcacctct gctaagggaa acaggcacag aaaccacaaa
121 ggggtggtaga gaggaaatag gacaatagga ctgtgtgagg gggataggag gcaccagag
181 gaggaaatgg ttacatctgt gtgaggaggt tggtaaggaa agactttaat agaaggggtc
241 tgtctggctg ggcttgcaag gatgtgtagg agtcatctag ggggcacaag tacactccag
301 gcagagggaa ttgcatgggt aaagatctgc agttgtggct tgtgggatg gatttcaagt
361 attctggaat gaagacagcc atggaaacaa gggcaggtga gaggatattt aagaggcttc
421 atgccaatgg ctccacttca gtttctgata agaactcagg ttccgtggac tccctgataa
481 aactgattaa gttgtttatg attccccata gaatatgaac tcaaaggagg taagcaaagg
541 ggtgtgtgcg attcttttgc adgggtgca gctgcagccc cacctccttc tccagcacat
601 aaacatttca gcagcttgac ctaagactgc tgtgcagggc agggatgctc caggcagaca
661 gcccagcaaa caacagcaca cagctgaaag taagactcag aggagacagt tgaagaaggc
721 aagtggcgat ggacctcatc ccaaatttgg cgggtgaaac ctggcttctc ctggctgtca
781 gcctggtgct cctctatctg tcagtaactg tccagattcc tctcctctgt

```

Seq ID: 236

>chzl_ch-v-040_206C>T

```

1 ggagtgcctt gattttccag gtgctgtctg tcaccctttt ctttgactag gaaagggaaac
61 tccttgaccc cttgcgcttc tcaagtgagg caatgcctcg ccctgcttcg gcttgtgcac
121 agcacgctgc acccactgtc ctgcaccac tgtctggcac tccctagtga gatgaaccg
181 gtacctcaga tgaaaatgca gaaatgaccc gtcttctgtg tcaactcacac tgggagctgt
241 agaccggagc tgttcctatt cggccatctt ggctccacc cccgagtttt ggcttttaac
301 tgaaagtgtg ttgatgtggg aaggagataa tgccatgcat ttatgagcac atattagagg
361 gtctgagaca atgcatgtga taaaagggtc cctaaggaag aaaaaagaa caagggaaga
421 cactggaaag aacgtgatgc tgggagtcct tgggccacca aagtctggag aaaagtggta
481 accacaaggc tcccagccta gtttactga agacctcgac actaggtgac ttatgggac
541 cttggtagga caagccttga aaagttttac aatagcaaat gtggacgttg tcagaaccaa
601 atgatgtcac gtgtgtattt gtgtgtgtgt gtcagtgtgt gtgtttaaaa atcatgacaa
661 ataaagcagg ctgtgaagag gggattccca tgctcgtgtg cctgataaca caactatcac
721 aaacgctttg cgaaaccaca agtttgcaca aaggcaatcc caaccttaca caaaa

```

21/21

Figure 5

>CYP3A5 insert in pKK233-2 (Seq ID 144)

```

1  ccATGgctct gttattagca gtttttCTGG TGCTCCTCTA TCTATATGGG ACCCGTACAC
61 ATGGACTTTT TAAGAGACTG GGAATTCCAG GGCCACACACC TCTGCCTTTG TTGGGAAATG
121 TTTTGTCTTA TCGTCAGGGT CTCTGGAAAT TTGACACAGA GTGCTATAAA AAGTATGGAA
181 AAATGTGGGG AACGTATGAA GGTCAACTCC CTGTGCTGGC CATCACAGAT CCCGACGTGA
241 TCAGAACAGT GCTAGTGAAA GAATGTTATT CTGTCTTCAC AAATCGAAGG TCTTTAGGCC
301 CAGTGGGATT TATGAAAAGT GCCATCTCTT TAGCTGAGGA TGAAGAATGG AAGAGAATAC
361 GGTCAATTGCT GTCTCCAACC TTCACCAGCG GAAAACCTCA GGAGATGTTT CCCATCATTTG
421 CCCAGTATGG AGATGTATTG GTGAGAAACT TGAGGCGGGA AGCAGAGAAA GGCAAGCCTG
481 TCACCTTGAA AGACATCTTT GGGGCCTACA GCATGGATGT GATTAETGGC ACATCATTTG
541 GAGTGAACAT CGACTCTCTC AACAATCCAC AAGACCCCTT TGTGGAGAGC ACTAAGAAGT
601 TCCTAAAATT TGGTTTCTTA GATCCATTAT TTCTCTCAAT AATACTCTTT CCATTCTTTA
661 CCCAGTTTTT TGAAGCATTA AATGTCTCTC TGTTTCCAAA AGATACCATA AATTTTTTTAA
721 GTAAATCTGT AAACAGAATG AAGAAAAGTC GCCTCAACGA CAAACAAAAG CACCGACTAG
781 ATTTCTTTCA GCTGATGATT GACTCCCAGA ATTTCGAAAG AACTGAGTCC CACAAAGCTC
841 TGTCTGATCT GGAGCTCGCA GCCCAGTCAA TAATCTTCAT TTTTGCTGGC TATGAAACCA
901 CCAGCAGTGT TCTTTCCTTC ACTTTATATG AACTGGCCAC TCACCCTGAT GTCCAGCAGA
961 AACTGCAAAA GGAGATTGAT GCAGTTTTGC CCAATAAGGC ACCACCTACC TATGATGCCG
1021 TGGTACAGAT GGAGTACCTT GACATGGTGG TGAATGAAAC ACTCAGATTA TTCCCAGTTG
1081 CTATTAGACT TGAGAGGACT TGCAAGAAAG ATGTTGAAAT CAATGGGGTA TTCATTCCCA
1141 AAGGGTCAAT GGTGGTGATT CCAAGTTATG CTCTTCACCA TGACCCAAAG TACTGGACAG
1201 AGCCTGAGGA GTTCCGCCCT GAAAGGTTCA GTAAGAAGAA GGACAGCATA GATCCTTACA
1261 TATACACACC CTTTGGAAC TGGACCCAGAA ACTGCATTGG CATGAGGTTT GCTCTCATGA
1321 ACATGAAACT TGCTCTAATC AGAGTCCTTC AGAACTTCTC CTTCAAACCT TGTAAAGAAA
1381 CACAGATCCC CTTGAAATTA GACACGCAAG GACTTCTTCA ACCAGAAAAA CCCATTGTTC
1441 TAAAGGTGGA TTCAAGAGAT GGAACCCTAA GTGGAGAAca tcaccatcac catcactGAg
1501 atctgcag

```

SEQUENCE LISTING

<110> EPIDAUROS Biotechnologie AG

<120> Identification of the genetic determinants of the
polymorphic CYP3A5 expression

<130> E 3103 PCT

<140>

<141>

<150> EP 00 12 8627.7

<151> 2000-12-28

<150> EP 01 10 0172.4

<151> 2001-01-16

<150> EP 01 11 8884.4

<151> 2001-08-16

<150> US 60/258,684

<151> 2000-12-28

<150> US 60/258,952

<151> 2000-12-29

<150> US 60/262,859

<151> 2001-01-18

<150> US 60/312,825

<151> 2001-08-16

<160> 239

<170> PatentIn Ver. 2.1

<210> 1

<211> 21

<212> DNA

<213> Homo sapiens

<400> 1

acaggcacag aaaccacaa g

21

<210> 2

<211> 19

<212> DNA

<213> Homo sapiens

<400> 2

atcgccactt gccttcttc

19

<210> 3

<211> 19

<212> DNA

<213> Homo sapiens

<400> 3

ccctgcttcg gcttgtgca

19

<210> 4
<211> 24
<212> DNA
<213> Homo sapiens

<400> 4
cacagcctgc tttatttgtc atga 24

<210> 5
<211> 21
<212> DNA
<213> Homo sapiens

<400> 5
gataccttggg aggacaagcc t 21

<210> 6
<211> 24
<212> DNA
<213> Homo sapiens

<400> 6
caagcactga tttgggtcact tcct 24

<210> 7
<211> 22
<212> DNA
<213> Homo sapiens

<400> 7
gggatgggac cgtaagtgga ac 22

<210> 8
<211> 26
<212> DNA
<213> Homo sapiens

<400> 8
taatcacatt ggagttctga caaatg 26

<210> 9
<211> 30
<212> DNA
<213> Homo sapiens

<400> 9
aaaaacctct tacaaaagta tcatcggata 30

<210> 10
<211> 27
<212> DNA
<213> Homo sapiens

<400> 10
cctactaggt ctctgacttg gaaccat 27

<210> 11
<211> 21
<212> DNA
<213> Homo sapiens

<400> 11
gccgagacgc accattacac t 21

<210> 12
<211> 21
<212> DNA
<213> Homo sapiens

<400> 12
cacccatccc ttcccactca t 21

<210> 13
<211> 28
<212> DNA
<213> Homo sapiens

<400> 13
tgatggttcc aagtcagaga cctagtag 28

<210> 14
<211> 35
<212> DNA
<213> Homo sapiens

<400> 14
aattgtagac atctttctct taagttaatt cccag 35

<210> 15
<211> 25
<212> DNA
<213> Homo sapiens

<400> 15
tctgcatgcc aacagtgaac aatct 25

<210> 16
<211> 19
<212> DNA
<213> Homo sapiens

<400> 16
ggcacgcacc agcatgtcc 19

<210> 17
<211> 19
<212> DNA
<213> Homo sapiens

<400> 17
ctggctgagt gccgtggct 19

<210> 18
<211> 25
<212> DNA
<213> Homo sapiens

<400> 18
tgagcgcttc atgtattctg gctat 25

<210> 19
<211> 31
<212> DNA
<213> Homo sapiens

<400> 19
aaatattttc aaagtcacac tctgacaaca g 31

<210> 20
<211> 29
<212> DNA
<213> Homo sapiens

<400> 20
taacaggatc tcatgctttt ttcattggct 29

<210> 21
<211> 30
<212> DNA
<213> Homo sapiens

<400> 21
cactccaata ttcacaatag ccactattca 30

<210> 22
<211> 24
<212> DNA
<213> Homo sapiens

<400> 22
actcctacgt atccttccaa gccc 24

<210> 23
<211> 28
<212> DNA
<213> Homo sapiens

<400> 23
gctaagggaac acaggcatag aaacttac 28

<210> 24
<211> 18
<212> DNA
<213> Homo sapiens

<400> 24
ggagcttccc tgccctgc 18

<210> 25
<211> 21
<212> DNA
<213> Homo sapiens

<400> 25
tccttctcca gcacataaat c 21

<210> 26
<211> 21
<212> DNA
<213> Homo sapiens

<400> 26
aaattagaag gtggatggga g 21

<210> 27
<211> 21
<212> DNA
<213> Homo sapiens

<400> 27
gagtaactca ccagccctct g 21

<210> 28
<211> 21
<212> DNA
<213> Homo sapiens

<400> 28
aaacctcaga actccctccc a 21

<210> 29
<211> 23
<212> DNA
<213> Homo sapiens

<400> 29
gacatctctg aatagcttcc ttc 23

<210> 30
<211> 21
<212> DNA
<213> Homo sapiens

<400> 30
gcacatagtt tataacggca a 21

<210> 31
<211> 23
<212> DNA
<213> Homo sapiens

<400> 31
agaacctaaag gttgctgtgt gtc 23

<210> 32
<211> 21
<212> DNA
<213> Homo sapiens

<400> 32
tgcaagatgt taccactggg c

21

<210> 33
<211> 20
<212> DNA
<213> Homo sapiens

<400> 33
cgccccacat aactcagaa

20

<210> 34
<211> 21
<212> DNA
<213> Homo sapiens

<400> 34
agaccatttt taggaagctc g

21

<210> 35
<211> 22
<212> DNA
<213> Homo sapiens

<400> 35
caaggggtag tccactgagt tc

22

<210> 36
<211> 18
<212> DNA
<213> Homo sapiens

<400> 36
ctctttggag ttgcagcg

18

<210> 37
<211> 21
<212> DNA
<213> Homo sapiens

<400> 37
aggtgagtct aactcagctt g

21

<210> 38
<211> 21
<212> DNA
<213> Homo sapiens

<400> 38
gacagctaaa gtgtgtgagg g

21

<210> 39
<211> 21
<212> DNA
<213> Homo sapiens

<400> 39
aatgggttcc agttgagaat c 21

<210> 40
<211> 21
<212> DNA
<213> Homo sapiens

<400> 40
attgttgatgc ctgatttcaa g 21

<210> 41
<211> 19
<212> DNA
<213> Homo sapiens

<400> 41
agaagccata gggagggtg 19

<210> 42
<211> 20
<212> DNA
<213> Homo sapiens

<400> 42
gactgtcctc caagcattct 20

<210> 43
<211> 21
<212> DNA
<213> Homo sapiens

<400> 43
gatgccatga tgaggagtgt g 21

<210> 44
<211> 19
<212> DNA
<213> Homo sapiens

<400> 44
accagggcca gcaatattg 19

<210> 45
<211> 25
<212> DNA
<213> Homo sapiens

<400> 45
aaatacttca cgaatactat gatca 25

<210> 46
<211> 24
<212> DNA
<213> Homo sapiens

<400> 46
cagggacata attgattatc ttg

24

<210> 47
<211> 19
<212> DNA
<213> Homo sapiens

<400> 47
tactggttg gaggtggag

19

<210> 48
<211> 23
<212> DNA
<213> Homo sapiens

<400> 48
catgatgttc ttaatgctac agg

23

<210> 49
<211> 25
<212> DNA
<213> Homo sapiens

<400> 49
gaagagttca agatacatgg tgtta

25

<210> 50
<211> 23
<212> DNA
<213> Homo sapiens

<400> 50
tgcacaacac tctacacaga ctc

23

<210> 51
<211> 11
<212> DNA
<213> Homo sapiens

<400> 51
tgggcttgca a

11

<210> 52
<211> 11
<212> DNA
<213> Homo sapiens

<400> 52
tgggcgtgca a

11

<210> 53
<211> 11
<212> DNA
<213> Homo sapiens

<400> 53
gcatgggtaa a 11

<210> 54
<211> 11
<212> DNA
<213> Homo sapiens

<400> 54
gcatgagtaa a 11

<210> 55
<211> 11
<212> DNA
<213> Homo sapiens

<400> 55
ggggtgtgtg c 11

<210> 56
<211> 11
<212> DNA
<213> Homo sapiens

<400> 56
ggggtatgtg c 11

<210> 57
<211> 11
<212> DNA
<213> Homo sapiens

<400> 57
tgtgcgattc t 11

<210> 58
<211> 11
<212> DNA
<213> Homo sapiens

<400> 58
tgtgcaattc t 11

<210> 59
<211> 11
<212> DNA
<213> Homo sapiens

<400> 59
gccccacctc c 11

<210> 60
<211> 11
<212> DNA
<213> Homo sapiens

<400> 60
gccccgcctc c 11

<210> 61
<211> 11
<212> DNA
<213> Homo sapiens

<400> 61
ctcacactgg g 11

<210> 62
<211> 11
<212> DNA
<213> Homo sapiens

<400> 62
ctcacgctgg g 11

<210> 63
<211> 11
<212> DNA
<213> Homo sapiens

<400> 63
gagacgcacc a 11

<210> 64
<211> 11
<212> DNA
<213> Homo sapiens

<400> 64
gagacacacc a 11

<210> 65
<211> 11
<212> DNA
<213> Homo sapiens

<400> 65
tgtgtgtggg a 11

<210> 66
<211> 11
<212> DNA
<213> Homo sapiens

<400> 66
tgtgtatggg a 11

<210> 67
<211> 11
<212> DNA
<213> Homo sapiens

<400> 67
atccatgtat a 11

<210> 68
<211> 11
<212> DNA
<213> Homo sapiens

<400> 68
atccacgtat a 11

<210> 69
<211> 11
<212> DNA
<213> Homo sapiens

<400> 69
catcttacc c 11

<210> 70
<211> 11
<212> DNA
<213> Homo sapiens

<400> 70
catctcacc c 11

<210> 71
<211> 11
<212> DNA
<213> Homo sapiens

<400> 71
tctattgcta t 11

<210> 72
<211> 11
<212> DNA
<213> Homo sapiens

<400> 72
tctatagcta t 11

<210> 73
<211> 11
<212> DNA
<213> Homo sapiens

<400> 73
ggcaggaag c 11

<210> 74
<211> 11
<212> DNA
<213> Homo sapiens

<400> 74
ggcagagaag c 11

<210> 75
<211> 11
<212> DNA
<213> Homo sapiens

<400> 75
ccaggcaaac a 11

<210> 76
<211> 11
<212> DNA
<213> Homo sapiens

<400> 76
ccaggtaaac a 11

<210> 77
<211> 11
<212> DNA
<213> Homo sapiens

<400> 77
tcaaggagaa g 11

<210> 78
<211> 11
<212> DNA
<213> Homo sapiens

<400> 78
tcaagaagta g 11

<210> 79
<211> 11
<212> DNA
<213> Homo sapiens

<400> 79
gtacacatgg a 11

<210> 80
<211> 11
<212> DNA
<213> Homo sapiens

<400> 80
gtacatatgg a 11

<210> 81
<211> 10
<212> DNA
<213> Homo sapiens

<400> 81
catggacttt 10

<210> 82
<211> 11
<212> DNA
<213> Homo sapiens

<400> 82
catgggactt t 11

<210> 83
<211> 11
<212> DNA
<213> Homo sapiens

<400> 83
gatagcaggc c 11

<210> 84
<211> 11
<212> DNA
<213> Homo sapiens

<400> 84
gatagtaggc c 11

<210> 85
<211> 11
<212> DNA
<213> Homo sapiens

<400> 85
agaatcgggc t 11

<210> 86
<211> 11
<212> DNA
<213> Homo sapiens

<400> 86
agaatagggc t 11

<210> 87
<211> 11
<212> DNA
<213> Homo sapiens

<400> 87
ttattctgtc t 11

<210> 88
<211> 11
<212> DNA
<213> Homo sapiens

<400> 88
ttattatgtc t 11

<210> 89
<211> 11
<212> DNA
<213> Homo sapiens

<400> 89
gtacaggaag g 11

<210> 90
<211> 11
<212> DNA
<213> Homo sapiens

<400> 90
cctaaaaaat g 11

<210> 91
<211> 11
<212> DNA
<213> Homo sapiens

<400> 91
tcttttatct t 11

<210> 92
<211> 11
<212> DNA
<213> Homo sapiens

<400> 92
tctttgatct t 11

<210> 93
<211> 11
<212> DNA
<213> Homo sapiens

<400> 93
gagtctgcac a 11

<210> 94
<211> 11
<212> DNA
<213> Homo sapiens

<400> 94
gagtccgcac a 11

<210> 95
<211> 11
<212> DNA
<213> Homo sapiens

<400> 95
gaagtcaaga a 11

<210> 96
<211> 11
<212> DNA
<213> Homo sapiens

<400> 96
agtcgtcaag a 11

<210> 97
<211> 11
<212> DNA
<213> Homo sapiens

<400> 97
aggaagtatt c 11

<210> 98
<211> 11
<212> DNA
<213> Homo sapiens

<400> 98
aggaattatt c 11

<210> 99
<211> 11
<212> DNA
<213> Homo sapiens

<400> 99
agagagcttc a 11

<210> 100
<211> 11
<212> DNA
<213> Homo sapiens

<400> 100
agagaacttc a 11

<210> 101
<211> 11
<212> DNA
<213> Homo sapiens

<400> 101
cttcaatagt a 11

<210> 102
<211> 11
<212> DNA
<213> Homo sapiens

<400> 102
cttcagtagt a 11

<210> 103
<211> 11
<212> DNA
<213> Homo sapiens

<400> 103
tccaacttat g 11

<210> 104
<211> 11
<212> DNA
<213> Homo sapiens

<400> 104
tccaaattat g 11

<210> 105
<211> 11
<212> DNA
<213> Homo sapiens

<400> 105
cgaaactaca t 11

<210> 106
<211> 11
<212> DNA
<213> Homo sapiens

<400> 106
cgaaattaca t 11

<210> 107
<211> 11
<212> DNA
<213> Homo sapiens

<400> 107
aaggatttct a 11

<210> 108
<211> 11
<212> DNA
<213> Homo sapiens

<400> 108
aaggacttct a 11

<210> 109
<211> 11
<212> DNA
<213> Homo sapiens

<400> 109
agctccgttg t 11

<210> 110
<211> 11
<212> DNA
<213> Homo sapiens

<400> 110
agctctgttg t 11

<210> 111
<211> 10
<212> DNA
<213> Homo sapiens

<400> 111
cacctaccta 10

<210> 112
<211> 11
<212> DNA
<213> Homo sapiens

<400> 112
caccttacct a 11

<210> 113
<211> 830
<212> DNA
<213> Homo sapiens

<400> 113
tggtcaccca ccatgtgtac agtaccctgc taggggccag ggtcatgaaa gtaaataata 60
ccagactgtg cccttgagga actcacctct gctaagggaa acaggcacag aaaccacaa 120
gggtggtaga gaggaatag gacaatagga ctgtgtgagg gggataggag gcaccagag 180
gaggaaatgg ttacatctgt gtgaggaggt tggtaaggaa agactttaat agaaggggtc 240
tgtctggctg ggcgtgcaag gatgtgtagg agtcactctag ggggcacaag tacactccag 300
gcagagggaa ttgcatgggt aaagatctgc agttgtggct tgtggggatg gatttcaagt 360
attctggaat gaagacagcc atggaaacaa gggcaggtga gaggatattt aagaggcttc 420
atgccaatgg ctccacttca gtttctgata agaactcagg ttccgtggac tccctgataa 480
aactgattaa gttgtttatg attccccata gaatatgaac tcaaaggagg taagcaaagg 540
ggtgtgtgcg attctttgct actggctgca gctgcagccc cgcctccttc tccagcacat 600
aaacatttca gcagcttgac ctaagactgc tgtgcagggc agggatgctc caggcagaca 660
gcccagcaaa caacagcaca cagctgaaag taagactcag aggagacagt tgaagaaggc 720
aagtggcgat ggacctcatc ccaaatttgg cgggtggaac ctggcttctc ctggctgtca 780
gcctggtgct cctctatctg tcagtaactg tccagattcc tctcctctgt 830

<210> 114
<211> 830
<212> DNA
<213> Homo sapiens

<400> 114

```
tggtcaccca ccatgtgtac agtaccctgc taggggccag ggatcatgaaa gtaaataata 60
ccagactgtg cccttgagga actcacctct gctaagggaa acaggcacag aaaccacaa 120
gggtggtaga gaggaaatag gacaatagga ctgtgtgagg gggataggag gcaccagag 180
gaggaaatgg ttacatctgt gtgaggaggt tggtaggaa agactttaat agaaggggtc 240
tgtctggctg ggcttgcaag gatgtgtagg agtcatctag ggggcacaag tacactccag 300
gcagagggaa ttgcatgagt aaagatctgc agttgtggct tgtggggatg gatttcaagt 360
attctggaat gaagacagcc atggaaacaa gggcaggtga gaggatattt aagaggcttc 420
atgccaatgg ctccacttca gtttctgata agaactcagg ttccgtggac tccctgataa 480
aactgattaa gttgtttatg attcccata gaatatgaac tcaaaggagg taagcaaagg 540
gggtgtgtcg attctttgct actggctgca gctgcagccc cacctccttc tccagcacat 600
aaacatttca gcagcttgac ctaagactgc tgtgcagggc agggatgctc caggcagaca 660
gcccagcaaa caacagcaca cagctgaaag taagactcag aggagacagt tgaagaaggc 720
aagtggcgat ggacctcatc ccaaatttgg cgggtgaaac ctggcttctc ctggctgtca 780
gcctgggtgct cctctatctg tcagtaactg tccagattcc tctcctctgt 830
```

<210> 115

<211> 830

<212> DNA

<213> Homo sapiens

<400> 115

```
tggtcaccca ccatgtgtac agtaccctgc taggggccag ggatcatgaaa gtaaataata 60
ccagactgtg cccttgagga actcacctct gctaagggaa acaggcacag aaaccacaa 120
gggtggtaga gaggaaatag gacaatagga ctgtgtgagg gggataggag gcaccagag 180
gaggaaatgg ttacatctgt gtgaggaggt tggtaggaa agactttaat agaaggggtc 240
tgtctggctg ggcttgcaag gatgtgtagg agtcatctag ggggcacaag tacactccag 300
gcagagggaa ttgcatgggt aaagatctgc agttgtggct tgtggggatg gatttcaagt 360
attctggaat gaagacagcc atggaaacaa gggcaggtga gaggatattt aagaggcttc 420
atgccaatgg ctccacttca gtttctgata agaactcagg ttccgtggac tccctgataa 480
aactgattaa gttgtttatg attcccata gaatatgaac tcaaaggagg taagcaaagg 540
ggatgtgtcg attctttgct actggctgca gctgcagccc cacctccttc tccagcacat 600
aaacatttca gcagcttgac ctaagactgc tgtgcagggc agggatgctc caggcagaca 660
gcccagcaaa caacagcaca cagctgaaag taagactcag aggagacagt tgaagaaggc 720
aagtggcgat ggacctcatc ccaaatttgg cgggtgaaac ctggcttctc ctggctgtca 780
gcctgggtgct cctctatctg tcagtaactg tccagattcc tctcctctgt 830
```

<210> 116

<211> 830

<212> DNA

<213> Homo sapiens

<400> 116

```
tggtcaccca ccatgtgtac agtaccctgc taggggccag ggatcatgaaa gtaaataata 60
ccagactgtg cccttgagga actcacctct gctaagggaa acaggcacag aaaccacaa 120
gggtggtaga gaggaaatag gacaatagga ctgtgtgagg gggataggag gcaccagag 180
gaggaaatgg ttacatctgt gtgaggaggt tggtaggaa agactttaat agaaggggtc 240
tgtctggctg ggcttgcaag gatgtgtagg agtcatctag ggggcacaag tacactccag 300
gcagagggaa ttgcatgggt aaagatctgc agttgtggct tgtggggatg gatttcaagt 360
attctggaat gaagacagcc atggaaacaa gggcaggtga gaggatattt aagaggcttc 420
atgccaatgg ctccacttca gtttctgata agaactcagg ttccgtggac tccctgataa 480
aactgattaa gttgtttatg attcccata gaatatgaac tcaaaggagg taagcaaagg 540
gggtgtgtgca attctttgct actggctgca gctgcagccc cacctccttc tccagcacat 600
aaacatttca gcagcttgac ctaagactgc tgtgcagggc agggatgctc caggcagaca 660
gcccagcaaa caacagcaca cagctgaaag taagactcag aggagacagt tgaagaaggc 720
aagtggcgat ggacctcatc ccaaatttgg cgggtgaaac ctggcttctc ctggctgtca 780
gcctgggtgct cctctatctg tcagtaactg tccagattcc tctcctctgt 830
```

<210> 117

<211> 775
<212> DNA
<213> Homo sapiens

<400> 117
ggagtgcacct gattttccag gtgctgtctg tcaccccttt ctttgactag gaaaggggaac 60
tccttgacct cttgcgcttc tcaagtgcag caatgcctcg ccctgcttcg gcttgtgcac 120
agcacgctgc acccactgtc ctgcacccac tgtctggcac tccctagtga gatgaaccgc 180
gtacctcaga tgaatatgca gaaatcaccg gtcttctgtg tcaactcacgc tgggagctgt 240
agaccggagc tgttcctatt cggccatctt ggctccaccc ccgagtttt ggcttttaaat 300
tgaaagtgtg ttgatgtggg aaggagataa tgccatgcat ttatgagcac atattagagg 360
gtctgagaca atgcatgtga taaaagggtc cctaaggaag aaaaaaagaa caaggggaaga 420
cactggaaag aacgtgatgc tgggagtcctc tggggccacca aagtctggag aaaagtggta 480
accacaaggc tccagccta gtttcactga agacctcgac actaggtgac ttatgggac 540
cttggttagga caagccttga aaagttttac aatagcaaat gtggacgttg tcagaaccaa 600
atgatgtcac gtgtgtatct gtgtgtgtgt gtcagtgtgt gtgtttaaaa atcatgacaa 660
ataaagcagg ctgtgaagag gggattccca tgctcgtgtg cctgataaca caactatcac 720
aaacgccttg cgaaaccaca agtttgcaca aaggcaatcc caaccttaca caaaa 775

<210> 118
<211> 1110
<212> DNA
<213> Homo sapiens

<400> 118
taatgaaaat aagaattatt ttgatggctc taacagtgac atttatatca tctgttttat 60
ctggagcatt ctataataag tttatattaa gcaaatcaat aaaaacctct tacaaaagta 120
tcacggata ctttcctgaa catlaaggag aaatctatag aactgaatga atgagaacca 180
acaagtaaat atatgtgatc attgtaacca ttgttgggtg ggggcatttg tcagaactcc 240
aatgtgatta ttaacatagg tgagaattaa tccactgtga ctttgcccat tgcttagaaa 300
gaacattcat agtttaatta tgcctttttt gaccaagcac agtggctcat gcctgtaate 360
ccagcacttt gggaggccga ggtgggtgga tcacctgagg tcaggagttc gagaccagcc 420
tgaccaacat ggtgaaaccc catctctact aaaaatacaa aaattagcta ggtgtgggtg 480
tatgcaccta taatctcagc taccaggag gctgaggcag gagaatcact tgaacctgga 540
ggcagagggt gcagtgagcc gagacacacc attacactcc agcctgggtg acagagttag 600
attccatctc aaaaaaaaaa aaaaaaaatt atgccttttt gaagcacata cattttataa 660
catacaactg aatcccttat tatattatta gttttgattt aatgttttca aaccatctcc 720
cctgatattt ctgggagatg ggaaacatgt tttcttacac ctcttgcatc ccattctcaa 780
ctcccaactg tcttactgca atgaacactt aataagaaac agtcaattgg tcaattgatt 840
gggcaacagg ctaaacacac tcattccttg tctgttccca cttctttctt tactttccct 900
tcctgagtaa cttatcctaa agtcattagg tgggtggcag ccagatggtg gccacacatt 960
aagtagcaca agagatgtgc atgatggtc caagtcagag acctagttag gtgaggatca 1020
agtaggtgtt cacgtggaga aacagcccg cctgtgtgtg ggagtcgaag caagcagaga 1080
aatgtcgcac acagaggggt ggcctgaaaa 1110

<210> 119
<211> 837
<212> DNA
<213> Homo sapiens

<400> 119
caaaaattag ctaggtgtgg tggatgcac ctataatctc agctaccag gaggtgagg 60
caggagaatc acttgaacct ggaggcagag gttgcagtga gccgagacgc accattacac 120
tcagcctgg gtgacagagt gagattccat ctcaaaaaaa aaaaaaaaaa attatgcctt 180
tttgaagcac atacatttta taacatacaa ctgaatccct tattatatta ttagttttga 240
tttaatgttt tcaaacatc tcccctgata tttctgggag atgggaaaca tgttttctta 300
cacctcttgc attccattct caactcccaa ctgtcttact gcaatgaaca ctttaataaga 360
aacagtcaat tgggtcaattg attgggcaac aggctaaaca cactcattcc ttgtctgttc 420
ccacttcttt ctttactttc ctttcctgag taacttatcc taaagtcatc aggtgggtgg 480
cagccagatg gtggccacac attaaggtag aaaagagagt gtcatgatgg ttccaagtca 540
gagacctagt agggtaggga tcaagtaggt gttcacgtgg agaaacagcc cggcctgtgt 600

```
atggggagtcc aagcaagcag agaaaatgtc gacacagagg ggtggcctga aaaagcagcc oov
agagcctaaa cagggcatgg agaacatatt tagggcatga ggtgaggagg gcatccatga 720
gtgggaaggg atgggtgagg ttctactaca taaaggggat tgatgaaata agtaataaaa 780
gtatactgga agccaggtgt gtcacttttg cagaaaagag tcatggattc agaaagg 837
```

<210> 120

<211> 1197

<212> DNA

<213> Homo sapiens

<400> 120

```
ttctttcttt actttccctt cctgagtaac ttatcctaaa gtcattaggt ggggtggcagc 60
cagatgggtgg ccacacatta aggtagaaaa gagagtgtca tgatggttcc aagtccagaga 120
cctagtaggg tgaggatcaa gtaggtgttc acgtggagaa acagcccggc ctgtgtgtgg 180
gagtccaagc aagcagagaa aatgtcgaca cagaggggtg gcctgaaaaa gcagccagag 240
cctaaacagg gcatggagaa cataatttagg gcatgagggtg aggagggcat ccatgagtgg 300
gaagggatgg gtgaggtttc actacataaa ggggattgat gaaataagta aataaagtat 360
actggaagcc aggtgtgtca cttttgcaga aaagagtcac ggattcagaa agggagaaaa 420
ctagcaggaa tcctatgaaa ttagattaaa atggatgtat ccacgtatat tcataccctt 480
ctagatagat aaatggttag ataggtgata aaaaagataac aagaggacaa gataattaga 540
tagacataaa tgtatgtatg tgtttgtgtg tgtgtacaaa aaaacatata ctccctactt 600
ctctccatgc atgggctag gtaacaatgg gtaattcaata gcaatgagca cacttagtgg 660
ccagatcctg gcttattaat accattttcc actgaaagga accagagctt tttagagaaa 720
tggtgattc cagggccagg attaagaatg ttcaagataa gcctaggata cattttgtgc 780
caggaagcaa gaagatgttc aaatgatttc caagtaatgt ttggaaatga tatttgaaaa 840
tgatttccaa atgatatttc caaatgattt ccaaatgata tatggaaaca cttaaagact 900
ccactaaaga actattagat ctgataaaca aattcagtaa tgttctgga taaaaaatca 960
acatacaaaa accagtagca tttctgcatg ccaacagtga acaatctggc aaaaataaaa 1020
aatgtaatcc catttacaat aaccctaat aaaactaat acctgggaat taacttaaga 1080
gaaagatgtc tacaattaat attgtaaaac actgatgaag gaaattgaag aagacacaaa 1140
aaagaaggat attccatggt tatatatgtt aagcattaat attgttaaaa atgtcca 1197
```

<210> 121

<211> 817

<212> DNA

<213> Homo sapiens

<400> 121

```
caaaagcaaaa atggacaaat ggatcagatc aagttaaaaa gcttctgtac caaaaagaaa 60
gcaatcaaca aagtgaagac acaaaccaca gaatgggaga aaatattttc aaagtcacac 120
tctgacaaca gattaatagc cagaatacat gaagcgctca acaactctg taaggaaaaa 180
tctaataatc caatcaaaaa atgggcaaaa ttggaataga catttttcaa aagaagacat 240
acaaatgccca caataaggta tgataagggtg ctcaacatca ctggtcatta gagaaatgca 300
aatcaaaaacc acaatgagat atcatctcac cccagctaaa atgggtttta tccaaaagac 360
aggcaacaac aaatgccagc gagaatgtgg agaaaaggga acccttgtag actgttggtg 420
taaattagtg caaccactat agagaacaat ttggagggtc ctcaaaacat taaaattaac 480
attaaataga gctaccacaa tatccagaaa tccccatgct gggatatata ctggaagaaa 540
ggaaatcata tattgaagag ataacatcac tccaatattc acaatagcca ctattcaca 600
atgccaagat ttggaagcaa cctaagtgct catcaacaga tgaatggata aagaaagtac 660
tccaattata cacaatggag cacaattcag ccatgaaaaa agcatgagat cctgttatct 720
gtaataatat ggatggaact ggaggtcatc atgttaagtg aaataagcca ggcacagaaa 780
cacagatatt gcaagttctc acatacttgt gggatct 817
```

<210> 122

<211> 1126

<212> DNA

<213> Homo sapiens

<400> 122

```
cattaaaaatt aacattaaat agagctacca caatatccag aaatccccat gctgggtata 60
```

```

tacctggaag aaaggaaatc atatattgaa gagataacat cactccaata cccacaacag 120
ccactattca caaatgccaa gatttggaag caacctaatg gtccatcaac agatgaatgg 180
ataaagaaag tactccaatt atacacaatg gagcacaatt cagccatgaa aaaagcatga 240
gatcctgtta tctgtaataa tatggatgga actggagggtc atcatgttaa gtgaaataag 300
ccaggcacag aaacacagat attgcaagtt ctcacatact tgtgggatct acaaatcaaa 360
acaactgagc taatgtcttg gccttagtca gtgtgtgacc caagtactgg gagcacagct 420
tttaaaatac atcatgaatg ctttaataca ggaatgaata gatgagaggc acaaactggg 480
tgggtgttct tctgatacac agtatcttcc ttgacagatt cagtacaact ctcaacagg 540
aagtctcttc atgttatgtt accttatgag gaattaagtg gcagaacatg atttctatta 600
ttttcctttg cagaacaaga ccaactttat tagttgggac acagtgtggc tgcatttgag 660
tccaagcaa ccattagtct atagctatca ccacagagtc agaggggatg agacgccag 720
caatctcacc caagacaact ccaccaacat tctgtgttac ccacatgtg tacagtaccc 780
tgctaggaac cagggtcatg aaagtaaata ataccagact gtgcccttga ggagctcacc 840
tctgctaagg gaaacaggca tagaaactta caatggtggt agagagaaaa gaggacaata 900
ggactgtgtg agggggatag gaggcaccca gagggagaaa tgggtacatt tgtgtgagga 960
ggttggttaag gaaaaatttt agcagaaggg gtctgtctgg ctgggcttgg aaggatacgt 1020
aggagtcatc tagagggcac aggtacactc caggcagagg gaatttcgtg ggtaaagatg 1080
tgtaggtgtg gcttgtgagg atggatttca attattctag aatgaa 1126

```

<210> 123

<211> 624

<212> DNA

<213> Homo sapiens

<400> 123

```

gattaagctt ttcattgattc ctcatagaac atgaactcaa aagaggtcag caaaggggtg 60
tgtgcgattc tttgctattg gctgcagcta tagccctgcc tccttctcca gcacataaat 120
ctttcagcag cttggctgaa gactgctgtg cagggcagag aagctccagg caaacagccc 180
agcaaacagc agcactcagc taaaaggaag actcacagaa cacagttaa gaaggaaagt 240
ggcgatggac ctcatcccaa atttggcggg ggaaacctgg cttctcctgg ctgtcagcct 300
ggtgctctc tatctgtgag taactgtcca aactcctctc tttgttctc tggacttggg 360
gtgctaatac ggcccccttt cccttatctg ttttgaagat caaaagagat gttcaaggag 420
aagtagctga agtggttgac gctacaaacg catagaagtt attattatct tatgcagatc 480
tatgaatgaa taaataagca tttctcccat ccaccttcta attttgggtga ctaggagggt 540
ttagggacag catttggtag tgggaatgat ttgattagct tagatctgac gaagactaat 600
caatgaaaac atggcagcgg caga 624

```

<210> 124

<211> 624

<212> DNA

<213> Homo sapiens

<400> 124

```

gattaagctt ttcattgattc ctcatagaac atgaactcaa aagaggtcag caaaggggtg 60
tgtgcgattc tttgctattg gctgcagcta tagccctgcc tccttctcca gcacataaat 120
ctttcagcag cttggctgaa gactgctgtg cagggcaggg aagctccagg taaacagccc 180
agcaaacagc agcactcagc taaaaggaag actcacagaa cacagttaa gaaggaaagt 240
ggcgatggac ctcatcccaa atttggcggg ggaaacctgg cttctcctgg ctgtcagcct 300
ggtgctctc tatctgtgag taactgtcca aactcctctc tttgttctc tggacttggg 360
gtgctaatac ggcccccttt cccttatctg ttttgaagat caaaagagat gttcaaggag 420
aagtagctga agtggttgac gctacaaacg catagaagtt attattatct tatgcagatc 480
tatgaatgaa taaataagca tttctcccat ccaccttcta attttgggtga ctaggagggt 540
ttagggacag catttggtag tgggaatgat ttgattagct tagatctgac gaagactaat 600
caatgaaaac atggcagcgg caga 624

```

<210> 125

<211> 621

<212> DNA

<213> Homo sapiens

<400> 125
 gattaagctt ttcattgatc ctcataagaac atgaactcaa aagagggtcag caaaggggtg 60
 tgtgcgattc tttgctattg gctgcagcta tagccctgcc tccttctcca gcacataaat 120
 ctttcagcag cttggctgaa gactgctgtg cagggcaggg aagctccagg caaacagccc 180
 agcaaacagc agcactcagc taaaaggaag actcacagaa cacagttgaa gaaggaaagt 240
 ggcgatggac ctcattccaa atttggcggg ggaaacctgg cttctcctgg ctgtcagcct 300
 ggtgctcctc tatctgtgag taactgtcca aactcctctc tttgtttcct tggacttggg 360
 gtgctaactg ggcccccttt ccttatctg ttttgaagat caaaagagat gttcaagaag 420
 tagctgaagt gttggacgct acaaacgcat agaagttatt attatcttat gcagatctat 480
 gaatgaataa ataagcattt ctcccatcca ctttctaatt ttggtgacta ggaggggtta 540
 gggacagcat ttggtagtgg gaatgatttg attagcttag atctgacgaa gactaatcaa 600
 tgaaaacatg gcagcggcag a 621

<210> 126
 <211> 465
 <212> DNA
 <213> Homo sapiens

<400> 126
 aggaaaggac ctgatgagt aatgcaatta ctgatgttgg agttgctgtt attattttatc 60
 gtgtacatat tacctccctc tcttgacctt tccagttcct gagtaactca ccagccctct 120
 gatctataaa gtcacaatcc ctgtgacctg atttctgttt cactttgtag atatgggacc 180
 cgtacatatg ggacttttta agagactggg aattccaggg cccacacctc tgcctttgtt 240
 gggaaatggt ttgtcctatc gtcagggtgag ttgcttgagc ttctctcttt gcttcttatg 300
 gttgcaaaca tcagcttagt tccatcagta aaaatgcccc tccttgggag ggagttctga 360
 ggtttcacat tttcagaaat ggtgggactg ggtgcagtgg atcatgcctg taatctcagc 420
 ctctgtgagg ccaagactgg caaattgctt gagcccagga gtttg 465

<210> 127
 <211> 33
 <212> PRT
 <213> Homo sapiens

<400> 127
 Met Asp Leu Ile Pro Asn Leu Ala Val Glu Thr Trp Leu Leu Leu Ala
 1 5 10 15
 Val Ser Leu Val Leu Leu Tyr Leu Tyr Gly Thr Arg Thr Tyr Gly Thr
 20 25 30

Phe

<210> 128
 <211> 602
 <212> DNA
 <213> Homo sapiens

<400> 128
 catagacaag ggtgagtcct tcagtactta gagaaaattc aagagtgact ttaaattccc 60
 cacttcaaat atattctctg ttttcttctg tttcccttaa gacatctctg aatagcttcc 120
 ttcaactgcc agtgaaagat agtaggcctg atttcattgg acgcaactgt ttccagcccc 180
 aattagagggt agggtttatt ctatttaaaa taataatcaa cttgtatttt gtttctctc 240
 ccagggtctc tggaaatttg acacagagtg ctataaaaag tatggaaaaa tgtgggggtg 300
 agtattctga aaacctccat tggatagacc tgctactgtg aggaggttac cccactgcag 360
 gatagtctct gccaggtct tcatgggatg aagctcttgt caacctaaat acaaacagag 420
 agagggtctc tgaaagaaga ggataattac ttgggagtag aatattgcaa tgggaatctg 480
 cttgccgtta taaactatgt gcaaattcag ggaggtaaac aagacaaaaga tgctccatag 540
 aaaatatgag aagaatctca taactgtttt gagataatta ttgttagcta caaagatcaa 600
 ta 602

<210> 129
<211> 594
<212> DNA
<213> Homo sapiens

<400> 129
cagtatctct tccctgtttg gaccacatta cccttcatca tatgaagcct tgggtggctc 60
ctgtgtgaga ctcttgctgt gtgtcacacc ctaatgaact agaacctaaag gttgctgtgt 120
gtcgtacaac taggggtatg gattacataa cataatgac aaagtctggc ttcctgggtg 180
tggctccagc tgcagaatag ggctagtga gtttaatcag ctccgttgct cccacacaga 240
acgtatgaag gtcaactccc tgtgctggcc atcacagatc cgcacgtgat cagaacagtg 300
ctagtgaag aatgttattc tgtcttcaca aatcgaagg taagcatcca ttttttgaaa 360
tttaataaat gattgatcca ctgattaaat ttttattttg aaaaaaacat atattcacag 420
aaggttacct aaaaaatgta caggaagggt ccatgtactc ttcacctgt cccgcccagt 480
ggtaacatct tgcaatcttg tatattgcaa tatatatcta gtatattcat attatcagg 540
tggcacaaaa gttaaaatgg caaactacag gctgggcata atggctcatg cctg 594

<210> 130
<211> 594
<212> DNA
<213> Homo sapiens

<400> 130
cagtatctct tccctgtttg gaccacatta cccttcatca tatgaagcct tgggtggctc 60
ctgtgtgaga ctcttgctgt gtgtcacacc ctaatgaact agaacctaaag gttgctgtgt 120
gtcgtacaac taggggtatg gattacataa cataatgac aaagtctggc ttcctgggtg 180
tggctccagc tgcagaatcg ggctagtga gtttaatcag ctctgttgct cccacacaga 240
acgtatgaag gtcaactccc tgtgctggcc atcacagatc cgcacgtgat cagaacagtg 300
ctagtgaag aatgttattc tgtcttcaca aatcgaagg taagcatcca ttttttgaaa 360
tttaataaat gattgatcca ctgattaaat ttttattttg aaaaaaacat atattcacag 420
aaggttacct aaaaaatgta caggaagggt ccatgtactc ttcacctgt cccgcccagt 480
ggtaacatct tgcaatcttg tatattgcaa tatatatcta gtatattcat attatcagg 540
tggcacaaaa gttaaaatgg caaactacag gctgggcata atggctcatg cctg 594

<210> 131
<211> 594
<212> DNA
<213> Homo sapiens

<400> 131
cagtatctct tccctgtttg gaccacatta cccttcatca tatgaagcct tgggtggctc 60
ctgtgtgaga ctcttgctgt gtgtcacacc ctaatgaact agaacctaaag gttgctgtgt 120
gtcgtacaac taggggtatg gattacataa cataatgac aaagtctggc ttcctgggtg 180
tggctccagc tgcagaatcg ggctagtga gtttaatcag ctccgttgct cccacacaga 240
acgtatgaag gtcaactccc tgtgctggcc atcacagatc cgcacgtgat cagaacagtg 300
ctagtgaag aatgttatta tgtcttcaca aatcgaagg taagcatcca ttttttgaaa 360
tttaataaat gattgatcca ctgattaaat ttttattttg aaaaaaacat atattcacag 420
aaggttacct aaaaaatgta caggaagggt ccatgtactc ttcacctgt cccgcccagt 480
ggtaacatct tgcaatcttg tatattgcaa tatatatcta gtatattcat attatcagg 540
tggcacaaaa gttaaaatgg caaactacag gctgggcata atggctcatg cctg 594

<210> 132
<211> 60
<212> PRT
<213> Homo sapiens

<400> 132
Met Trp Gly Thr Tyr Glu Gly Gln Leu Pro Val Leu Ala Ile Thr Asp

1 5 10 15
Pro Asp Val Ile Arg Thr Val Leu Val Lys Glu Cys Tyr Tyr Val Phe
 20 25 30
Thr Asn Arg Arg Ser Leu Gly Pro Val Gly Phe Met Lys Ser Ala Ile
 35 40 45
Ser Leu Ala Glu Asp Glu Glu Trp Lys Arg Ile Arg
 50 55 60

<210> 133
<211> 601
<212> DNA
<213> Homo sapiens

<400> 133
cagtatctct tccctgtttg gaccacatta cccttcatca tatgaagcct tgggtggctc 60
ctgtgtgaga ctcttgctgt gtgtcacacc cataatgaact agaacctaa gttgctgtgt 120
gtcgtacaac taggggtatg gattacataa cataatgatc aaagtctggc ttcttgggtg 180
tggctccagc tgcagaatcg ggctagtga gtttaatcag ctccgttgtc cccacacaga 240
acgtatgaag gtcaactccc tgtgctggcc atcacagatc ccgacgtgat cagaacagt 300
ctagtgaag aatgttattc tgtcttcaca aatcgaagg taagcatcca ttttttgaaa 360
tttaaataat gattgatcca ctgattaaat ttttattttg aaaaaaacat atattcacag 420
aaggttacct aaaaaatgta cctaaaaaat gaaggttcca tgtactcttc atcctgtccc 480
gccagtggt aacatcttgc aatcttgtat attgcaatat atatctagta tattcatatt 540
atcaggttgg cacaaaagtt aaaatggcaa actacaggct gggcataatg gctcatgcct 600
g 601

<210> 134
<211> 603
<212> DNA
<213> Homo sapiens

<400> 134
agcggaaaac tcaaggaggt atgaaaataa gatgagtctt aattagaaat gtaaagaatg 60
aatctgggga caggtagaaa gtaagatcac agtccgtttc caaggggtag tccactgagt 120
tcgagcttcc taaaaatggt ctttgatctt tatgtacaga aaagacatca caaaattcat 180
tacaaaatgt cacttactgc tccatgctgg agaaagccat atccttctgg gacttgagtc 240
tgcacattta actacaggta ctgatctgtt ttgtgcttag atgttcccca tcattgcccc 300
gtatggagat gtattggtga gaaacttgag gcgggaagca gagaaaggca agcctgtcac 360
cttgaaagag taagtaggag cacagccatg gggttctgag ctgtcatgag cccttccagc 420
tgccctgcca ggagtcgaca gtcgcactgt tgggttactc cagtgaccag acaaaagcag 480
ggcagcgctg caactccaaa gagccaccta agagggagtg gctcccatga ggcggcaagt 540
cagcaaggga aaagggcctt ctctcctgtg cacaggagcc aggatttact tatctgttaa 600
ctt 603

<210> 135
<211> 603
<212> DNA
<213> Homo sapiens ,

<400> 135
agcggaaaac tcaaggaggt atgaaaataa gatgagtctt aattagaaat gtaaagaatg 60
aatctgggga caggtagaaa gtaagatcac agtccgtttc caaggggtag tccactgagt 120
tcgagcttcc taaaaatggt cttttatctt tatgtacaga aaagacatca caaaattcat 180
tacaaaatgt cacttactgc tccatgctgg agaaagccat atccttctgg gacttgagtc 240
cgcacattta actacaggta ctgatctgtt ttgtgcttag atgttcccca tcattgcccc 300
gtatggagat gtattggtga gaaacttgag gcgggaagca gagaaaggca agcctgtcac 360
cttgaaagag taagtaggag cacagccatg gggttctgag ctgtcatgag cccttccagc 420

tgctgccat	ggagtcgaca	gtcgcactgt	tgggttactc	cagtgaccag	acaaagcag	700
ggcagcgctg	caactccaaa	gagccaccta	agaggggagt	gtcccatga	ggcggcaagt	540
cagcaaggga	aaagggcctt	ctctcctgtg	cacaggagcc	aggatttact	tatctgttaa	600
ctt						603

```
<210> 136
<211> 626
<212> DNA
<213> Homo sapiens
```

<400> 136						
attggacatg	atagctagat	ttgtttcagg	aaaacatcct	gctttccaag	gatttagatg	60
aatgtttttg	ttcactgggt	actcaggtaa	cacgtcttca	agaagccata	gggaggttga	120
gggaggggaag	tcgtcaagaa	gggaggttga	ggactgcact	tttgatttac	ttctgacttc	180
acagctcact	ttctgccaaa	gaatctcttc	cttttgcttc	tagcacccag	tagatttctc	240
tcagctgatg	attgactccc	agaattcgaa	agaaactgag	tccacacaag	gtaaccaagg	300
agtgcctctg	agggctactg	gcggggacac	taagagggag	ggccttgctc	tgaaaatgtg	360
caggaagtat	tccaggaaga	tgagaatttt	tgccacatag	cagaacaaca	cacatttaga	420
tgttataaat	ggtagcttga	ggcactttcc	agaagcccac	aggtatagcc	atgttccagg	480
ctgaaagggc	aaccctaagc	aaaccttaga	tgcttggagg	acagtcagtg	gtttgtggat	540
cacctacatg	agatcaaatg	ccagttctca	gcctcctcca	gatccaccaa	gtgagaacct	600
ctacttggaa	atttatatca	aacata				626

```
<210> 137
<211> 623
<212> DNA
<213> Homo sapiens
```

<400> 137						
attggacatg	atagctagat	ttgtttcagg	aaaacatcct	gctttccaag	gatttagatg	60
aatgtttttt	ttcactggtg	actcaggtaa	cacgtcttca	agaagccata	gggaggttga	120
gggagggaag	tcaagaaggg	aggttgagga	ctgcactttt	gattttacttc	tgacttcacg	180
agtcactttc	tgccaaagaa	atctctcctt	ttgtctctag	caccgactag	atttccttca	240
gctgattgatt	gctaccacga	attcgaagaa	aactgagtc	cacaaaggtg	accaaggagt	300
gcttctgagg	gctactggcg	gggacactaa	gagggagggc	cttgttctga	aaatgtgcag	360
gaattattcc	aggaagatga	gaatttttgc	cacatagcag	aacaacacac	atttagatgt	420
tataaatggg	agctggaggc	actttccaga	agcccacagg	tatagccatg	ttccaggctg	480
aaagggcaac	cctaagcaaa	cctagaatgc	ttggaggaca	gtcagtgggt	tgtggatcac	540
ctacatagaa	tcaaatgcca	gttctcagcc	tcctccagat	ccaccaagtg	agaacctcta	600
cttggaatt	tatatcaaac	ata				623

```
<210> 138
<211> 826
<212> DNA
<213> Homo sapiens
```

<400> 138						
agataaagta	cttttaggat	cattcaaggc	acacacccat	aacactgagt	atgtaagaca	60
gaaatgctct	ctctggaat	tacagcagtg	ctggtgctgg	gatgccatga	tgaggagtgt	120
gtggccaca	atcatgtaga	ccttgggaaa	acctggatta	aaatgatttt	gcgtcatcct	180
ggccctgtat	aagatacata	tcagaatgaa	aaccactccc	agtgtgactt	tgaattgctt	240
tccacttttt	tcttcttggg	attagagaac	ttcacttaga	tttcacttaa	gctgtgatgt	300
tgtacgttga	cctgatttac	ctaaaaatgtc	tttctctccc	tttcagctct	gtctgatctg	360
gagctcgcag	cccagtcaat	aatcttcatt	tttgctggct	atgaaaccac	cagcagtgtt	420
ctttccttca	ctttatatga	actggccact	cacctgatg	tccagcagaa	actgcaaaag	480
gagattgatg	cagttttgcc	caataagggtg	aggggatgac	ccctggagat	gaaggggaaga	540
ggtgaagcct	tagcaaaaat	gcctcctcac	cactccccag	gagaattttt	ataaaaagca	600
taatcactga	ttccttcact	gacataatgt	aggaagcctc	tgaggagaaa	aacaagggga	660
gaaacactaga	gaacggttgc	tactgacaga	agcataagat	ctttgtacaa	tattgctggc	720
cctgggtcac	ctgtttactg	ttatcacaat	aatgctaagt	aaaaaaaaaa	aaaaaaaaaa	780

aaaaaaaaa aggagtgtgg cgagaagatg gccaaacagg aacagc

020

<210> 139

<211> 795

<212> DNA

<213> Homo sapiens

<400> 139

```
gtccctgggg tgaggatggt cttgaatatt tcctacattc ataactcctc cacacatctc 60
agtaggtcac tgagcacatc aatggacatg ccagttatta aaatacttca cgaatactat 120
gatcatttac cagtatgagt tattctctgg agcttctaata acttcagtag tactgcatgg 180
actcagttga gagttaattc aaaatctcag attatccaat tctgtttctt tccttccagg 240
caccacctac ctatgatgcc gtggtacaga tggagtacct tgacatgggt gtgaatgaaa 300
cactcagatt attcccagtt gctattagac ttgagaggac ttgcaagaaa gatgttgaaa 360
tcaatggggg attcattccc aaagggtcaa tgggtggtgat tccaacttat gctcttcacc 420
atgacccaaa gtactggaca gagcctgagg agttccgccc tgaaaggtag aagtctccag 480
ggaaatggag ctacacctga cccaggctgg ttcaagcata ttctgcctct cttaatctac 540
atgacaatcg tgtggttgta caatcatttg cttgtaagtc tttttatcac aaaaaagtga 600
taattatcaa actttacaaa ccacagacta gaaaaaacga aactacatcc atccacagtc 660
ccagcaccaag acaaaagata tcaattatgt cctgtgggc atttttctac gcctatatag 720
atttttaaaa attagaatgg tatcactttt tatttgggtt gaattgctgc ttacttgatt 780
taacaggaaa ctatc
```

795

<210> 140

<211> 796

<212> DNA

<213> Homo sapiens

<400> 140

```
gtccctgggg tgaggatggt cttgaatatt tcctacattc ataactcctc cacacatctc 60
agtaggtcac tgagcacatc aatggacatg ccagttatta aaatacttca cgaatactat 120
gatcatttac cagtatgagt tattctctgg agcttctaata acttcaatag tactgcatgg 180
actcagttga gagttaattc aaaatctcag attatccaat tctgtttctt tccttccagg 240
caccacctta cctatgatgc cgtggtacag atggagtacc ttgacatgggt ggtgaatgaa 300
acactcagat tattcccagt tgctattaga cttgagagga cttgcaagaa agatgttgaa 360
atcaatgggg tattcattcc caaagggtca atgggtggtga ttccaactta tgctcttcac 420
catgacccaa agtactggac agagcctgag gagttccgcc ctgaaaggta caagtctcca 480
gggaaatgga gctcaccctg acccaggctg gttcaagcat attctgcctc tcttaattca 540
catgacaatc gtgtggttgt acaatcattt gcttgaagt ctttttatca caaaaaagtg 600
ataattatca aactttacaa accacagact agaaaaaacg aaactacatc catccacagt 660
cccagcacaa gacaaagata atcaattatg tccctgtggg catttttcta cgcctatata 720
gatttttaaa aattagaatg gtatcacttt ttatttgggt tgaattgctg cttacttgat 780
ttaacaggaa actatc
```

796

<210> 141

<211> 59

<212> PRT

<213> Homo sapiens

<400> 141

Ala Leu Ser Asp Leu Glu Leu Ala Ala Gln Ser Ile Ile Phe Ile Phe
1 5 10 15

Ala Gly Tyr Glu Thr Thr Ser Ser Val Leu Ser Phe Thr Leu Tyr Glu
20 25 30

Leu Ala Thr His Pro Asp Val Gln Gln Lys Leu Gln Lys Glu Ile Asp
35 40 45

Ala Val Leu Pro Asn Lys Ala Pro Pro Tyr Leu

50

55

<210> 142
<211> 795
<212> DNA
<213> Homo sapiens

<400> 142
gtccctgggg tgaggatggt cttgaatata tcctacattc ataactcctc cacacatctc 60
agtaggtcac tgagcacatc aatggacatg ccagttatta aaatacttca cgaatactat 120
gatcatttac cagtatgagt tattctcttg agcttctaata acttcaatag tactgcatgg 180
actcagttga gagttaattc aaaatctcag attatccaat tctgtttctt tccttccagg 240
caccacctac ctatgatgcc gtggtacaga tggagtagct tgacatgggt gtgaatgaaa 300
cactcagatt attccagtt gctatttagac ttgagaggac ttgcaagaaa gatgttgaaa 360
tcaatggggg attcattccc aaagggtcaa tgggtggtgat tccaacttat gctcttcacc 420
atgacccaaa gtactggaca gagcctgagg agttccgccc tgaaaggtag aagtctccag 480
ggaaatggag ctacccctga ccaggtctgg ttcaagcata ttctgcctct cttaactctac 540
atgacaatcg tgtggttgta caatcatttg cttgtaagtc tttttatcac aaaaaagtga 600
taattatcaa actttacaaa ccacagacta gaaaaaacga aattacatcc atccacagtc 660
ccagcacaag acaagataa tcaattatgt ccctgtgggc atttttctac gcctatatag 720
atttttaaaa attagatgg tatcactttt tatttggttt gaattgctgc ttacttgatt 780
taacaggaaa ctatc 795

<210> 143
<211> 616
<212> DNA
<213> Homo sapiens

<400> 143
caggcctggc acagagtcag tgctccataa atattttggt aaacgatgga tggtagtgct 60
ttttactatc cagtatttac ccagcttata gattaagtat gaagagttca agatacatgg 120
tgtaagagt cgtttttata tgcttgcaaa gcatttttgt catatttttt ctactttgct 180
tccatctttt cttctttcac ttcatttatt aattctccat atgcttggtt aactattgta 240
gatccccttg aaattagaca cgcaaggact tcttcaacca gaaaaaccca ttgttctaaa 300
ggtggattca agagatggaa ccctaagtgg agaattgagt attctaagga cttctacttt 360
ggtcttcaag aaagctgtgc ccagaaacac cagagatttc aacttagtca ataaaacctt 420
gaaataaaga tgggcttaat ctaattgtact gcatgagtag ttgggtgatt tgtacattca 480
ttgagctctc ccagagtcctg ttagagtggt tgtgcattat gtagtataaa ggaggtagac 540
aggtaagtga cagataggta gactcagctt ctctgcttct cataggacta cctctaccca 600
cctctagtta gcatta 616

<210> 144
<211> 1508
<212> DNA
<213> Homo sapiens

<400> 144
ccatggctct gttattagca gtttttctgg tgctcctcta tctatatggg acccgtacac 60
atggactttt taagagactg ggaattccag ggccacacac tctgcctttg ttgggaaatg 120
ttttgtccta tcgtcagggg ctctggaaat ttgacacaga gtgctataaa aagtatggaa 180
aaatgtgggg aacgtatgaa ggtcaactcc ctgtgctggc catcacagat cccgacgtga 240
tcagaacagt gctagtgaag gaattgtatt ctgtcttcac aaatcgaagg tcttttaggc 300
cagtgggatt tatgaaaagt gccatctctt tagctgagga tgaagaatgg aagagaatac 360
ggtcattgct gtctccaacc ttcaccagcg gaaaactcaa ggagatgttc cccatcattg 420
cccagtatgg agatgtattg gtgagaaact tgaggcggga agcagagaaa ggcaagcctg 480
tcaccttgaa agacatcttt ggggcctaca gcattggatgt gattactggc acatcatttg 540
gagtgaacat cgactctctc aacaatccac aagaccctt tgtggagagc actaagaagt 600
tcctaaaatt tggtttctta gatccattat ttctctcaat aatactcttt ccattcctta 660
ccccagtttt tgaagcatta aatgtctctc tgtttccaaa agataccata aattttttta 720
gtaaatctgt aaacagaatg aagaaaagtc gcctcaacga caaacaaaag caccgactag 780

```

atttccttca gctgatgatt gactcccaga attcgaaaga aactgagtcc cacaaagctc 840
tgctctgatct ggagctcgca gcccagtc aaatcttcat ttttgctggc tatgaaacca 900
ccagcagtggt tctttccttc actttatatg aactggccac tcacctgat gtccagcaga 960
aactgcaaaa ggagattgat gcagttttgc ccaataaggc accacctacc tatgatgccg 1020
tgggtacagat ggagtacctt gacatgggtg tgaatgaaac actcagatta ttcccagttg 1080
ctattagact tgagaggact tgcaagaaag atgttgaaat caatggggta ttcattccca 1140
aagggtcaat ggtggtgatt ccaacttatg ctcttcacca tgacccaaag tactggacag 1200
agcctgagga gttccgccct gaaagggtca gtaagaagaa ggacagcata gatccttaca 1260
tatacacacc ctttgggaact ggaccagaa actgcattgg catgagggtt gctctcatga 1320
acatgaaact tgctctaata agagtccttc agaacttctc cttcaaacct tgtaaagaaa 1380
cacagatccc cttgaaatta gacacgcaag gacttcttca accagaaaaa cccattgttc 1440
taaagggtga ttcaagagat ggaaccctaa gtggagaaca tcaccatcac catcactgag 1500
atctgcag                                     1508

```

<210> 145

<211> 60

<212> PRT

<213> Homo sapiens

<400> 145

```

Pro Val Ala Ile Arg Leu Glu Arg Thr Cys Lys Lys Asp Val Glu Ile
  1             5             10             15

```

```

Asn Gly Val Phe Ile Pro Lys Gly Ser Met Val Val Ile Pro Asn Tyr
      20             25             30

```

```

Ala Leu His His Asp Pro Lys Tyr Trp Thr Glu Pro Glu Glu Phe Arg
    35             40             45

```

```

Pro Glu Arg Phe Ser Lys Lys Lys Asp Ser Ile Asp
    50             55             60

```

<210> 146

<211> 11

<212> DNA

<213> Homo sapiens

<400> 146

```

tttcagtatc t                                     11

```

<210> 147

<211> 11

<212> DNA

<213> Homo sapiens

<400> 147

```

tttcaatatc t                                     11

```

<210> 148

<211> 11

<212> DNA

<213> Homo sapiens

<400> 148

```

tttaatagaa g                                     11

```

<210> 149

<211> 11

<212> DNA
<213> Homo sapiens

<400> 149
tttaacagaa g 11

<210> 150
<211> 11
<212> DNA
<213> Homo sapiens

<400> 150
attccccata g 11

<210> 151
<211> 11
<212> DNA
<213> Homo sapiens

<400> 151
attcctcata g 11

<210> 152
<211> 11
<212> DNA
<213> Homo sapiens

<400> 152
tagaatatga a 11

<210> 153
<211> 11
<212> DNA
<213> Homo sapiens

<400> 153
tagaacatga a 11

<210> 154
<211> 11
<212> DNA
<213> Homo sapiens

<400> 154
gtaacttatc c 11

<210> 155
<211> 11
<212> DNA
<213> Homo sapiens

<400> 155
gtaacgtatc c 11

<210> 156
<211> 11

<212> DNA
<213> Homo sapiens

<400> 156
ttcacgtgga g 11

<210> 157
<211> 11
<212> DNA
<213> Homo sapiens

<400> 157
ttcacatgga g 11

<210> 158
<211> 11
<212> DNA
<213> Homo sapiens

<400> 158
tggacgcaac t 11

<210> 159
<211> 11
<212> DNA
<213> Homo sapiens

<400> 159
tggacacaac t 11

<210> 160
<211> 11
<212> DNA
<213> Homo sapiens

<400> 160
gaggataatt a 11

<210> 161
<211> 11
<212> DNA
<213> Homo sapiens

<400> 161
gaggaaaatt a 11

<210> 162
<211> 11
<212> DNA
<213> Homo sapiens

<400> 162
catcattgcc c 11

<210> 163
<211> 11

<212> DNA
<213> Homo sapiens

<400> 163
catcactgcc c 11

<210> 164
<211> 11
<212> DNA
<213> Homo sapiens

<400> 164
cagtcgcact g 11

<210> 165
<211> 11
<212> DNA
<213> Homo sapiens

<400> 165
cagtcacact g 11

<210> 166
<211> 11
<212> DNA
<213> Homo sapiens

<400> 166
actaagaagt t 11

<210> 167
<211> 11
<212> DNA
<213> Homo sapiens

<400> 167
actaaaaagt t 11

<210> 168
<211> 11
<212> DNA
<213> Homo sapiens

<400> 168
gatccattat t 11

<210> 169
<211> 11
<212> DNA
<213> Homo sapiens

<400> 169
gatccgttat t 11

<210> 170
<211> 11

<212> DNA
<213> Homo sapiens

<400> 170
caattccatt g 11

<210> 171
<211> 11
<212> DNA
<213> Homo sapiens

<400> 171
caatttcatt g 11

<210> 172
<211> 11
<212> DNA
<213> Homo sapiens

<400> 172
tgtcaatcta g 11

<210> 173
<211> 11
<212> DNA
<213> Homo sapiens

<400> 173
tgtcagtcta g 11

<210> 174
<211> 11
<212> DNA
<213> Homo sapiens

<400> 174
ttgtttgttt t 11

<210> 175
<211> 11
<212> DNA
<213> Homo sapiens

<400> 175
ttgttcgttt t 11

<210> 176
<211> 11
<212> DNA
<213> Homo sapiens

<400> 176
aaataaagaa g 11

<210> 177
<211> 11

<212> DNA
<213> Homo sapiens

<400> 177
aaatacagaa g 11

<210> 178
<211> 11
<212> DNA
<213> Homo sapiens

<400> 178
tttgcgtcat c 11

<210> 179
<211> 11
<212> DNA
<213> Homo sapiens

<400> 179
tttgcattcat c 11

<210> 180
<211> 11
<212> DNA
<213> Homo sapiens

<400> 180
ttgacctgat t 11

<210> 181
<211> 11
<212> DNA
<213> Homo sapiens

<400> 181
ttgacttgat t 11

<210> 182
<211> 11
<212> DNA
<213> Homo sapiens

<400> 182
tattgtagat c 11

<210> 183
<211> 11
<212> DNA
<213> Homo sapiens

<400> 183
tattgcagat c 11

<210> 184
<211> 11

<212> DNA
<213> Homo sapiens

<400> 184
ccttttccct t 11

<210> 185
<211> 11
<212> DNA
<213> Homo sapiens

<400> 185
cctttccct t 11

<210> 186
<211> 11
<212> DNA
<213> Homo sapiens

<400> 186
cttatgcaga t 11

<210> 187
<211> 11
<212> DNA
<213> Homo sapiens

<400> 187
cttatacaga t 11

<210> 188
<211> 11
<212> DNA
<213> Homo sapiens

<400> 188
aatacgggtca t 11

<210> 189
<211> 11
<212> DNA
<213> Homo sapiens

<400> 189
aatacagtca t 11

<210> 190
<211> 11
<212> DNA
<213> Homo sapiens

<400> 190
ggaggtatga a 11

<210> 191
<211> 11

<212> DNA
<213> Homo sapiens

<400> 191
ggaggcatga a 11

<210> 192
<211> 11
<212> DNA
<213> Homo sapiens

<400> 192
agtccgtttc c 11

<210> 193
<211> 11
<212> DNA
<213> Homo sapiens

<400> 193
agtccatttc c 11

<210> 194
<211> 11
<212> DNA
<213> Homo sapiens

<400> 194
tctgccaaag a 11

<210> 195
<211> 11
<212> DNA
<213> Homo sapiens

<400> 195
tctgcgaaag a 11

<210> 196
<211> 11
<212> DNA
<213> Homo sapiens

<400> 196
accattgtt c 11

<210> 197
<211> 11
<212> DNA
<213> Homo sapiens

<400> 197
accactgtt c 11

<210> 198
<211> 11

<212> DNA
<213> Homo sapiens

<400> 198
gctactggct g

11

<210> 199
<211> 11
<212> DNA
<213> Homo sapiens

<400> 199
gctaccggct g

11

<210> 200
<211> 11
<212> DNA
<213> Homo sapiens

<400> 200
gaaatcaccc g

11

<210> 201
<211> 11
<212> DNA
<213> Homo sapiens

<400> 201
gaaattaccc g

11

<210> 202
<211> 33
<212> DNA
<213> Homo sapiens

<400> 202
gctctactgt catttctaac cataatctct tta

33

<210> 203
<211> 27
<212> DNA
<213> Homo sapiens

<400> 203
gcttcatatg atgaagggtat atgtggt

27

<210> 204
<211> 18
<212> DNA
<213> Homo sapiens

<400> 204
tgtctttcag tatctctt

18

<210> 205
<211> 19

<212> DNA

<213> Homo sapiens

<400> 205

tgtctttcaa tatctcttc

19

<210> 206

<211> 444

<212> DNA

<213> Homo sapiens

<400> 206

catttagtcc	ttgtgagcac	ttgatgattt	acctgccttc	aatttttcac	tgaccttaata	60
ttctttttga	taatgaagta	ttttaaacat	ataaaacatt	atggagagtg	gcataggaga	120
tacccacgta	tgtaccaccc	agcttaacga	atgctctact	gtcatttcta	accataatct	180
ctttaaagag	ctctttttgtc	tttcaatata	tcttccctgt	ttggaccaca	ttacccttca	240
tcatatgaag	ccttggtggtg	ctcctgtgtg	agactcttgc	tgtgtgtcac	accctaataa	300
actagaacct	aagggtgtctg	tgtgtcgtac	aactaggggt	atggattaca	taacataatg	360
atcaaagtct	ggcttcctcg	gtgtggctcc	agctgcagaa	tcgggctagt	gaagtttaata	420
cagctccggt	gtccccacac	agaa				444

<210> 207

<211> 830

<212> DNA

<213> Homo sapiens

<400> 207

tggtcaccca	ccatgtgtac	agtaccctgc	taggggtccag	ggatcatgaaa	gtaaataata	60
ccagactgtg	cccttgagga	actcacctct	gctaagggaa	acaggcacag	aaaccacaa	120
gggtggtaga	gaggaaatag	gacaatagga	ctgtgtgagg	gggataggag	gcaccagag	180
gaggaaatgg	ttacatctgt	gtgaggaggt	tggttaaggaa	agactttaac	agaaggggtc	240
tgtctggctg	ggcttgcaag	gatgtgtagg	agtcacttag	ggggcacaag	tacactccag	300
gcagagggaa	ttgcatgggt	aaagatctgc	agttgtggct	tgtggggatg	gatttcaagt	360
attctggaat	gaagacagcc	atggaaacaa	gggcagggtga	gaggatattt	aagaggcttc	420
atgccaatgg	ctccacttca	gtttctgata	agaactcagg	ttccgtggac	tccctgataa	480
aactgattaa	gttggtttatg	attccccata	gaatatgaac	tcaaaggagg	taagcaaagg	540
ggtgtgtgctg	attctttgct	actggctgca	gctgcagccc	cacctccttc	tccagcacat	600
aaacatttca	gcagcttgac	ctaagactgc	tgtgcagggc	agggatgctc	caggcagaca	660
gcccagcaaa	caacagcaca	cagctgaaag	taagactcag	aggagacagt	tgaagaaggc	720
aagtggcgat	ggacatcatc	ccaaatttgg	cgggtggaac	ctggcttctc	ctggctgtca	780
gcctgggtgct	cctctatctg	tcagtaactg	tccagattcc	tctcctctgt		830

<210> 208

<211> 830

<212> DNA

<213> Homo sapiens

<400> 208

tggtcaccca	ccatgtgtac	agtaccctgc	taggggtccag	ggatcatgaaa	gtaaataata	60
ccagactgtg	cccttgagga	actcacctct	gctaagggaa	acaggcacag	aaaccacaa	120
gggtggtaga	gaggaaatag	gacaatagga	ctgtgtgagg	gggataggag	gcaccagag	180
gaggaaatgg	ttacatctgt	gtgaggaggt	tggttaaggaa	agactttaat	agaaggggtc	240
tgtctggctg	ggcttgcaag	gatgtgtagg	agtcacttag	ggggcacaag	tacactccag	300
gcagagggaa	ttgcatgggt	aaagatctgc	agttgtggct	tgtggggatg	gatttcaagt	360
attctggaat	gaagacagcc	atggaaacaa	gggcagggtga	gaggatattt	aagaggcttc	420
atgccaatgg	ctccacttca	gtttctgata	agaactcagg	ttccgtggac	tccctgataa	480
aactgattaa	gttggtttatg	attcctcata	gaatatgaac	tcaaaggagg	taagcaaagg	540
ggtgtgtgctg	attctttgct	actggctgca	gctgcagccc	cacctccttc	tccagcacat	600
aaacatttca	gcagcttgac	ctaagactgc	tgtgcagggc	agggatgctc	caggcagaca	660
gcccagcaaa	caacagcaca	cagctgaaag	taagactcag	aggagacagt	tgaagaaggc	720

aagtggcgat ggacctcadc ccaaatttgg cgggtggaaac ctggcttctc ctggctgtca 780
gcctggtgct cctctatctg tcagtaactg tccagattcc tctcctctgt 830

<210> 209

<211> 830

<212> DNA

<213> Homo sapiens

<400> 209

tggtcaccca ccatgtgtac agtaccctgc taggggccag ggtcatgaaa gtaaataata 60
ccagactgtg cccttgagga actcacctct gctaagggaa acaggcacag aaaccacaa 120
gggtggtaga gaggaaatag gacaatagga ctgtgtgagg gggataggag gcaccagag 180
gaggaaatgg ttacatctgt gtgaggaggt tggtaaggaa agactttaat agaaggggtc 240
tgtctggctg ggcttgcaag gatgtgtagg agtcatctag ggggcacaag tacactccag 300
gcagagggaa ttgcatgggt aaagatctgc agttgtggct tgtggggatg gatttcaagt 360
attctggaat gaagacagcc atggaaacaa gggcagggtgaggatattt aagaggcttc 420
atgccaatgg ctccacttca gtttctgata agaactcagg ttccgtggac tccctgataa 480
aactgattaa gttgtttatg attccccata gaacatgaac tcaaaggagg taagcaaagg 540
gggtgtgtcg attctttgct actggctgca gctgcagccc cacctccttc tccagcacat 600
aaacatttca gcagcttgac ctaagactgc tgtgcagggc agggatgctc caggcagaca 660
gcccagcaaa caacagcaca cagctgaaag taagactcag aggagacagt tgaagaaggc 720
aagtggcgat ggacctcadc ccaaatttgg cgggtggaaac ctggcttctc ctggctgtca 780
gcctggtgct cctctatctg tcagtaactg tccagattcc tctcctctgt 830

<210> 210

<211> 837

<212> DNA

<213> Homo sapiens

<400> 210

caaaaattag ctagggtgtg tggtatgcac ctataatctc agctaccag gaggtgagg 60
caggagaatc acttgaacct ggaggcagag gttgcagtga gccgagacgc accattacac 120
tccagcctgg gtgacagagt gagattccat ctcaaaaaaa aaaaaaaa attatgcctt 180
tttgaagcac atacatttta taacatacaa ctgaatccct tattatatta ttagttttga 240
tttaatgttt tcaaaccatc tccctgata tttctgggag atgggaaaca tgttttctta 300
cacctcttgc attccattct caactcccaa ctgtcttact gcaatgaaca cttaataaga 360
aacagtcaat tgggtcaattg attgggcaac aggctaaca cactcattcc ttgtctgttc 420
ccacttcttt ctttactttc ctttctgag taacgtatcc taaagtcatt aggtgggtgg 480
cagccagatg gtggccacac attaaagtag aaaagagagt gtcattgatg ttccaagtca 540
gagacctagt aggggtgagga tcaagtaggt gttcacgtgg agaaacagcc cggcctgtgt 600
gtgggagtcc aagcaagcag agaaaatgac gacacagagg ggtggcctga aaaagcagcc 660
agagcctaaa cagggcatgg agaacatatt tagggcatga ggtgaggagg gcatccatga 720
gtgggaaggg atgggtgagg tttcactaca taaaggggat tgatgaaata agtaataaaa 780
gtatactgga agccaggtgt gtcacttttg cagaaaagag tcatggattc agaaagg 837

<210> 211

<211> 837

<212> DNA

<213> Homo sapiens

<400> 211

caaaaattag ctagggtgtg tggtatgcac ctataatctc agctaccag gaggtgagg 60
caggagaatc acttgaacct ggaggcagag gttgcagtga gccgagacgc accattacac 120
tccagcctgg gtgacagagt gagattccat ctcaaaaaaa aaaaaaaa attatgcctt 180
tttgaagcac atacatttta taacatacaa ctgaatccct tattatatta ttagttttga 240
tttaatgttt tcaaaccatc tccctgata tttctgggag atgggaaaca tgttttctta 300
cacctcttgc attccattct caactcccaa ctgtcttact gcaatgaaca cttaataaga 360
aacagtcaat tgggtcaattg attgggcaac aggctaaca cactcattcc ttgtctgttc 420
ccacttcttt ctttactttc ctttctgag taacttatcc taaagtcatt aggtgggtgg 480
cagccagatg gtggccacac attaaagtag aaaagagagt gtcattgatg ttccaagtca 540


```

gagacctagt aggggtgagga tcaagtaggt gttcacatgg agaaacagcc - - - - -
gtgggagtc aagcaagcag agaaaatgtc gacacagagg ggtggcctga aaaagcagcc 660
agagcctaaa cagggcatgg agaacatatt tagggcatga ggtgaggagg gcatccatga 720
gtgggaaggg atgggtgagg ttctactaca taaaggggat tgatgaaata agtaataaaa 780
gtatactgga agccagggtg gtcacttttg cagaaaagag tcatggattc agaaagg 837

```

<210> 212

<211> 602

<212> DNA

<213> Homo sapiens

<400> 212

```

catagacaag ggtgagtcct tcagtactta gagaaaattc aagagtgact ttaaattccc 60
cacttcaaat atattctctg ttttcttgtc ttcccttaa gacatctctg aatagcttcc 120
ttcaactgcc agtgaaagat agcaggcctg atttcattgg acacaactgt ttccagcccc 180
aattagaggt aggggtttatt ctatttataa taataatcaa ctgtattttt gtttctctc 240
ccagggtctc tggaaatttg acacagagtg ctataaaaag tatggaaaaa tgggggggtg 300
agtattctga aaacctccat tggatagacc tgctactgtg aggagggttac cccactgcag 360
gatagtctct gccagggtct tcatgggatg aagctcttgt caacctaaat acaaacagag 420
agagggttctc tgaagaaga ggataattac ttgggagtag aatattgcaa tgggaatctg 480
cttgccgtta taaactatgt gcaaattcag ggaggtaaac aagacaaaga tgctccatag 540
aaaatatgag aagaatctca taactgtttt gagataatta ttgttagcta caaagatcaa 600
ta 602

```

<210> 213

<211> 602

<212> DNA

<213> Homo sapiens

<400> 213

```

catagacaag ggtgagtcct tcagtactta gagaaaattc aagagtgact ttaaattccc 60
cacttcaaat atattctctg ttttcttgtc ttcccttaa gacatctctg aatagcttcc 120
ttcaactgcc agtgaaagat agcaggcctg atttcattgg acgcaactgt ttccagcccc 180
aattagaggt aggggtttatt ctatttataa taataatcaa ctgtattttt gtttctctc 240
ccagggtctc tggaaatttg acacagagtg ctataaaaag tatggaaaaa tgggggggtg 300
agtattctga aaacctccat tggatagacc tgctactgtg aggagggttac cccactgcag 360
gatagtctct gccagggtct tcatgggatg aagctcttgt caacctaaat acaaacagag 420
agagggttctc tgaagaaga ggaaattac ttgggagtag aatattgcaa tgggaatctg 480
cttgccgtta taaactatgt gcaaattcag ggaggtaaac aagacaaaga tgctccatag 540
aaaatatgag aagaatctca taactgtttt gagataatta ttgttagcta caaagatcaa 600
ta 602

```

<210> 214

<211> 603

<212> DNA

<213> Homo sapiens

<400> 214

```

agcggaaaac tcaaggaggt atgaaaataa gatgagtctt aattagaaat gtaaagaatg 60
aatctgggga caggtagaaa gtaagatcac agtccgtttc caaggggtag tccactgagt 120
tcgagcttcc taaaaatggg cttttatctt tatgtacaga aaagacatca caaaattcat 180
tacaaaatgt cacttactgc tccatgctgg agaaagccat atccttctgg gacttgagtc 240
tgcacattta actacaggta ctgatctggt ttgtgcttag atgttcecca tcttgccca 300
gtatggagat gtattggtga gaaacttgag gcgggaagca gagaaaggca agcctgtcac 360
cttgaaagag taagtaggag cacagccatg ggggtctgag ctgtcatgag cccttcacg 420
tgcctgccat ggagtcgaca gtcgcactgt tgggttactc cagtgaccag acaaaagcag 480
ggcagcgctg caactccaaa gagccacctt agagggagtg gctcccatga ggcggaagt 540
cagcaaggga aaagggcctt ctctcctgtg cacaggagcc aggatattact tatctgttaa 600
ctt 603

```

<210> 215
<211> 60
<212> PRT
<213> Homo sapiens

<400> 215
Ser Leu Ala Glu Asp Glu Glu Trp Lys Arg Ile Arg Ser Leu Leu Ser
1 5 10 15
Pro Thr Phe Thr Ser Gly Lys Leu Lys Glu Met Phe Pro Ile Thr Ala
20 25 30
Gln Tyr Gly Asp Val Leu Val Arg Asn Leu Arg Arg Glu Ala Glu Lys
35 40 45
Gly Lys Pro Val Thr Leu Lys Asp Ile Phe Gly Ala
50 55 60

<210> 216
<211> 603
<212> DNA
<213> Homo sapiens

<400> 216
agcggaaaac tcaaggaggt atgaaaataa gatgagtctt aattagaaat gtaaagaatg 60
aatctgggga caggtagaaa gtaagatcac agtccgtttc caaggggtag tccactgagt 120
tcgagcttcc taaaaatggt cttttatctt tatgtacaga aaagacatca caaaattcat 180
tacaaaatgt cacttactgc tccatgctgg agaaagccat atccttcttg gacttgagtc 240
tgcacattta actacaggtg ctgatctggt ttgtgcttag atgttcccca tcattgcccc 300
gtatggagat gtattggtga gaaacttgag gcgggaagca gagaaaggca agcctgtcac 360
cttgaaagag taagtaggag cacagccatg ggggttctgag ctgtcatgag cccttccagc 420
tgcttgccat ggagtcgaca gtcacactgt tgggttactc cagtgaccag acaaaagcag 480
ggcagcgctg caactccaaa gagccaccta agagggagtg gctcccatga ggcggcaagt 540
cagcaaggga aaagggcctt ctctcctgtg cacaggagcc aggatttact tatctgttaa 600
ctt 603

<210> 217
<211> 778
<212> DNA
<213> Homo sapiens

<400> 217
cagagcttac atatcttata tcatccacac tcaacacatg ctactgtagt tgtctgataa 60
tgggtctctg tcttcctatg actgggctcc ttgacctcag aggtgagtct aactcagctt 120
ggtgtctcca tcaccccag catagggcca gctccatcac tggcaccaga taaccacctt 180
ctgagggagt agatggaaga tgattcagca gatagtcttg aaagtctgtg gctctttatg 240
tgtcttgact ggatatgtgg gtttcttgct gcatgtatag tggaaggacg gtaagagggtg 300
ctgattttaa ttttccatat ctttctccac tcagcatctt tggggcctac agcatggatg 360
tgattactgg cacatcattt ggagtgaaca tcgactctct caacaatcca caagaccctt 420
ttgtggagag cactaaaaag ttccataaat ttggtttctt agatccatta tttctctcaa 480
taagtatgtg ggctattatt tctttctctc tttttaaaaa taactgcttt cttgacatat 540
aattcacata tcgtataatt catccactta aaaggtacaa ttccattggt ttttaagataa 600
tcaaaaaatg gtatgaccat tactattgta aactaaaatg tttttgtcaa tctagagccc 660
tcacacactt tagctgtcaa caccaccaca caaaccacac tgccttaagc atccaataat 720
caactttctg cctctataga tttgcctatt ctggacactt catagaaata atatcatt 778

<210> 218
<211> 778
<212> DNA

<213> Homo sapiens

<400> 218

```
cagagcttac atatcttata tcatccacac tcaacacatg ctactgtagt tgtctgataa 60
tggtgtctctg tcttcctatg actgggctcc ttgacctcag aggtgagtct aactcagctt 120
ggtgtctcca tcacccccag catagggcca gctccatcac tggcaccaga taaccacctt 180
ctgagggagt agatggaaga tgattcagca gatagttctg aaagtctgtg gctctttatg 240
tgtcttgact ggatatgtgg gtttcttgct gcatgtatag tggaggagcg gtaagaggtg 300
ctgattttaa ttttccatat ctttctccac tcagcatctt tggggcctac agcatggatg 360
tgattactgg cacatcattt ggagtgaaca tcgactctct caacaatcca caagaccctt 420
ttgtggagag cactaagaag ttccataaat ttggtttctt agatccgtta tttctctcaa 480
taagtatgtg ggctattatt tctttctctc tttttaaaaa taactgcttt cttgacatat 540
aattcacata tcgtataatt catccactta aaaggtacaa ttccattggt ttttaagataa 600
tcaaaaatat gtatgacctt tactattgta aactaaaatg tttttgtcaa tctagagccc 660
tcacacactt tagctgtcaa caccaccacca caaacccac tgccctaagc atccaataat 720
caactttctg cctctataga tttgcctatt ctggacactt catagaaata atatcatt 778
```

<210> 219

<211> 778

<212> DNA

<213> Homo sapiens

<400> 219

```
cagagcttac atatcttata tcatccacac tcaacacatg ctactgtagt tgtctgataa 60
tggtgtctctg tcttcctatg actgggctcc ttgacctcag aggtgagtct aactcagctt 120
ggtgtctcca tcacccccag catagggcca gctccatcac tggcaccaga taaccacctt 180
ctgagggagt agatggaaga tgattcagca gatagttctg aaagtctgtg gctctttatg 240
tgtcttgact ggatatgtgg gtttcttgct gcatgtatag tggaggagcg gtaagaggtg 300
ctgattttaa ttttccatat ctttctccac tcagcatctt tggggcctac agcatggatg 360
tgattactgg cacatcattt ggagtgaaca tcgactctct caacaatcca caagaccctt 420
ttgtggagag cactaagaag ttccataaat ttggtttctt agatccatta tttctctcaa 480
taagtatgtg ggctattatt tctttctctc tttttaaaaa taactgcttt cttgacatat 540
aattcacata tcgtataatt catccactta aaaggtacaa ttccattggt ttttaagataa 600
tcaaaaatat gtatgacctt tactattgta aactaaaatg tttttgtcaa tctagagccc 660
tcacacactt tagctgtcaa caccaccacca caaacccac tgccctaagc atccaataat 720
caactttctg cctctataga tttgcctatt ctggacactt catagaaata atatcatt 778
```

<210> 220

<211> 778

<212> DNA

<213> Homo sapiens

<400> 220

```
cagagcttac atatcttata tcatccacac tcaacacatg ctactgtagt tgtctgataa 60
tggtgtctctg tcttcctatg actgggctcc ttgacctcag aggtgagtct aactcagctt 120
ggtgtctcca tcacccccag catagggcca gctccatcac tggcaccaga taaccacctt 180
ctgagggagt agatggaaga tgattcagca gatagttctg aaagtctgtg gctctttatg 240
tgtcttgact ggatatgtgg gtttcttgct gcatgtatag tggaggagcg gtaagaggtg 300
ctgattttaa ttttccatat ctttctccac tcagcatctt tggggcctac agcatggatg 360
tgattactgg cacatcattt ggagtgaaca tcgactctct caacaatcca caagaccctt 420
ttgtggagag cactaagaag ttccataaat ttggtttctt agatccatta tttctctcaa 480
taagtatgtg ggctattatt tctttctctc tttttaaaaa taactgcttt cttgacatat 540
aattcacata tcgtataatt catccactta aaaggtacaa ttccattggt ttttaagataa 600
tcaaaaatat gtatgacctt tactattgta aactaaaatg tttttgtcag tctagagccc 660
tcacacactt tagctgtcaa caccaccacca caaacccac tgccctaagc atccaataat 720
caactttctg cctctataga tttgcctatt ctggacactt catagaaata atatcatt 778
```

<210> 221

<211> 670

<212> DNA

<213> Homo sapiens

<400> 221

```
agaaggtgcc attgatctca ctgctgtagt ggtgtttcct atgtatagac ctgcccttgc 60
tcagtcgccg gcctgaaaga agggcaaaca tgataaaagg aatgggttcc agttgagaat 120
catgatgttc ttattcttat tactggtaga gaaaattata attgctccag gtaaagtttg 180
cattttcaat gatttccttt tgttcgtttt gtttttccca cagtactctt tccattcctt 240
acccagttt ttgaagcatt aaatgtctct ctgtttccaa aagataccat aaatttttta 300
agtaaatctg taaacagaat gaagaaaagt cgcctcaacg acaaacaaaa ggtaaaatct 360
gatgggtggtt aaatgacgat gtttaggttt tgataaattt agattttata cacatgatag 420
agcatgtatc tgtattttta aaaataaaga cagagaactt atgttttagaa caagagaagc 480
catttggttag aaataaagaa ggagattggg gaaggagatg agaatgagtc agagagatag 540
catttaaaac ttgaaatcag gcacaacaat tagtatgtca tgatataaac agtattgaga 600
taaaatttta ccacttctct tccctttaat aaattgtcaa aggataaagt ttctgtttg 660
aaaatatatt
```

<210> 222

<211> 670

<212> DNA

<213> Homo sapiens

<400> 222

```
agaaggtgcc attgatctca ctgctgtagt ggtgtttcct atgtatagac ctgcccttgc 60
tcagtcgccg gcctgaaaga agggcaaaca tgataaaagg aatgggttcc agttgagaat 120
catgatgttc ttattcttat tactggtaga gaaaattata attgctccag gtaaagtttg 180
cattttcaat gatttccttt tgtttgtttt gtttttccca cagtactctt tccattcctt 240
acccagttt ttgaagcatt aaatgtctct ctgtttccaa aagataccat aaatttttta 300
agtaaatctg taaacagaat gaagaaaagt cgcctcaacg acaaacaaaa ggtaaaatct 360
gatgggtggtt aaatgacgat gtttaggttt tgataaattt agattttata cacatgatag 420
agcatgtatc tgtattttta aaaataaaga cagagaactt atgttttagaa caagagaagc 480
catttggttag aaatacagaa ggagattggg gaaggagatg agaatgagtc agagagatag 540
catttaaaac ttgaaatcag gcacaacaat tagtatgtca tgatataaac agtattgaga 600
taaaatttta ccacttctct tccctttaat aaattgtcaa aggataaagt ttctgtttg 660
aaaatatatt
```

<210> 223

<211> 826

<212> DNA

<213> Homo sapiens

<400> 223

```
agataaagta ctttttaggat cattcaaggc acacacccat aacactgagt atgtaagaca 60
gaaatgctct ctctggaaat tacagcagtg ctggtgctgg gatgccatga tgaggagtgt 120
gtggcccaca atcatgtaga ccttgggaaa acctggatta aaatgatttt gcatcatcct 180
ggccctgtat aagatacata tcagaatgaa aaccactccc agtgtgactt tgaattgctt 240
ttccattttt tcttcttggg attagagagc ttcacttaga tttcatctaa gctgtgatgt 300
tgtacgttga cctgatttac ctaaaatgtc tttcctctcc tttcagctct gtctgatctg 360
gagctcgag cccagtcaat aatcttcatt tttgctggt atgaaaccac cagcagtgtt 420
ctttccttca ctttatatga actggccact caccctgatg tccagcagaa actgcaaaag 480
gagattgatg cagttttgcc caataagggt aggggatgac ccctggagat gaagggaaga 540
gggtgaagcct tagcaaaaat gcctcctcac cactcccag gagaattttt ataaaaagca 600
taatcactga ttcttctact gacataatgt aggaagcctc tgaggagaaa aacaaaggga 660
gaaacataga gaacggttgc tactggcaga agcataagat ctttgtacaa tattgctggc 720
cctggttcac ctgtttactg ttatcacaat aatgctaagt aaaaaaaaaa aaaaaaaaaa 780
aaaaaaaaaa aggagtgtgg cgagaagatg gccaaacagg aacagc
```

<210> 224

<211> 826

<212> DNA

<213> Homo sapiens

<400> 224

```
agataaagta ctttttaggat cattcaaggc acacacccat aacactgagt atgtaagaca 60
gaaatgctct ctctggaaat tacagcagtg ctgggtgctgg gatgccatga tgaggagtgt 120
gtggcccaca atcatgtaga ccttgggaaa acctggatta aaatgatttt gcgtcatcct 180
ggcctgtat aagatacata tcagaatgaa aaccactccc agtgtgactt tgaattgctt 240
ttccattttt tcttcttggg attagagagc ttcacttaga tttcatctaa gctgtgatgt 300
tgtacgttga cttgatttac ctaaaatgtc tttcctctcc tttcagctct gtctgatctg 360
gagctcgag cccagtcaat aatcttcatt tttgctggct atgaaaccac cagcagtgtt 420
ctttccttca ctttatatga actggccact caccctgatg tccagcagaa actgcaaaag 480
gagattgatg cagttttgcc caataagggtg aggggatgac ccctggagat gaaggggaaga 540
ggtgaagcct tagcaaaaat gcctcctcac cactcccag gagaattttt ataaaaagca 600
taatcactga ttccttcaact gacataatgt aggaagcctc tgaggagaaa aacaaaggga 660
gaaacataga gaacggttgc tactggcaga agcataagat ctttgtacaa tattgtctggc 720
cctggttcac ctgtttactg ttatcacaaat aatgctaagt aaaaaaaaaa aaaaaaaaaa 780
aaaaaaaaaa aggagtgtgg cgagaagatg gccaaacagg aacagc 826
```

<210> 225

<211> 616

<212> DNA

<213> Homo sapiens

<400> 225

```
caggcctggc acagagtcag tgctccataa atattttgtt aaacgatgga tgggtgagtgc 60
ttttactatc cagtatttac ccagcttata gattaagtat gaagagttca agatacatgg 120
tgtaagagt cgtttttata tgcttgcaaa gcatttttgt catatttttt ctactttgct 180
tccatctttt cttctttcac ttcatttatt aattctccat atgcttgttt aactattgca 240
gatccccttg aaattagaca cgcaaggact tcttcaacca gaaaaacca ttgttctaaa 300
ggtggattca agagatggaa ccctaagtgg agaatgagtt attctaagga tttctacttt 360
ggtcttcaag aaagctgtgc ccagaacac cagagatttc aacttagtca ataaaacctt 420
gaaataaaga tgggcttaat ctaatgtact gcatgagtag ttgggtgattt tgtacattca 480
ttgagctctc ccagagctctg tgtagagtgt tgtgcattat gtagtataaa ggaggtgacc 540
aggtaagtga cagataggta gactcagctt ctctgcttct cataggacta cctctaccca 600
cctctagtta gcatta 616
```

<210> 226

<211> 624

<212> DNA

<213> Homo sapiens

<400> 226

```
gattaagctt ttcattgattc ctcatagaac atgaactcaa aagaggtcag caaaggggtg 60
tgtgcgattc tttgctattg gctgcagcta tagccctgcc tcttctcca gcacataaat 120
ctttcagcag cttggctgaa gactgctgtg cagggcaggg aagctccagg caaacagccc 180
agcaaacagc agcactcagc taaaagggaag actcacagaa cacagttgaa gaaggaaagt 240
ggcgatggac ctcatcccaa atttggcggg ggaaacctgg cttctcctgg ctgtcagcct 300
ggtgctcttc tatctgtgag taactgtcca aactcctctc tttgtttcct tggacttggg 360
gtgctaactc ggcccctttc cccttatctg ttttgaagat caaaagagat gttcaaggag 420
aagtagctga agtgttggac gctacaaacg catagaagtt attattatct tatgcagatc 480
tatgaatgaa taaataagca tttctcccat ccaccttcta attttgggtga ctaggagggg 540
ttagggacag catttggttag tgggaatgat ttgattagct tagatctgac gaagactaat 600
caatgaaaac atggcagcgg caga 624
```

<210> 227

<211> 624

<212> DNA

<213> Homo sapiens

<400> 227

```
gattaagctt ttcattgattc ctcatagaac atgaactcaa aagaggtcag caaaggggtg 60
```

```

tgtgcgattc tttgctattg gctgcagcta tagccctgcc tccttctcca gacacataa 120
ctttcagcag cttgggtgaa gactgctgtg cagggcaggg aagctccagg caaacagccc 180
agcaaacagc agcactcagc taaaaggaag actcacagaa cacagttgaa gaaggaaagt 240
ggcgatggac ctcatcccaa atttggcggg ggaaacctgg cttctcctgg ctgtcagcct 300
ggtgctcctc tatctgtgag taactgtcca aactcctctc tttgtttcct tggacttggg 360
gtgctaatacg ggcccctttt cccttatctg ttttgaagat caaaagagat gttcaaggag 420
aagtagctga agtggtggac gctacaaacg catagaagtt attattatct tatacagatc 480
tatgaatgaa taaataagca tttctcccat ccaccttcta attttgggtga ctaggagggt 540
ttagggacag catttggtag tgggaatgat ttgattagct tagatctgac gaagactaat 600
caatgaaaac atggcagcgg caga                                     624

```

<210> 228

<211> 626

<212> DNA

<213> Homo sapiens

<400> 228

```

gaacagttcc ctaccacgtg gagcatttgc aattaaagg agactgagat atagaggcag 60
gagaccacac cagatggctg ggtctcccca ctcccacccc cgccccacat acactcagaa 120
gaggctaggc atctaggatc tccattgagc atcttgaata tggcttgcca taatatcata 180
tacagtcaat aaatatttgt taaataagga tgcctcttca atatattttg tgcaaccatg 240
aagatcacca caactaatgt gagaaaaaat gtttctgttg aactctagtc tttaggccca 300
gtgggattta tgaaaagtgc catctcttta gctgaggatg aagaatggaa gagaatacag 360
tcattgctgt ctccaacctt caccagcggg aaactcaagg aggtatgaaa ataagatgag 420
tcttaattag aaatgtaaag aatgaatctg gggacaggta gaaagtaaga tcacagtccg 480
tttccaaggg gtagtccact gagttcgagc ttcttaaaaa tgggtcttita tctttatgta 540
cagaaaagac atcacaaaat tcattacaaa atgtcactta ctgctccatg ctggagaaag 600
ccatatcctt ctgggacttg agtctg                                     626

```

<210> 229

<211> 60

<212> PRT

<213> Homo sapiens

<400> 229

```

Ser Val Phe Thr Asn Arg Arg Ser Leu Gly Pro Val Gly Phe Met Lys
  1                      5                      10                      15

Ser Ala Ile Ser Leu Ala Glu Asp Glu Glu Trp Lys Arg Ile Gln Ser
          20                      25                      30

Leu Leu Ser Pro Thr Phe Thr Ser Gly Lys Leu Lys Glu Met Phe Pro
          35                      40                      45

Ile Ile Ala Gln Tyr Gly Asp Val Leu Val Arg Asn
          50                      55                      60

```

<210> 230

<211> 626

<212> DNA

<213> Homo sapiens

<400> 230

```

gaacagttcc ctaccacgtg gagcatttgc aattaaagg agactgagat atagaggcag 60
gagaccacac cagatggctg ggtctcccca ctcccacccc cgccccacat acactcagaa 120
gaggctaggc atctaggatc tccattgagc atcttgaata tggcttgcca taatatcata 180
tacagtcaat aaatatttgt taaataagga tgcctcttca atatattttg tgcaaccatg 240
aagatcacca caactaatgt gagaaaaaat gtttctgttg aactctagtc tttaggccca 300
gtgggattta tgaaaagtgc catctcttta gctgaggatg aagaatggaa gagaatacgg 360
tcattgctgt ctccaacctt caccagcggg aaactcaagg aggcattgaaa ataagatgag 420

```

tcttaattag aaatgtaaag aatgaatctg gggacaggta gaaagtaaga tcacagtccg 480
tttccaaggg gtagtccact gagttcgagc ttcctaaaaa tggctcttta tctttatgta 540
cagaaaagac atcacaaaat tcattacaaa atgtcactta ctgctccatg ctggagaaag 600
ccatatcctt ctgggacttg agtctg 626

<210> 231

<211> 626

<212> DNA

<213> Homo sapiens

<400> 231

gaacagttcc ctaccacgtg gagcatttgc aattaaagg agactgagat atagaggcag 60
gagaccacac cagatggctg ggtctcccca ctcccacccc cgccccacat acactcagaa 120
gaggctaggc atctaggatc tccattgagc atcttgaata tggcttgcca taatatcata 180
tacagtcaat aaatatttgt taaataagga tgcctcttca atatatattg tgcaaccatg 240
aagatcacca caactaatgt gagaaaaaat gtttctgttg aactctagtc tttaggccca 300
gtgggattta tgaaaagtgc catctcttta gctgaggatg aagaatggaa gagaatacgg 360
tcattgctgt ctccaacctt caccagcgga aaactcaagg aggtatgaaa ataagatgag 420
tcttaattag aaatgtaaag aatgaatctg gggacaggta gaaagtaaga tcacagtcca 480
tttccaaggg gtagtccact gagttcgagc ttcctaaaaa tggctcttta tctttatgta 540
cagaaaagac atcacaaaat tcattacaaa atgtcactta ctgctccatg ctggagaaag 600
ccatatcctt ctgggacttg agtctg 626

<210> 232

<211> 623

<212> DNA

<213> Homo sapiens

<400> 232

attggacatg atagctagat ttgtttcagg aaaacatcct gctttccaag gatttagatg 60
aatgtttttg ttcactggtg actcaggtaa cagctcttca agaagccata gggagggtga 120
gggaggggaag tcaagaaggg aggttgagga ctgcactttt gatttacttc tgacttcacg 180
agtcactttc tgcgaaagaa atctctcctt ttgcttctag caccgactag atttccttca 240
gctgatgatt gactccaga attcgaaaga aactgagtcc cacaaaggta accaaggagt 300
gcttctgagg gctactggcg gggacactaa gagggagggc cttgttctga aaatgtgcag 360
gaagtattcc aggaagatga gaatttttgc cacatagcag aacaacacac atttagatgt 420
tataaatggg agctggaggc actttccaga agcccacagg tatagccatg ttccaggctg 480
aaagggcaac cctaagcaaa cctagaatgc ttggaggaca gtcagtgggt tgtggatcac 540
ctacatgaga tcaaatgccg gttctcagcc tcttcagat ccaccaagtg agaacctcta 600
cttggaatt tatatcaaac ata 623

<210> 233

<211> 616

<212> DNA

<213> Homo sapiens

<400> 233

caggcctggc acagagtcag tgctccataa atattttgtt aaacgatgga tggtagtgct 60
ttttactatc cagtatttac ccagcttata gattaagtat gaagagttca agatacatgg 120
tgtaagagt cgtttttata tgcttgcaaa gcatttttgt catatttttt ctactttgct 180
tccatctttt cttctttcac ttcatttatt aattctccat atgcttggtt aactattgta 240
gatcccttg aaattagaca cgcaaggact tcttcaacca gaaaaacca ctgttctaaa 300
ggtggattca agagatggaa ccctaagtgg agaagtgatt attctaagga tttctacttt 360
ggtcttcaag aaagctgtgc ccagaacac cagagatttc aacttagtca ataaaacctt 420
gaaataaaga tgggcttaat ctaatgtact gcatgagtag ttggtgattt tgtacattca 480
ttgagctctc ccagagctg tgtagagtgt tgtgcattat gtagtataaa ggaggtgacc 540
aggtaagtga cagataggta gactcagctt ctctgcttct cataggacta cctctacca 600
cctctagtta gcatta 616

<210> 234
 <211> 59
 <212> PRT
 <213> Homo sapiens

<400> 234
 Met Arg Phe Ala Leu Met Asn Met Lys Leu Ala Leu Ile Arg Val Leu
 1 5 10 15
 Gln Asn Phe Ser Phe Lys Pro Cys Lys Glu Thr Gln Ile Pro Leu Lys
 20 25 30
 Leu Asp Thr Gln Gly Leu Leu Gln Pro Glu Lys Pro Thr Val Leu Lys
 35 40 45
 Val Asp Ser Arg Asp Gly Thr Leu Ser Gly Glu
 50 55

<210> 235
 <211> 830
 <212> DNA
 <213> Homo sapiens

<400> 235
 tgggtcaccca ccatgtgtac agtaccctgc taggggtccag ggtcatgaaa gtaaataata 60
 ccagactgtg cccttgagga actcacctct gctaaggga acaggcacag aaaccacaa 120
 ggggtggtaga gaggaaatag gacaatagga ctgtgtgagg gggataggag gcaccagag 180
 gaggaaatgg ttacatctgt gtgaggaggt tggtaaggaa agactttaat agaaggggtc 240
 tgtctggctg ggcttgcaag gatgtgtagg agtcatctag ggggcacaag taccctccag 300
 gcagagggaa ttgcatgggt aaagatctgc agttgtggct tgtggggatg gatttcaagt 360
 attctggaat gaagacagcc atggaaacaa gggcagggtga gaggatattt aagaggcttc 420
 atgccaatgg ctccacttca gtttctgata agaactcagg ttccgtggac tccctgataa 480
 aactgattaa gttgtttatg attccccata gaatatgaac tcaaaggagg taagcaaagg 540
 ggtgtgtgcg attctttgct accggctgca gctgcagccc cacctccttc tccagcacat 600
 aaacatttca gcagcttgac ctaagactgc tgtgcagggc agggatgctc caggcagaca 660
 gccagcaaaa caacagcaca cagctgaaag taagactcag aggagacagt tgaagaaggc 720
 aagtggcgat ggacctcatc ccaaatttgg cgggtgaaac ctggcttctc ctggctgtca 780
 gcctggtgct cctctatctg tcagtaactg tccagattcc tctcctctgt 830

<210> 236
 <211> 775
 <212> DNA
 <213> Homo sapiens

<400> 236
 ggagtgaacct gattttccag gtgctgtctg tcaccctttt ctttgactag gaaagggaa 60
 tccttgaccc cttgcgcttc tcaagtgagg caatgcctcg ccctgcttcg gcttgtgcac 120
 agcacgctgc acccactgtc ctgcacccac tgtctggcac tccctagtga gatgaacctg 180
 gtacctcaga tgaaaatgca gaaattaccc gtcttctgtg tcaactcacac tgggagctgt 240
 agaccggagc tgttcctatt cggccatctt ggctccaccc cccgagtttt ggcttttaat 300
 tgaaagtgtg ttgatgtggg aaggagataa tgccatgcat ttatgagcac atattagagg 360
 gtctgagaca atgcatgtga taaaagggtc cctaagggaag aaaaaagaa caagggaaga 420
 cactggaaag aacgtgatgc tgggagtccc tgggccacca aagtctggag aaaagtggta 480
 accacaaggc tcccagccta gtttcactga agacctcgac actaggtgac ttatgggatac 540
 cttggttagga caagccttga aaagtgttac aatagcaaat gtggacgttg tcagaaccaa 600
 atgatgtcac gtgtgtattt gtgtgtgtgt gtcagtgtgt gtgtttaaaa atcatgacaa 660
 ataaagcagg ctgtgaagag gggattccca tgctcgtgtg cctgataaca caactatcac 720
 aaacgctttg cgaaaccaca agtttgcaca aaggcaatcc caaccttaca caaaa 775

<210> 237

<211> 25
<212> DNA
<213> Homo sapiens

<400> 237
ttggtgggaa atgttttgtc ctatc

25

<210> 238
<211> 24
<212> DNA
<213> Homo sapiens

<400> 238
acagggagtt gaccttcata cggt

24

<210> 239
<211> 33
<212> DNA
<213> Homo sapiens

<400> 239
tcagggtctc tggaaatttg acacagagtg cta

33

1

49/49

\\Ntvossius1\\Allgemein\\Daten-1\\sg\\sequencelisting\\E3103PCT\\E3103PCT.APP

1

47/47

1

4/47

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
11 July 2002 (11.07.2002)


PCT

(10) International Publication Number
WO 02/053775 A3

- (51) International Patent Classification⁷: C12Q 1/68, C12N 15/00, 5/10, 9/02, C07K 16/00, C12Q 1/26, G01N 33/573, A61K 39/00, 38/00, 48/00
- (71) Applicant (for all designated States except US): EPIDAUROS BIOTECHNOLOGIE AG [DE/DE]; Am Neuland 1, 82347 Bernried (DE).
- (21) International Application Number: PCT/EP01/15290
- (72) Inventors; and
- (22) International Filing Date: 21 December 2001 (21.12.2001)
- (75) Inventors/Applicants (for US only): WOJNOWSKI, Leszek [DE/DE]; Ebenauerstrasse 9, 80637 München (DE). HABERL, Michael [DE/DE]; Waxensteinstrasse 24, 82347 Bernried (DE). HUSTERT, Elisabeth [DE/DE]; Geschwister Scholl Ring 2, 82110 Germering (DE).
- (25) Filing Language: English
- (74) Agent: VOSSIUS & PARTNER; Siebertstrasse 4, 81675 Munich (DE).
- (26) Publication Language: English
- (30) Priority Data:
- | | | |
|------------|-------------------------------|----|
| 00128627.7 | 28 December 2000 (28.12.2000) | EP |
| 60/258,684 | 28 December 2000 (28.12.2000) | US |
| 60/258,952 | 29 December 2000 (29.12.2000) | US |
| 01100172.4 | 16 January 2001 (16.01.2001) | EP |
| 60/262,859 | 18 January 2001 (18.01.2001) | US |
| 01118884.4 | 16 August 2001 (16.08.2001) | EP |
| 60/312,825 | 16 August 2001 (16.08.2001) | US |
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

[Continued on next page]

(54) Title: IDENTIFICATION OF GENETIC DETERMINANTS OF POLYMORPHIC CYP3A5 EXPRESSION



(57) Abstract: The present invention relates to a polymorphic CYP3A5 polynucleotide. Moreover, the invention relates to genes or vectors comprising the polynucleotides of the invention and to a host cell genetically engineered with the polynucleotide or gene of the invention. Further, the invention relates to methods for producing molecular variant polypeptides or fragments thereof, methods for producing calls capable of expressing a molecular variant polypeptide and to a polypeptide or fragment thereof encoded by the polynucleotide or the gene of the invention or which is obtainable by the method or from the cells produced by the method of the invention. Furthermore, the invention relates to an antibody which binds specifically the polypeptide of the invention. Moreover, the invention relates to a transgenic non-human animal. The invention also relates to a solid support comprising one or a plurality of the above mentioned polynucleotides, genes, vectors, polypeptides, antibodies or host cells. Furthermore, methods of identifying a polymorphism, identifying and obtaining a pro-drug or drug or an inhibitor are also encompassed by the present invention. In addition, the invention relates to methods for producing of a pharmaceutical composition and methods of diagnosing a disease. Further, the invention relates to a method of

detection of the polynucleotide of the invention. Furthermore, comprised by the present invention are a diagnostic and a pharmaceutical composition. Even more the invention relates to uses of the polynucleotides, genes, vectors, polypeptides or antibodies of the invention. Finally, the invention relates to a diagnostic kit.

WO 02/053775 A3



(84) **Designated States (regional):** ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) **Date of publication of the international search report:**

4 September 2003

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

INTERNATIONAL SEARCH REPORT

Int Application No
PCT/EP 01/15290

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12Q1/68 C12N15/00 C12N5/10 C12N9/02 C07K16/00
C12Q1/26 G01N33/573 A61K39/00 A61K38/00 A61K48/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C12Q C07K G01N A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

BIOSIS, EPO-Internal, EMBL, MEDLINE, EMBASE, PAJ, WPI Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	PAULUSSEN AIMEE ET AL: "Two linked mutations in transcriptional regulatory elements of the CYP3A5 gene constitute the major genetic determinant of polymorphic activity in humans." PHARMACOGENETICS, vol. 10, no. 5, July 2000 (2000-07), pages 415-424, XP008015489 ISSN: 0960-314X cited in the application the whole document abstract page 415, line 15 - line 18	1,3-20, 22-24, 29, 33-35, 38,44
Y	---	1-39,43, 44
	---	-/--

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

25 March 2003

Date of mailing of the international search report

03 JUL 2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Tuynman, A

INTERNATIONAL SEARCH REPORT

Int: Application No
PCT/EP 01/15290

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 00 39332 A (JANSSEN PHARMACEUTICA NV ;PAULUSSEN AIMEE DYMPHNE CATHER (BE); ARM) 6 July 2000 (2000-07-06) the whole document	1-20, 22-24, 29, 33-35, 38,44
Y	---	1-39,43, 44
Y	WO 98 44939 A (WANG REGINA W ;LU ANTHONY Y H (US); MERCK & CO INC (US)) 15 October 1998 (1998-10-15) example 1 ---	1-39,43, 44
X	WO 98 24914 A (INST NAT SANTE RECH MED ;GENSET SA (FR); TCHOUMAKOV ILIA (FR); BAC) 11 June 1998 (1998-06-11) fragment2.FM0x nucleotides 3450-3460 figure 10 ---	1,3-8, 11-18, 34,44
P,X	HUSTERT ELISABETH ET AL: "The genetic determinants of the CYP3A5 polymorphism." PHARMACOGENETICS, vol. 11, no. 9, December 2001 (2001-12), pages 773-779, XP008015487 ISSN: 0960-314X the whole document -----	1-35,38, 43,44

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP 01/15290

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☒ Claims Nos.: 41 (fully) ; 1-40,42-44 (in part)
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1-39, 43, 44 partially

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 41 (fully) ; 1-40,42-44 (in part)

The search has been not been carried out for claim 41 and those parts of claims 1-40 and 42-44 that refer back to accession numbers, because a molecule which is only identified by reference to a disclosure outside the application filed, which is not a sequence listing according to Rule 5.2, cannot fulfill the requirement of sufficiency of disclosure of Article 5 PCT.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

Inventions 1-102: Claims: 1-39,43,44 (partially)

Each of the polynucleotides comprising a polynucleotide according to SEQ 54,56,58,62,64,66,68,70,72,74, 76,78,80,84,86,90,92,94,96,98,100,102,106,108,110,113,114,115,116,117,118,119,120,121,122,123,124,125,126,128,129,130,131,133,134,135,136,137,138,139,140,142,143,149,151,153,155,157,159,161,163,165,169,171,173,175,177,179,181,183,185,187,189,193,195,197,199,201,207,208,209,210,211,212,213,214,216,218,219,220,221,222,223,224,225,226,227,228,231,232,233,235, or 236, respectively, and methods and uses involving these.

Inventions 103-105: claims 1-40,42-44 (partially)

Each of the polynucleotides comprising a polynucleotide according to SEQ 82,88 or 112, respectively, and methods and uses involving these.

Inventions 106-108: claims 1-40,42-44 (partially)

A polynucleotide encoding a polypeptide according to SEQ ID 127,132, or 141, respectively, and methods and uses involving these.

Inventions 109-111: claims 1-39,43,44 (partially)

A polynucleotide encoding a polypeptide according to SEQ ID 215,229, or 234, respectively, and methods and uses involving these.

Invention 112: 38-40,42-44 (partially)

A polynucleotide comprising a polynucleotide according to SEQ ID NO: 104 and the use thereof.

Invention 113: Claims 38-40,42-44 (partially)

A polynucleotide encoding a polypeptide comprising SEQ ID 145 and the use thereof.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 01/15290

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 0039332	A	06-07-2000	AU	1878300 A	31-07-2000
			CA	2355658 A1	06-07-2000
			CN	1331756 T	16-01-2002
			EP	1141398 A1	10-10-2001
			WO	0039332 A1	06-07-2000
			JP	2002533136 T	08-10-2002

WO 9844939	A	15-10-1998	EP	1011708 A1	28-06-2000
			JP	2000513742 T	17-10-2000
			US	6300476 B1	09-10-2001
			WO	9844939 A1	15-10-1998

WO 9824914	A	11-06-1998	FR	2756845 A1	12-06-1998
			AU	746293 B2	18-04-2002
			AU	5327198 A	29-06-1998
			EP	0941341 A1	15-09-1999
			WO	9824914 A1	11-06-1998
			JP	2001505430 T	24-04-2001
			US	6551792 B1	22-04-2003
